"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by and welcome to the Express Scripts Fourth Quarter 2009 Earnings Call. [Operator Instructions] I'd now like to turn the conference over to the Vice President of Investor Relations, David Myers. Please go ahea",42,"Ladies and gentlemen, thank you for standing by and welcome to the Express Scripts Fourth Quarter 2009 Earnings Call. [Operator Instructions] I'd now like to turn the conference over to the Vice President of Investor Relations, David Myers. Please go ahead, sir."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you. Good morning, everyone. Thanks for joining us on our call. With me today are George Paz, our CEO; and Jeff Hall, our CFO.Before we begin, I need to read the following statement. Statements or comments made on this conference call may be forward",145,"Thank you. Good morning, everyone. Thanks for joining us on our call. With me today are George Paz, our CEO; and Jeff Hall, our CFO.Before we begin, I need to read the following statement. Statements or comments made on this conference call may be forward-looking and may include but are not necessarily limited to financial projections or other statements of the company's plans, objectives, expectations or intentions. These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statements due to a variety of factors, which are discussed in detail in our filings with the SEC. In addition, the reconciliation of EBITDA to net income can be found in our earnings release, which is posted on our website.At this point, I'll turn the call over to Jeff who will discuss our fourth quarter results."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, David. Yesterday, we released our fourth quarter results, as well as our 2010 guidance. I'll start today by reviewing our strong quarterly performance, then provide some additional color around our 2010 outlook. For 2009, GAAP EPS was $3.11. Ex",731,"Thank you, David. Yesterday, we released our fourth quarter results, as well as our 2010 guidance. I'll start today by reviewing our strong quarterly performance, then provide some additional color around our 2010 outlook. For 2009, GAAP EPS was $3.11. Excluding transaction related charges and amortization, adjusted EPS was $3.58. As most of you know, this includes $0.35 of financing cost we incurred prior to the December 1 close of the acquisition. So on an apples-to-apples basis, EPS was up 24% over last year, with nearly all of this growth coming from operations.For clarity, in the remainder of the call, we will discuss adjusted EPS as defined in Tables 3 and 4 of our press release. For the quarter, our adjusted EPS was $0.97. This includes just one month of NextRx results for the full quarter of financing cost. Total adjusted claims were up 23% for the quarter and 5% for the year. As expected, our base business claims for the full year were flat with last year, so the year-over-year increase is attributable to NextRx. The quarter also included our new Department of Defense contract, which was implemented on November 4. As you know, we began recording DoD revenues on a gross basis with the new contract. This increased both revenues and cost of goods sold by $1.8 billion in the quarter. As a result of this change, while gross profit dollars increased 25% for the fourth quarter, gross profit margin declined to 8.4% from 10%.SG&A expenses increased $36 million sequentially, reflecting not only the addition of NextRx but also the continued investment in our core business we are making to drive long-term growth and profitability. EBITDA per claim, which was also impacted by the acquisition, was $3.16 for the quarter and $3.20 for the year, 18% growth over 2008. Cash flow was $844 million for the quarter and $1.8 billion for the year, an increase of 60%. Before I discuss 2010 guidance, let me reiterate something I've said many times over the past several months. Historical NextRx results will not be indicative of our future performance. To be clear, it would be inaccurate to extrapolate the benefit we will derive from NextRx for 2010 and beyond from the historical NextRx results.As we planned, we have a new pricing structure with a WellPoint, new supply-chain economics and are integrating operations, all of which will cause significant deviations from historical NextRx performance. For 2010, our adjusted EPS is expected to be in a range of $4.80 to $5, with a normal quarterly progression. Our press release contains a detailed schedule showing potential transaction-related charges and amortization we have excluded from this guidance. The transaction-related charges include only expenses that are expected to end when the integration is complete.This guidance assumes total adjusted claims including NextRx of $740 million to $760 million. As expected, NextRx is contributing significantly fewer claims than their historical run rates mainly due to the loss of Part D Dual Eligible lives [ph]. Claims in our core business are expected to be up 2% to 4% for the year. SG&A is expected to increase 6% to 8%. EBITDA per adjusted claim is forecasted to be $3.15 to $3.25. And as a result of including a full quarter of NextRx results, EBITDA per adjusted claim in Q1 is expected to be between $2.85 and $2.95. The tax rate for the year is expected to be in the range of 37% to 37 1/2% and cash flow from operations is expected to be in excess of $2 billion.Overall, this guidance shows growth of 22% to 27% over 2009 and again, nearly all of this growth is coming from operations. As I've said in the past, profit maximization is not our primary goal for 2010. We are willing to incur a higher cost structure in the near term to ensure a flawless integration. We will rationalize our footprint, eliminate redundancies and realize synergies as we make progress towards executing our integration plan. Thanks to a lot of hard work by both Express Scripts and WellPoint teams. We believe the integration will be completed closer to the lower end of the 12 to 18 months we've been discussing in the past. Once this integration is complete, we continue to expect the acquisition of NextRx to generate more than $1 billion of incremental EBITDA. And with that, I'll turn it over to George."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, Jeff and good morning, everyone. 2009 was an outstanding year in which we had numerous accomplishments. To name a few, we acquired NextRx, raised favorable financing in a difficult market and launched a long-term alliance with WellPoint that wi",520,"Thank you, Jeff and good morning, everyone. 2009 was an outstanding year in which we had numerous accomplishments. To name a few, we acquired NextRx, raised favorable financing in a difficult market and launched a long-term alliance with WellPoint that will provide game-changing capabilities from improved health outcomes and drive out waste. In November, we implemented our new contract with the Department of Defense. This contract includes additional service such as claims, adjudication and specialty-pharmacy management. This was one of our largest and most successful implementations in our history. We enjoyed a every successful selling season with eight signature wins, over 300 wins in total and a 98% retention rate.We attribute our success to our business model of alignment coupled with outstanding service and Consumerology, our tools set that improves clinical programs to increase member engagement. As a result of our company's dedication and passion to service, we've produced record operating earnings and cash flow in 2009. While it's great to take a moment to reflect on the successful year, we continue to focus on our model of alignment, which creates value for our clients and superior returns for our stockholders. We are on track with respect to NextRx, and we are on a path to a flawless execution. Our strategic alliance opens new horizons for improving patient outcomes while driving down overall health care costs.There is still a tremendous opportunity to eliminate significant waste in healthcare by driving positive clinical behavior. Through Consumerology, we have increased member engagement across our entire book of business, not just for those members that use our Home Delivery Pharmacies. We know there are many aspects involved in improving health outcomes. For example, we deploy a full set of tools, including an understanding of demographics and the role that genetics play. However, a recent study found that behavior has the single largest impact on health, determining about 40% of overall health outcomes. Programs and initiatives that incorporate comprehensive health information with individual behavior patterns create empowered patients that can fully participate in developing a better healthcare regime. Today, Americans waste approximately $173 billion in pharmaceutical-related spend, $116 billion in medical cost and lost productivity due to non-adherence, and $57 billion in drug and channel mix.We are addressing these areas of waste with our behavior centric approach. For example, our patient outreach activities and innovations this year resulted in statistically significant improvements in inherence and several important therapy classes, including diabetes and cholesterol. Express Scripts' clients saved $1.4 billion from greater use of lower cost brands and generics. Of this amount, our behavior centric approach accounted for $780 million of these savings. At Express Scripts are enabling better health and value by driving positive clinical behavior one patient at a time. Our clinical offerings powered by our behavior centric approach providing an unparalleled and differentiated value proposition in the marketplace. As the selling season unfolds, we are optimistic about what is shaping up to be a robust pipeline of new opportunities. Our optimism for the future is reflected in our strong guidance for 2010. At this point, we'd be happy to answer any questions. Operator?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Operator","[Operator Instructions] And our first question is from the line of Lisa Gill from JPMorgan.",15,"[Operator Instructions] And our first question is from the line of Lisa Gill from JPMorgan."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","The $1 billion run rate, so when we think about this George, the 12 months of integration, will that be December of 2010, so therefore, we should see that the $1 billion in 2011, is that how we should be thinking about that?",43,"The $1 billion run rate, so when we think about this George, the 12 months of integration, will that be December of 2010, so therefore, we should see that the $1 billion in 2011, is that how we should be thinking about that?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","The $1 billion will be achieved when we're fully integrated. Right now, we're in a path as we've said to integrate from 12 to 18 months, looking towards the lower end of that schedule. So the $1 billion run rate will be realized once our integration activ",66,"The $1 billion will be achieved when we're fully integrated. Right now, we're in a path as we've said to integrate from 12 to 18 months, looking towards the lower end of that schedule. So the $1 billion run rate will be realized once our integration activities are complete and we'll keep you posted on that as we progress through the course of the year. Jeff?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","That's exactly right.",4,"That's exactly right."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","Around the Select Home Delivery, can you just give us an idea of what your expectations are around mail scripts. I know that the book of business for NextRx has lower mail penetration than your existing book. But what are you seeing on a same-store basis",66,"Around the Select Home Delivery, can you just give us an idea of what your expectations are around mail scripts. I know that the book of business for NextRx has lower mail penetration than your existing book. But what are you seeing on a same-store basis in your existing book George, as far as uptake of Select Home Delivery and overall mail older scripts for 2010?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","Select Home Delivery has been a very strong program for us. It allows us as you know, to go to clients with labor contracts that can't or won't accept necessarily a benefit design. And help us to favor driving out waste and improving health outcomes to th",142,"Select Home Delivery has been a very strong program for us. It allows us as you know, to go to clients with labor contracts that can't or won't accept necessarily a benefit design. And help us to favor driving out waste and improving health outcomes to these programs. So it's been incredibly successful. We have several hundred clients that have signed up for this coming year and we're looking for a very nice growth. To your point though, until we get NextRx fully integrated, it's really hard to introduce those programs. The NextRx platforms do not have the tools that we need in order to really drive Select Home Delivery. So as we integrate platforms, then we can start talking about the different health plans and driving Select Home Delivery, but until we get there, we really can't do much with that."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","But you have a growth rate as far as the number of accounts or the number of scripts you're expecting for overall mail trends in 2010. I know that Jeff talked about 2% to 4% overall script trends but can you give us some indication how we should think abo",53,"But you have a growth rate as far as the number of accounts or the number of scripts you're expecting for overall mail trends in 2010. I know that Jeff talked about 2% to 4% overall script trends but can you give us some indication how we should think about mail trends?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","We haven't guided specifically to where we think Home Delivery rates are going to go and I don't think we're going to at this point. There's a lot going on with integration this year. Certainly, we're very optimistic about what we can do there in our core",95,"We haven't guided specifically to where we think Home Delivery rates are going to go and I don't think we're going to at this point. There's a lot going on with integration this year. Certainly, we're very optimistic about what we can do there in our core business. We're firing on all cylinders in both operations and the account management teams and we're happy about. What we have, going there, customers are seeing the benefit. So we think we'll see it trend up but we're not going to give specific guidance at this point."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Operator","Next we'll go to the line of Charles Boorady with Citi.",12,"Next we'll go to the line of Charles Boorady with Citi."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","What are the next key milestones and dates in the NextRx integration or things like staff transition and also technology? And how will you monitor the service levels, customer satisfaction and other key metrics along the way as you integrate the two busin",43,"What are the next key milestones and dates in the NextRx integration or things like staff transition and also technology? And how will you monitor the service levels, customer satisfaction and other key metrics along the way as you integrate the two businesses?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","What we did on day one was we took all of the operations and IT functions and record them into our people here at Express Scripts. So operation's reports the fad, facts to me and his charge is to make sure that we are monitoring service. It's something we",409,"What we did on day one was we took all of the operations and IT functions and record them into our people here at Express Scripts. So operation's reports the fad, facts to me and his charge is to make sure that we are monitoring service. It's something we take a lot of pride on here at Express Scripts. So we put in place all the metrics and monitoring programs that we need to make sure we're on top of it. So similar to our own call centers and our own pharmacies, we have a daily mechanism by which we gauge our service levels. Having said all that though, one of our first moves was to bring the pharmacies together. We're just about complete with that. So we moved the fulfillment functions out of the NextRx sites into the Express Scripts sites and that's pretty much there. We haven't shut down the sites yet. We're in a process of doing that. So that will be the first thing we achieved, is the actual jettisoning[ph] of the actual pharmacies. But let me also be clear that we're not expecting to give up certain of the office spaces because we're going to convert those into our front end. At Express Scripts, we've got a history of keeping the best and brightest and looking for best practices. So quite a few of the sites from the NextRx acquisition will remain. We've already made the decision to stay in Indianapolis with our Specialty Pharmacy. We will close down some sites. We have given notice at certain areas that we are shutting down some call center operations, shutting down as I said, the mail pharmacies. So all these things are on a schedule. The big, big items to be frank, are getting off the platforms. We're on a process to do that and we're carefully monitoring the progression on that path. It's critically important that we get the NextRx membership onto our platforms. Once we do that, as we're talking with Lisa a few minutes ago, that's how we can then start driving clinical changes, driving best practices, getting our reporting tools into the hands of the people at WellPoint. So to really grow, help them grow their book of business and offer best in class operations, we need to get onto our platforms. We have a path to do that and we'll keep you in the loop as we've progressed on that path."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Operator","Next is the line of Ross Muken with Deutsche Bank.",10,"Next is the line of Ross Muken with Deutsche Bank."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","Can you talk a bit about sort of the success you had in the last selling season relative to sort of the Consumerology offering. I know Georgia you talked to some of the benefits that you drove in terms of savings to the cost -- to your existing customer b",97,"Can you talk a bit about sort of the success you had in the last selling season relative to sort of the Consumerology offering. I know Georgia you talked to some of the benefits that you drove in terms of savings to the cost -- to your existing customer base using that behavior centric approach. Is that starting to gain momentum both in the consultant community, as well as sort of in the kind of the potential customer base? And then how do we think about using that tool set and applying it to the NextRx business?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","Actually, I would say we're beyond gaining momentum. We've got momentum. It's going incredibly well. I think it resonates with a lot of companies. We sell to Fortune 500 companies and a lot of other companies as well. But when you walk into a company that",232,"Actually, I would say we're beyond gaining momentum. We've got momentum. It's going incredibly well. I think it resonates with a lot of companies. We sell to Fortune 500 companies and a lot of other companies as well. But when you walk into a company that does its own marketing and understands the importance of making sure that their products are meeting the needs of the customer and then there are advertising approach to selling their products, then we walk in and start talking about, it can't just be about economics but it's going to be about messaging so people take better control of their healthcare. I think that it really resonates and we have had significant wins and discussions around these areas. I don't want to speak for WellPoint but I believe that one of the benefits of this acquisition is that once we get fully integrated, we cannot only use our behavior centric approach to improve the adherence, the step therapy programs, the mail-order programs and all the different things that we do. But we can use that to help drive a better medical adherence as well. There's a lot of waste on the medical side and I think with our commitment to driving out waste in WellPoint, focused on improving the health outcomes of their membership together, we will have a new paradigm, which I think will be unparalleled."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","And maybe Jeff, can you talk a bit about some of the working capital opportunities here, getting the sort of NextRx business to your sort of traditional standards and obviously, that's kind of the decent portion of some of that really strong cash flow you",51,"And maybe Jeff, can you talk a bit about some of the working capital opportunities here, getting the sort of NextRx business to your sort of traditional standards and obviously, that's kind of the decent portion of some of that really strong cash flow you're going to be generating this year?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, I think that's right, Ross. Certainly, there's no reason to think that as we get these businesses integrated that the WellPoint business should be on the same kind of working capital basis that the rest of our businesses on. Treasury team did a grea",95,"Well, I think that's right, Ross. Certainly, there's no reason to think that as we get these businesses integrated that the WellPoint business should be on the same kind of working capital basis that the rest of our businesses on. Treasury team did a great job or is in Q4, getting it integrated quickly and realizing some quick wins there. Still a lot of work ahead and we're driving it forward. But I think once we're integrated, the working capital will look the same as it looks for the rest of our book of business."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Operator","Next is the line of Randall Stanicky with Goldman Sachs.",10,"Next is the line of Randall Stanicky with Goldman Sachs."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","Just a follow-up on that and George can you talk about an encouraging 2011 outlook for the selling season. Can you talk maybe about where are you seeing some of those opportunities? And then secondly, given that you have a management change at the PBM [Ph",81,"Just a follow-up on that and George can you talk about an encouraging 2011 outlook for the selling season. Can you talk maybe about where are you seeing some of those opportunities? And then secondly, given that you have a management change at the PBM [Pharmacy Benefit Management] of one of your bigger competitors, your footprint obviously changed. Should we be thinking about any changes or are you seeing any different changes in the current competitive landscape for the PBMs?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","Well I think I got your question, there's a lot of clients that contracts are coming due in the upcoming year. So that's what I'm referring to by a robust pipeline. I think when you look at, there's a lot of opportunities for -- to continue to do what we",400,"Well I think I got your question, there's a lot of clients that contracts are coming due in the upcoming year. So that's what I'm referring to by a robust pipeline. I think when you look at, there's a lot of opportunities for -- to continue to do what we do, where clients have gone with the adjudication only services and the in source, a lot of different functions and I'm talking about managed care plans that are now looking whether or not it makes more sense to outsource the entire program. So there's a lot of medium-sized managed care companies out there that we're bidding on or will be bidding on. There's always some state business that comes up on a three-year rotation that will also come to market over the course of the year. And then there's just the normal run of large, medium and small groups that are opportunities for us. So this looks like a pretty strong year. Again, you got a keep in mind that we had a 98% retention rate. I think Medco has a very high in the 90s retention rate as well and Caremark has done their share. So we're certainly going to bid to the extent that there's opportunities for people that are looking for different models. And those are jump balls and we do very well on a jump ball situation. In other words we're going from an adjudicator to a full PBM offering. I think we will do incredibly well in that part of the selling season. But you know I think we're very disciplined company. When we look at what's out there and at the end of the day, it's all about relationships when you're selling. So the question is have we put the right people in place, have we nurtured our relationship and can we get our message out there. We're certainly focused on that. Payer [ph] has been in our industry for a long time. We welcome back into the industry. To be honest with you, we would rather have some strong competitors quite frankly. It really helps push the industry forward and keeps us all working hard and focused on driving better healthcare outcomes. And we think we're very well situated. I think our numbers speak for ourselves. Our 2010 selling season speaks for itself. And we're excited about the opportunities we face for 2011."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, if I could just ask you one quick question, on the generic front, any way that you could give us some qualitative color on what you're expecting in terms of benefit to your full year this year, maybe perhaps relative to last year?",44,"Jeff, if I could just ask you one quick question, on the generic front, any way that you could give us some qualitative color on what you're expecting in terms of benefit to your full year this year, maybe perhaps relative to last year?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","Sure. Outlook on that really hasn't changed over the last couple of quarters. But 2009 was kind of weaker than average year for generic fill rates benefit to EPS. And 2010, as we've been saying, looks a little bit better than that, moderately better but n",92,"Sure. Outlook on that really hasn't changed over the last couple of quarters. But 2009 was kind of weaker than average year for generic fill rates benefit to EPS. And 2010, as we've been saying, looks a little bit better than that, moderately better but not significantly better as a contribution to EPS for us. The 2009 generics were more back-end loaded, so we're going to see more of that benefit coming into 2010. 2010 it will still probably a little bit below average from an EPS growth contribution year from generic."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Operator","Next is the line of Robert Willoughby with Bank of America.",11,"Next is the line of Robert Willoughby with Bank of America."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","You mentioned that the WellPoint scripts were coming in below plan. I know they have a contractual obligation to give you a certain amount of scripts. Are they in compliance with that agreement or is the clock running on them to make amends?",43,"You mentioned that the WellPoint scripts were coming in below plan. I know they have a contractual obligation to give you a certain amount of scripts. Are they in compliance with that agreement or is the clock running on them to make amends?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","There's two pieces to this. One is the -- where they're coming up short, for the most part is in the Medicare side of the business. They've loss their Dual Eligibles. We are working very closely with them, hand-in-glove and trying to make sure that they r",115,"There's two pieces to this. One is the -- where they're coming up short, for the most part is in the Medicare side of the business. They've loss their Dual Eligibles. We are working very closely with them, hand-in-glove and trying to make sure that they rectify any situations with CMS and hopefully, they'll be in a position to gain more Medicare lives next year. Keep in mind that that's a two-year test on claim count. So we gain them all back next year, then we're back to par. So we'll just definitely do our share to make sure that they grow their business. Jeff, I don't know if you want to add anything?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","No, I think that's fine. I think you're probably going to hear this from us a lot over the coming quarters. We don't really like to talk in details about individual clients for obvious reasons and we certainly don't plan to change that as it relates to We",76,"No, I think that's fine. I think you're probably going to hear this from us a lot over the coming quarters. We don't really like to talk in details about individual clients for obvious reasons and we certainly don't plan to change that as it relates to WellPoint. I think going forward you're going to hear us say probably on every call and going forward but we're just not going to go into details of WellPoint."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","You touched on the cash flow opportunity from WellPoint coming and moving into your balance sheet metrics basically, it's a big bowls of cash comes through. But am I viewing that as largely a one-time opportunity that could potentially cash flow dip in 20",52,"You touched on the cash flow opportunity from WellPoint coming and moving into your balance sheet metrics basically, it's a big bowls of cash comes through. But am I viewing that as largely a one-time opportunity that could potentially cash flow dip in 2011 from the guidance you've given for this year?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","Robert, you've known us for a long time. We never view cash flow as one time, I will get a new treasurer. We are very focused on ROIC, cash generation and managing our payables and receivables. So obviously, it's a negative working capital business when y",72,"Robert, you've known us for a long time. We never view cash flow as one time, I will get a new treasurer. We are very focused on ROIC, cash generation and managing our payables and receivables. So obviously, it's a negative working capital business when you bring in a new client, we're going to see a spike. But we will continuously work all sides of our balance sheet to improve cash flow."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Operator","Next we go to the line of Larry Marsh with Barclays Capital.",12,"Next we go to the line of Larry Marsh with Barclays Capital."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","On the clinical side, George, you and Dr. Miller have talked a lot about the Home Delivery, the opt out and the benefits there. Your biggest competitors have really talked a lot more about personalized medicine, making investments in it. My question is fr",85,"On the clinical side, George, you and Dr. Miller have talked a lot about the Home Delivery, the opt out and the benefits there. Your biggest competitors have really talked a lot more about personalized medicine, making investments in it. My question is from where you sit in the marketplace, specially now with WellPoint, is that going to be an important focus to provide similar services or is that an area that your customers aren't as focused on and you're not as focused on today?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","If we're talking about personalized medicine, it's really what do you mean by that. If personalized medicine is improving the outcome of the person, one person at a time to we are absolutely focused on that. That's what we do each and everyday. That's wha",392,"If we're talking about personalized medicine, it's really what do you mean by that. If personalized medicine is improving the outcome of the person, one person at a time to we are absolutely focused on that. That's what we do each and everyday. That's what our patient advocates do and we go through a process by which we evaluate each of our members adherence, their drug regimens, gaps in coverage and we address those things. The reality is though identifying those situations, the gap in coverage from whether or not somebody's had the proper testing. All that is important so that we understand the gap. We take a little bit of a different approach though. Think about somebody who's got Express Scripts who has -- they were recorded by a Fortune 500 company who has a managed care plan and they also have a disease management program, so if you're a diabetic and you have all those three touch points, how crazy is it if you've got three different people calling on you trying to influence your behavior. It gets old and it doesn't necessarily work. Our job is not to be the one who's going to necessarily make that call. Our job is to empower through that client to figure out who is the best deliverer of that care in order to improve that individual's healthcare outcomes. So if it's our role, if we are the one selected by having a meeting with our client and the other healthcare vendors, then we're happy to do that and we do that for a lot of clients. However, if it's better orchestrated to the Disease Management Program by feeding the health information from the managed-care player and the PBM, we want to be part of that solution. we're not an eagle driven company where we have to be the one who's out in front. We want to drive better healthcare outcomes for that member. And so it goes into everything. We can monitor per testing, we'll do the proper test for the individual at the right time and we'll make sure that those gaps in coverage are all taken care of. But we want to operate in our place with our clients to improve their members outcomes. If we do that, we'll maintain our current retention rates and we'll grow our business."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","You're guiding to an EBITDA for just the script that's comparable fairly to one of your peers. But you still have Caremark that reports an EBITDA of over $4. I know in the past your guidance, there's no reason you wouldn't be as profitable as your peers g",76,"You're guiding to an EBITDA for just the script that's comparable fairly to one of your peers. But you still have Caremark that reports an EBITDA of over $4. I know in the past your guidance, there's no reason you wouldn't be as profitable as your peers given the value drive the market. Over the long term, is there any reason to think you couldn't close that gap with at least one of your peers?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","We will definitely be focused on that gap. I also -- I think you've heard us say in the past that you never manage business by any metric, whether its growth in revenues, whether its growth in scripts or whether it's EBITDA per script, we have to measure",169,"We will definitely be focused on that gap. I also -- I think you've heard us say in the past that you never manage business by any metric, whether its growth in revenues, whether its growth in scripts or whether it's EBITDA per script, we have to measure our business across all metrics. Otherwise, you'll find yourself doing things that probably aren't prudent for the long term. So obviously, WellPoint is a very big company. And when you buy, we get involved with something big like that, it can have a negative impact on EBITDA per script. Of course the other side of this equation is, we have our model of alignment. So as we were closer with WellPoint improve their home delivery, improve their generic fill rate, work with them to drive clinical programs, our EBITDA per script will go up. So our focus is to make sure that we're doing smart things and then driving the metrics that even make it look smarter in the long run."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","NextRx said I think 2011 adjudication platforms and I know George always talk about how important it is to get to one to move to anchor. To elaborate, it's just kind of a step function you are trying to consolidate one or so a month to get to that 12 mont",61,"NextRx said I think 2011 adjudication platforms and I know George always talk about how important it is to get to one to move to anchor. To elaborate, it's just kind of a step function you are trying to consolidate one or so a month to get to that 12 month goal or should we not think of it that way?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","I think I'm just going to go back to what I said about a minute ago. We're just not going to go into details around WellPoint. We're very happy with how the integration is going, both sides are engaged and working very hard. You've heard us say this a mil",76,"I think I'm just going to go back to what I said about a minute ago. We're just not going to go into details around WellPoint. We're very happy with how the integration is going, both sides are engaged and working very hard. You've heard us say this a million times before, we believe one platform is the only way to go and we will get everything under one platform as we get it integrated."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Operator","Next is the line of Ricky Goldwasser with Morgan Stanley.",10,"Next is the line of Ricky Goldwasser with Morgan Stanley."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","Just in clarification on the guidance range, do you assume any additional membership losses associated with the normal course of integrating the business in addition to the Part D losses that we know of? And then secondly, when you think about your cash f",63,"Just in clarification on the guidance range, do you assume any additional membership losses associated with the normal course of integrating the business in addition to the Part D losses that we know of? And then secondly, when you think about your cash flow, the guidance is for a very strong cash generation, are you factoring any buybacks in your numbers for '10?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","As it relates to the first part of the question, we're already factoring in additional losses. I'm not going give specific comments but certainly, we look, when we do our budget and forecast every year, we literally do it bottoms up client by client. So w",262,"As it relates to the first part of the question, we're already factoring in additional losses. I'm not going give specific comments but certainly, we look, when we do our budget and forecast every year, we literally do it bottoms up client by client. So we're comparable with what we've assume at this point. As it relates to cash flow, as we look into 2010, obviously, we think the cash flow is going to be strong. And our primary or top focus right now is the bank debt that we have is expiring over the course of the year. So that's going to be our first focus going to take care of that and we've actually assumed in this guidance that we pay off that debt as it comes due. Once we get past that, certainly, our uses of cash hasn't changed from what I've been saying for the past couple of years, which is generally the best use of cash for us is to reinvest in internal projects, we've got a lot of really smart people here that are really delivering and executing, so we like to them money when they have good ideas. Next beyond that is solid accretive acquisitions. Like WellPoint, we're very excited about that acquisition and when we can deploy capital for that, we think that makes a lot of sense. And then we've exhausted bucket one and bucket two, we still have cash flows over it, it ends up going into the buyback category. But primary focus for this year is really the debt that's maturing."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","In the prepared comments you've provided SG&A growth guidance of 6% to 8%, so just to clarify remodel, does that include -- should we view that as GAAP or non-GAAP SG&A number? Because it's in a lot of the amortization flows through the SG&A?",45,"In the prepared comments you've provided SG&A growth guidance of 6% to 8%, so just to clarify remodel, does that include -- should we view that as GAAP or non-GAAP SG&A number? Because it's in a lot of the amortization flows through the SG&A?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","That's non-GAAP.",3,"That's non-GAAP."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Operator","Next is the line of Glenn Garmont from ThinkEquity.",9,"Next is the line of Glenn Garmont from ThinkEquity."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","Just on the M&A front, I mean do you have the capacity just from a sort of an internal integration resource perspective to take on additional PBM acquisitions? Should something become available in the near term?",37,"Just on the M&A front, I mean do you have the capacity just from a sort of an internal integration resource perspective to take on additional PBM acquisitions? Should something become available in the near term?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","The way we're doing our integration with WellPoint is we're treating them as a client and reimplementing them on to our system. We do that hundreds of times a year with new accounts and it's very clean. We bring over the data history without getting in to",130,"The way we're doing our integration with WellPoint is we're treating them as a client and reimplementing them on to our system. We do that hundreds of times a year with new accounts and it's very clean. We bring over the data history without getting in too much detail. We're very good at this I think we are always rated very high if not the highest in our industry on implementations. And so we are -- we've got to focus on this and this is something we do all the time. I think we're a very opportunistic company. So if there's opportunities out there, I do believe we have the manpower. We have the capabilities and we have the financial wherewithal to take advantage of opportunities as they arise."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","Obviously, we're proud of our team. We think we have a world class team on M&A and on integration. And when we find opportunities that the value to us is in line with the price, we stand ready to go and execute.",42,"Obviously, we're proud of our team. We think we have a world class team on M&A and on integration. And when we find opportunities that the value to us is in line with the price, we stand ready to go and execute."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Operator","It's from the line of Steven Valiquette from UBS.",10,"It's from the line of Steven Valiquette from UBS."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Analysts","Based on some recent survey work that we've done, it seems more and more PBM customers are starting to rank specialty drug cost curtailment at the top of the list of priorities when thinking about their PBM. So I'm just curious, do you think you have full",79,"Based on some recent survey work that we've done, it seems more and more PBM customers are starting to rank specialty drug cost curtailment at the top of the list of priorities when thinking about their PBM. So I'm just curious, do you think you have fully adequate infrastructure and capabilities in that regard in terms of addressing that issue or is this something you are sort of analyzing more carefully. What are your general thoughts around that?"
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Executives","When you think about what's taking place in our industry and our ability to control the oral solid space, I think all PBMs do a decent job. I think we're second to none. But we have a focus here because were able to put together strong formularies. There'",344,"When you think about what's taking place in our industry and our ability to control the oral solid space, I think all PBMs do a decent job. I think we're second to none. But we have a focus here because were able to put together strong formularies. There's a healthcare summit taking place today and there's going to be a lot of conversation around how you curtail costs and improve health outcomes and try to capitalizing costs. Part of this has got to start with getting generics into the specialty space. Without that lever, there's a lot of things we can do. We can do power authorizations, we can do step therapy, we can do counseling, we can focus on adherence. But really to drive costs, we need competition. The best form of competition is generics entering into this marketplace. With the entry of generics, it also forces the manufacturers to continue to evolve new innovative products in space that already exists. And I think the combination of those things, new brand launches coming to market coupled with a pipeline of generics that are taking the place of older products that have been out there, gives us the tools we need to help actually drive down costs. That is, by the way, the number one thing that we hear about from clients today. Because we do do a good job of controlling costs in the oral solid space. But you're looking at mid-teen type inflation rates in the specialty space. This has got to come under control. And the best way to do that again is through competition. So we hope as part of this healthcare summit, with or without the answer to overall healthcare, there is no reason that specialty pathway for generic drug shouldn't come to get through Congress. We need that to control costs in the future.Again, we appreciate everyone giving up your morning to be with us. And appreciate you following our company and we look forward to talking to you in the near term. Have a great day."
317975,85086214,51632,"Express Scripts Inc., Q4 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, that does conclude your conference for today. Thank you for using AT&T Executive TeleConference Service. You may now disconnect.",22,"Ladies and gentlemen, that does conclude your conference for today. Thank you for using AT&T Executive TeleConference Service. You may now disconnect."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the First Quarter 2010 Earnings Conference Call. [Operator Instructions] I now like to turn the call over to the Vice President of Investor Relations, David Myers.",37,"Ladies and gentlemen, thank you for standing by, and welcome to the First Quarter 2010 Earnings Conference Call. [Operator Instructions] I now like to turn the call over to the Vice President of Investor Relations, David Myers."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, and good morning, everyone. Welcome to our First Quarter Conference Call. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO.Before we begin, I need to read the following statement. Statements or comments made on this",186,"Thank you, and good morning, everyone. Welcome to our First Quarter Conference Call. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO.
Before we begin, I need to read the following statement. Statements or comments made on this conference call may be forward-looking statements and may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. 
These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors, which are discussed in detail in our SEC reports. 
For clarity purposes, all numbers we talk about today will be on an adjusted basis. Please refer to the tables on our press release for reconciliation of GAAP to the adjusted numbers we will be discussing. The reconciliation of EBITDA to net income can also be found in our earnings release. Earnings release is posted on our website.
Now at this point, I'll turn the call over to Jeff, who'll discuss our first quarter financial results."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, David. Yesterday, we reported solid first quarter EPS of $1.10, which represents an increase of 25% over last year. Other highlights in the quarter were EBITDA per Rx at $2.92, the high end of our guidance range for the quarter. Cash flows from",517,"Thank you, David. Yesterday, we reported solid first quarter EPS of $1.10, which represents an increase of 25% over last year. Other highlights in the quarter were EBITDA per Rx at $2.92, the high end of our guidance range for the quarter. Cash flows from operations was strong at $761 million, up 166% from the prior year. We made significant progress with the implementation of NextRx live and now have more than 15% integrated onto our system. And we raised the low end and midpoint of our EPS guidance range for the year.
Last year, we indicated that our focus for uses of cash in the first half of the year would be the $1.3 billion of 2010 debt maturity. This is still our primary focus. However, as a result of strong cash flow, which includes $25.7 million from our 338(h)(10) election for NextRx, we were able to repurchase 2.2 million shares and repay $180 million of debt in the quarter. We still expect cash from operations for the year to be more than $2 billion.
Our Q1 results reflected a full quarter of both NextRx, which closed on December 1, and the new DoD contract, which was implemented on November 4. As you know, we began recording DoD revenues on a gross basis which increased revenues and cost of revenues by $2 billion in the quarter. 
Gross profit dollars increased 35% from last year. However, as a result of the change in DoD revenue and the addition of the NextRx business, gross profit margin declined to 6.4% from 9.8%. As we continue to make progress executing our integration plan, we expect gross profit margin to increase sequentially.
During the quarter, our focus is on the successful start up of our new clients, including NextRx, which resulted in a higher level of spending charged to cost of goods sold. As a result of this focus, we also spent less on SG&A projects than we were in subsequent quarters. We continue to expect that SG&A, excluding charges and amortization, will be $865 million to $881 million for the year. 
As a result of our performance so far this year, we're now expecting earnings per share, excluding transaction-related charges and amortization, to be in the range of $4.85 to $5. This range represents a growth of 23% to 27% over 2009, excluding three closed financing costs last year. 
After our call last quarter, we realized that while EPS and EBITDA estimates were in line with our guidance, many of the details were not. As a result, mid-quarter, we provided specific guidance for several line items, including revenue and SG&A. We provide the details on our IR website. Please consider our detailed guidance as updated[ph], as you adjust your model for the remainder of the year.
As the year progresses, you will see us rationalize our footprint, eliminate redundancies, implement more eyes [ph] onto our system and realize synergies as we made progress towards delivering to more than $1 billion in incremental EBITDA we expect to achieve in the NextRx transaction. 
And with that, I'll turn it over to George."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, Jeff. Good morning, everyone. In addition to solid financial performance, we've been successful on a number of fronts this year. Earlier this month, we successfully integrated the first major group of NextRx slides onto our platforms. This migr",526,"Thank you, Jeff. Good morning, everyone. In addition to solid financial performance, we've been successful on a number of fronts this year. Earlier this month, we successfully integrated the first major group of NextRx slides onto our platforms. This migration represented over 15% of total membership. 
Our focus on integration is continuing. This will allow us to provide Express Scripts high level of services and tools to NextRx patients and clients. In turn, this will help WellPoint maintain and grow its business.
Last week, we held our outcomes conference in St. Louis and simultaneously released our industry-leading Drug Trend Report. The Drug Trend Report quantifies and analyzes the underlying factors that influence prescription spending patterns in the United States. 
Following several years of declines, overall drug trend increased to 6.4%. Traditional PBM trend was 4.8%, while specialty trend was 19.5%. These trends were mainly driven by branded-drug price inflation of 9.1% on the traditional side and 11.5% on the specialty side. 
Of course, those clients can actively take advantage of our tools, can drive their drug trends to zero or below. In order to come back to these increasing trends, we are pleased that healthcare reform legislation has empowered the FDA to establish a regulatory pathway for the approval of biogenerics. The availability of these lower cost drugs will significantly change the industry landscape and provide opportunities to leverage our expertise in innovative ways.
This year in our Drug Trend Report, we reported that a strong influence or a drug trend is patient behavior. As a result, our Drug Trend Report includes a first time analysis of pharmacy-related behaviors that if optimized, could eliminate $163 billion in annual pharmacy-related waste resulting from non-adherence, drug mix and distribution channel. Over the next 10 years, over $2 trillion could be saved by better management of prescription drug trend.
These findings could never be more timely or relevant. The message from our clients is loud and clear. In these economic times, they're willing to try new strategies to garner lower costs, optimize health outcomes and reduce member disruption. 
Fortunately, we have a solution for their dilemma. And that is the application of proven programs that leverage our behavior-centric approach. The power of these programs is that they are voluntary, at the member level, but effective in encouraging the optimum clinical behavior. This means driving greater therapy adherence, greater use of generics and clinically equivalent lower-cost brands and increasing usage of home delivery. 
Much of our success over the years has been attributable to our business model alignment. That is, if we save our clients and patients money, our performance improves. For example, last year, Express Scripts clients saved $1.4 billion from greater use of lower-cost brands and generics. The work with our clients in addressing patient behavior drove approximately $790 million of these savings over and above market factors, such as branded patent expirations.
Our world-class clinical tools powered by our behavior-centric approach is resonating in the marketplace. Since it is still early in the sales season, we will update you on our sales results later this year. 
At this point, we'll be happy to answer any questions. Operator?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","[Operator Instructions] And our first question today will come from the line of Larry Marsh with Barclays Capital.",18,"[Operator Instructions] And our first question today will come from the line of Larry Marsh with Barclays Capital."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","One is, it seems like a key part of the strategy besides integrating NextRx is to continue to drive value to your customers, extending [ph] base of business. I guess my question is, how would you and Ed and his team defend any sort of efforts of aggressiv",74,"One is, it seems like a key part of the strategy besides integrating NextRx is to continue to drive value to your customers, extending [ph] base of business. I guess my question is, how would you and Ed and his team defend any sort of efforts of aggressive pricing in the marketplace? And what are you guys hearing so far in your best and finals in terms of customer concerns or feedback around pricing?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","I think that every year, pricing is an issue for us, only because of the dynamics of our industry. When you think about what happens in our industry, is we just talk about high drug trends, inflation rates that are growing at very fast rates. So think abo",754,"I think that every year, pricing is an issue for us, only because of the dynamics of our industry. When you think about what happens in our industry, is we just talk about high drug trends, inflation rates that are growing at very fast rates. So think about a static situation. In a static situation, you don't have a lot of moving parts, and so price is easier to look at. But when you have drug prices that are growing at 9%, 10%, 11%, spending of your traditional or your specialties, and you got drugs losing patent protection, you got generics, some of which are steady, some which might have a slight increase, some of them are actually declining. This is a very dynamic pricing metric with thousands and thousands of price points. And then on top of all that, we got our pricing tools. As I tell Ed and I tell our sales team and when I have a chance to talk to our clients, pricing is clearly an important component of our business. It's important piece of any business. I really don't believe though that our business is commoditized. I think that there are -- at the end of the day, it's the relationships, similar to most of your businesses where you're dealing with investors. You have to show your rates of return and you have to have the relationships, the tool and everything that helps sell your business to your clients. We have to have the same thing in our business. We have to have good account managers. We have to have clinicians that are leading edge are going after the client and discussing changes that are taking place in the marketplace and giving them options to understand the market. Our account management team has to understand the predicament or the opportunities that sit in front of our clients to understand labor contracts, changing market dynamics, the financial straits of any given corporation to understand what opportunities may exist. And then all that, once we create the strategy, is that how do you implement that strategy. And that's where consumerology kicks in. So it's not just trying to push a step therapy onto a target bunch of individuals. But instead, try to get those individuals to resonate with the message to take control of their spend and become part of the solution, as opposed to part of the problem. So I think there's a lot more to our business than pricing. Also keep in mind that not all clients were going to resonate with any given PBM. Our whole approach is around the consumer-centric side. That resonates with a lot of companies. Some companies aren't necessarily going to take that approach, and they're going to go to one of my competitors. Obviously, some of my competitors have different approaches, that's going to resonate with other clients. So I do think that as we look at the pricing environment, and you've heard me say this since 1998, every year is a tough year. Every year, we have to look at what's taking place in the marketplace and meet the needs. I'm a very competitive person. I hate to lose. But also to be smart enough not to win, if it's not right for business. If, in fact, a client is looking to go a direction that our business isn't equipped to do, in other words they're not going to promote generics, they don't want to promote mail, they don't want to put in ant kind of programs. They want to put in programs that don't line up with our formulary. Those are not clients we need to win. And keep in mind, that clients are on static either. Clients have changes in their HR department. A new person comes income that came from a different company of a new approach, and they want to shake up the company. They want to put a different type of formulary. And if it doesn't line up with our programs, we may lose that client. At the end of the day, I don't like losing clients. But if we lose it for the right reasons, then you move on. And I think every time we win or lose a major account, we just don't sale, good or bad. We sit down and we analyze what took place and try to make sure we stay competitive in the market. Pricing is just one factor that goes into the overall decision on how wide a PBM is selected."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, and so is it -- from where you said here early in the selling season, it sounds like you're saying -- are you seeing any difference in pricing behavior in the marketplace? Or based on what you said, is pricing always a conversation in these meetin",47,"George, and so is it -- from where you said here early in the selling season, it sounds like you're saying -- are you seeing any difference in pricing behavior in the marketplace? Or based on what you said, is pricing always a conversation in these meetings?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, I wish I could go get the tape from 1998. I think I said the same thing. It's extremely competitive market, it's always been extremely competitive because we're not selling to individuals, we're selling to businesses. Businesses are sophisticated. T",278,"Well, I wish I could go get the tape from 1998. I think I said the same thing. It's extremely competitive market, it's always been extremely competitive because we're not selling to individuals, we're selling to businesses. Businesses are sophisticated. They're good purchasers. And so what we've got do is we got to resonate that our tools can drive down costs. I said this many time over the years, you can take an extra dime or quarter out of me, But that's a fraction of the savings. If you really want to save money, let's convert 10% from retail to mail. Let's convert a 3% increase in generics. Let's drive people to lower-cost brands if you have a high three-tier element. Let's start eliminating drugs off the formulary and getting it more focused, driving up rebates, driving up the use of low-cost brands. All those tools are going to dwarf whatever the price point is. Take my total profit and divide it by my total scripts, do the same thing for my other two biggest competitors and for the other players in the industry, there's not enough money there at the end of the day to make the big changes. The money to be made is in how you affect drug trends, and we do that through the behavioral approach. If I can go in, if the clients looking for another $0.50 of script off, but that I can drive a dollar off by influencing those behaviors with the right programs and the right outcomes, I'm a hero. And that's our job of our account management team is to be that hero for every one of those clients."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, you guys are, I guess, very aggressive in 2005 in getting in front of Zocor to really promote the brand savings into simvastatin. Are there other opportunities to be creative or innovative coming into the Lipitor cliff here at the end of 11? Or is",57,"George, you guys are, I guess, very aggressive in 2005 in getting in front of Zocor to really promote the brand savings into simvastatin. Are there other opportunities to be creative or innovative coming into the Lipitor cliff here at the end of 11? Or is this story still too early to communicate any kind of programs?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","No, I think that's a great question. As you know, Larry, what ends up happening as drug starts to lose their patent protection, typically, they're not supported by the manufacturers. So you see there's a whole lot of erosion in market share that can take",187,"No, I think that's a great question. As you know, Larry, what ends up happening as drug starts to lose their patent protection, typically, they're not supported by the manufacturers. So you see there's a whole lot of erosion in market share that can take place in the year leading up to the loss of the patent. So our job is to make sure the clients understand why that erosion is taking place. Sometimes other competing products can increase rebate offers to drive behavior or do more advertising and more detailing. Our job is to give the clients their alternatives and let them decide, do they one first year economic benefits of driving to a different position, or do they want to maintain their share and get a higher pull-through on the generic when it grows. I think, again, this isn't one-size-fits-all. We've got thousands and thousands of clients in our account management team working with Dr. Miller, our Chief Medical Officer, is to go out and design the programs that make the most sense for each and every client, to meet the needs of that client."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question will come from the line of Lisa Gill with JPMorgan.",13,"Our next question will come from the line of Lisa Gill with JPMorgan."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, I just had a couple of questions around Select Home Delivery. Can you just give us some thoughts around what you're hearing in the marketplace and what the opportunities are? I know you said that it's early for 2011, but my guess would be that you",110,"George, I just had a couple of questions around Select Home Delivery. Can you just give us some thoughts around what you're hearing in the marketplace and what the opportunities are? I know you said that it's early for 2011, but my guess would be that you're out and you're making presentations. And I'm just wondering, what you're seeing as far as interest and uptake around that program. And then secondly, on the specialty side, maybe can you quantify the opportunity in your book of business? Can you maybe give us a percentage of your PBM customers that are using your specialty business today, and what the potential opportunities are?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Sure. That's a very, very popular program. We're seeing -- if you look at same-store sales, we're up about 7%, thereabouts, in mission [ph]trends. And keep in mind, that a lot of these clients are just kicking off. So they're hitting their first block at",470,"Sure. That's a very, very popular program. We're seeing -- if you look at same-store sales, we're up about 7%, thereabouts, in mission [ph]trends. And keep in mind, that a lot of these clients are just kicking off. So they're hitting their first block at retail. Obviously, they can opt out of that block but this is -- so it's very early on. And we're seeing some very nice pull-through again on a same-store basis. We got over 200 clients that have selected the program and seeing some very strong results. Now keep in mind, that a client is already at 40%, the pick up is going to be not nearly as great as the client that's at 5%. So the results vary by client. But still the impact, the movement of 1% or 2% is still pretty significant, especially in tough economic times. So I think the program is working very well for us. And I think what the clients like most is when we come in and we put -- it's dependent, again, on a client. If a client has a tough situation and they need immediate savings fast, then they can put in exclusive home delivery. And then obviously, they get the bump right away. They may not have a choice, they may need to do that in order to garner the savings. But where there is a choice, they can, in fact, put in Select Home Delivery and get almost to the same level of results, not quite, but they can get fairly close by just letting our teams use consumerology to drive. What we see in a couple of clients is that they've actually put in Select Home Delivery, they've ran that for a while, they took a couple of cases, they took it from low teens, up to the high 30s percent penetration rates. And then they put in exclusive home delivery because at that point, they've converted so many [indiscernible] to mail, that the next step was then just to go ahead and get the rest of them, maximize the savings, and it was already a very widely accepted benefit inside the company. So it can be -- Select Home Delivery can either be a stand-alone product or it can be a stepping stone to exclusive home delivery. So it's what the client needs in their timing. As far as specialty goes, specialty has been one of our bright spots. We don't break it out any longer, because we really do believe it's just one of our tools to battle overall drug trends. But this year has been an incredible year for us, an exclusive in specialty. We've seen margin expansion. We've seen significant increase in the number of prescriptions in this area. And so we're really excited about our specialty offering today."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Can you give us an idea though of how penetrated your book is? And how big that opportunity remains around specialty to fully penetrate specialty and your PBM book of business? Do you have a number around that?",38,"Can you give us an idea though of how penetrated your book is? And how big that opportunity remains around specialty to fully penetrate specialty and your PBM book of business? Do you have a number around that?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","There's two pieces to this. One is, how much do we penetrate into our existing book. And then the other piece is, this is clearly the fastest-growing area of PBM. So those are two -- I'm not trying to avoid your question. I just don't have a number off th",80,"There's two pieces to this. One is, how much do we penetrate into our existing book. And then the other piece is, this is clearly the fastest-growing area of PBM. So those are two -- I'm not trying to avoid your question. I just don't have a number off the top of my head. I'm not exactly sure I know what the penetration rate on my clients is today. So I'll have to try to get that for you."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","But I think it would be fair to say, George, right, that there's still a lot of runway here, that there's still a lot of opportunity around Specialty?",28,"But I think it would be fair to say, George, right, that there's still a lot of runway here, that there's still a lot of opportunity around Specialty?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Absolutely.",1,"Absolutely."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Absolutely, Lisa. There's lots of room to run in this space where, as George said, we've seen very nice growth. And we think there's lots of opportunity over the coming years, to really grow this business and grow it nicely. This is a huge area spend for",83,"Absolutely, Lisa. There's lots of room to run in this space where, as George said, we've seen very nice growth. And we think there's lots of opportunity over the coming years, to really grow this business and grow it nicely. This is a huge area spend for our clients. This is an area where you can really help and save a lot of money. And we think we have unique offering in this space, and we're going to see this grow our business."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","The other side to that, just to pile on. I think that when you think about behaviors, this is an area that's ripe for this, and that we're going to see a massive opportunity when you think about Consumerology. The side effect profile, the results that the",147,"The other side to that, just to pile on. I think that when you think about behaviors, this is an area that's ripe for this, and that we're going to see a massive opportunity when you think about Consumerology. The side effect profile, the results that these disease have on a given family can be devastating. And so being able to message both the doctors, the patients, the nurses, all that's up and down in that ladder, are incredibly important. And as biogenerics come into this marketplace, it's going to be very important that we're out in front of that, because once somebody gets them that first fill, it's going to be hard to get them to change if they stabilize. So giving the information to the doctors, they know what the options are, are very, very important. So this is a big, big thing for us."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, you talked about gross profit and you talked about it improving throughout the year. Can you just help us understand this. Is it the incremental cost of employees that you had in COGS for implementation and integration that will go away? Or is there",59,"Jeff, you talked about gross profit and you talked about it improving throughout the year. Can you just help us understand this. Is it the incremental cost of employees that you had in COGS for implementation and integration that will go away? Or is there other key drivers that will drive gross profit as we move throughout the year?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes and yes, is the simple answer. Certainly, the implementation efforts have increased cost of goods sold in the first quarter, and that will trend down over time as we move through the year. But we've also got a lot of programs that's got a large acquis",137,"Yes and yes, is the simple answer. Certainly, the implementation efforts have increased cost of goods sold in the first quarter, and that will trend down over time as we move through the year. But we've also got a lot of programs that's got a large acquisition that we're in the process of implementing on. We've got an operations team here, which is focused on continuous improvement and they're going to keep driving down costs. And we're just going to keep executing. And I mean, you'd heard us say this time and time again, we are focused on alignment. We make money when our clients make money, and we are going to keep doing everything we can using all of our Consumerology tools to save our clients' money. And as we do that, we'd see margin grow."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Next, we'll go to line of Bob Willoughby with Bank of America.",12,"Next, we'll go to line of Bob Willoughby with Bank of America."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","How much did the base business grow? And can you remind us what you have for start-ups as of July 1, if anything? And then secondarily, is it possible to say in any way, shape or form, of the incremental billion you hope to generate from the WellPoint dea",67,"How much did the base business grow? And can you remind us what you have for start-ups as of July 1, if anything? And then secondarily, is it possible to say in any way, shape or form, of the incremental billion you hope to generate from the WellPoint deal? What you actually saw flow through, what percentage of that might have been apparent in the first quarter?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Bob, this is Jeff. Let me just say this just upfront. No, I'm not going to answer the second part of your question. And yes I can, and no I'm not going to. We're just not going to break it out. Actually, it's pretty hard to break it out, as it's integrate",138,"Bob, this is Jeff. Let me just say this just upfront. No, I'm not going to answer the second part of your question. And yes I can, and no I'm not going to. We're just not going to break it out. Actually, it's pretty hard to break it out, as it's integrated into the core business. As we think back to -- I'm sorry, I forgot the first part of -- in the core business on a Script basis, we obviously had a good selling season last year, we said. So I think we haven't been precise other than to say that, in the core business, year-over-year, we expect growth in Scripts. And so I'm not going to get a whole lot more detailed than that. But certainly, we think the core business, x WellPoint, certainly was growing."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Is there a July 1 start-up of any consequence or...",11,"Is there a July 1 start-up of any consequence or..."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","No meaningful July 1. I mean, it certainly doesn't move the numbers from that, I see one way or the other.",21,"No meaningful July 1. I mean, it certainly doesn't move the numbers from that, I see one way or the other."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","And we factored those already into our guidance, Bob.",9,"And we factored those already into our guidance, Bob."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And you've given us a number of line items for guidance, but nothing on your share base. Where do you expect that to be for the year?",28,"And you've given us a number of line items for guidance, but nothing on your share base. Where do you expect that to be for the year?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","It's really hard to predict share base, so we try to stay out of that game, because it's so dependent on where the share price goes, over the course of the year. When we gave our original guidance, we assumed some kind of de minimis impact from share buyb",95,"It's really hard to predict share base, so we try to stay out of that game, because it's so dependent on where the share price goes, over the course of the year. When we gave our original guidance, we assumed some kind of de minimis impact from share buybacks, 1% to 2%. We still think that we'll get about 1% to 2% of EPS gain from share buybacks. So I think you can model that in, but that would get you to a place that's probably not meaningfully different than where we are today."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is coming from John Kreger with William Blair.",11,"Our next question is coming from John Kreger with William Blair."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, if you think about the renewal discussions you're having today and maybe contrast them to a year ago, or clearly, in a different economic place broadly, how have those changed? And is your WellPoint combination influencing those discussions? How d",44,"George, if you think about the renewal discussions you're having today and maybe contrast them to a year ago, or clearly, in a different economic place broadly, how have those changed? And is your WellPoint combination influencing those discussions? How do clients perceive that?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","At the end of last year, throughout the third and fourth quarter and even into the first quarter, I think that many clients asked the question, how will WellPoint integration affect us? Will we lose our account manager? Will it change the timeliness of ou",275,"At the end of last year, throughout the third and fourth quarter and even into the first quarter, I think that many clients asked the question, how will WellPoint integration affect us? Will we lose our account manager? Will it change the timeliness of our reporting? Anytime a company goes through a major acquisition, from the client-side, there's always a little bit of noise. And the reason that noise exist, of course, is my competitors are up at their tone [ph]. The noise should exist. And as you know, we've done a lot of these things. And we've grown both organically -- we've grown organically through our acquisitions. So as we've added more and more lives into our business, we've always kept the discipline around selling and around growing the base. And that continues to be our focus. And the best thing that happened to us in the first quarter was the migration of the first tier. Because now the clients can, when they ask the question, ""How am I going to be affected?"" we say, ""Well, how are you affected in the first quarter?"" And most of them didn't sense a thing. None of them, to my knowledge, had any concerns, any issues, nothing. It's not only is it operations as normal, it's a continued focus on Consumerology and driving out the waste. And they didn't even know what occurred. And that's the best view of an integration. And I think if you reach out to the consultant community and ask that question, you'll hear that same comment that the integration is going extremely well and that there is not noise on the street."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Are you seeing client priorities change at all now that presumably, they are maybe a little less worried about the economic backdrop?",22,"Are you seeing client priorities change at all now that presumably, they are maybe a little less worried about the economic backdrop?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well,  I think CEOs and CFOs, at least the ones I know, and I know quite a few, are still very worried about the economic backdrop. A lot of the companies we deal with are global in nature, and you got some issues in Greece and Spain and on and on and on.",334,"Well,  I think CEOs and CFOs, at least the ones I know, and I know quite a few, are still very worried about the economic backdrop. A lot of the companies we deal with are global in nature, and you got some issues in Greece and Spain and on and on and on. And I think that companies have to make tough decisions back in the last year in reducing workforce and making cost-cutting moves. The last thing a CEO wants to do to his organization is to have a roller coaster ride. I think it's going to take a little while before employment comes back. I think companies are going to want to make sure that, that light at the end of the tunnel isn't a train, and they're going to make sure that they, in fact, can see their way. So I think the focus today is every business is focused on cost reduction as possible. Keep in mind, that really plays into our sweet spot. We've been out there for 15 years talking about cost constraints around these things that were really better for health outcomes. And we only got so much noise. Over the last couple of years, it's resonated with companies. And now what companies realize is, in fact, they were able to get those cost savings. We didn't impact members unfavorably. We actually improved clients and member satisfaction, and at the same time, reduced cost. So once we got that training in place, with the clients understand they can take out the cost, while not adversely affecting their relationship with their members, that sets the driveway into the coming years. Even as the economy turns, I think the work we did during this last couple of years paves the way, especially to the earlier question about Lipitor, and other drugs that are coming off patent, to really position us nicely to take advantage of those opportunities. And I have to worry about member disruption to the same level."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Next, we'll go to the line of Ross Muken with Deutsche Bank.",12,"Next, we'll go to the line of Ross Muken with Deutsche Bank."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Given sort of the renewed focus on sort of attracting larger clients and what you'd call kind of the marquee accounts, can you talk a bit about the strategy there for this selling season? And what sort have you learned from WellPoint? And how you're using",70,"Given sort of the renewed focus on sort of attracting larger clients and what you'd call kind of the marquee accounts, can you talk a bit about the strategy there for this selling season? And what sort have you learned from WellPoint? And how you're using some of the newer parts of the Consumerology offering to kind of use as a differentiator as you attempt to attract those accounts?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","When we go into this year, we're looking at opportunities again. The opportunities -- there's a lot of opportunities out there, just to be clear. And we would need to find opportunities that resonate with our book of business, as I said earlier. So that's",256,"When we go into this year, we're looking at opportunities again. The opportunities -- there's a lot of opportunities out there, just to be clear. And we would need to find opportunities that resonate with our book of business, as I said earlier. So that's always the first call, is to make sure we can find those clients that want our offerings, that has to accept our approach, and then we can stay focused on the core things we do. So once that occurs and we find them, then I think it goes back to Consumerology and our approach. We love going into a client, and not only signing off on day one, but then selling them Select Home Delivery. In addition to that, our teams are working very hard on other programs, such as step therapies and other similar-type programs, in order to -- limited networks and curtailing are shrinking the size of the formularies. We're doing a lot of different things in using the Consumerology approach to attack those situations. Also, adherence is a major, major driver. As I said in my prepared comments, there's $163 billion, the majority of which is attributable to adherence. That's an opportunity for us to drive down overall healthcare costs. And so that's our approach to the marketplace. That's what we try to get to resonate, not just with marquee clients but any client. We're looking at opportunities in all of the different segments we operate in. And we're trying to drive better cost outcomes for our clients."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And Jeff, on the balance sheet, you have a lot of cash flow that's being generated this year. You're obviously paying down some debt and buying back some shares. But from an M&A standpoint, how are you thinking about sort of the environment? There's a lot",85,"And Jeff, on the balance sheet, you have a lot of cash flow that's being generated this year. You're obviously paying down some debt and buying back some shares. But from an M&A standpoint, how are you thinking about sort of the environment? There's a lot of assets right now in the private market. And also, potentially, with the financing environment still being attractive, people are looking at other types of deals. How would you sort of characterize the activity you're seeing on that front?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Obviously, I'm not going to comment on specific deals. But I think our position, my position, hasn't really changed over the years here. It's pretty simple. We look at opportunities for our cash. And I mean, absolutely you're right, we certainly got a ver",226,"Obviously, I'm not going to comment on specific deals. But I think our position, my position, hasn't really changed over the years here. It's pretty simple. We look at opportunities for our cash. And I mean, absolutely you're right, we certainly got a very strong cash flow year, and we have a very strong cash balance. So certainly, as I said in my prepared remarks, first goal is to pay down, pay off the debt that's coming due here in 2010. But even after that, we're left with a very strong cash position. And as we look at that cash position, we say, first off, we want to invest in the projects that are driving this company. We've got a bunch of great people here. They always have great ideas, and we want to invest in those ideas and keep driving our return on invested capital with new ideas. After that comes M&A. Certainly, we've had great experience with good accretive M&A over the life of this business. We're happy with the M&A. We're integrating at the moment with NextRx. And to the extent there are more opportunities out there that we think have the same kind of positive returns, we're anxious and interested at getting them done at the right price and the right terms. But other than that, it's hard to comment on specifics."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is coming from the line of Tom Gallucci with Lazard Capital Markets.",15,"Our next question is coming from the line of Tom Gallucci with Lazard Capital Markets."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","I guess on the selling season, as it pertains to WellPoint, you sort of talked about customers wondering how it was going to impact that negatively. What about from a positive standpoint, do you feel like you're positioned any different this year in the s",71,"I guess on the selling season, as it pertains to WellPoint, you sort of talked about customers wondering how it was going to impact that negatively. What about from a positive standpoint, do you feel like you're positioned any different this year in the selling season for different types of customers, given the bigger scale that you've got? And is there any sort of tangible evidence of that at this point?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Ed Ignaczak and his team is really focused on integrating our approach and our sales into the WellPoint approach. I think when you look at our website, when you look at our tools and what we can do, it's significantly better than what NextRx has to offer",298,"Ed Ignaczak and his team is really focused on integrating our approach and our sales into the WellPoint approach. I think when you look at our website, when you look at our tools and what we can do, it's significantly better than what NextRx has to offer today. So we're trying to integrate our sales approaches and we're holding sessions with the NextRx people to update them on how to sell PBM, and how to approach the marketplace, how to be better at it. As I've told my counterpart over at WellPoint, our view is, I would prefer to grow through them as to grow directly. It's a tremendous opportunity for us to combine our forces in order to grow our joint book of business. And we are absolutely fixated on that, and it's a great approach to the marketplace. So yes, I think the real value, though, is still a couple of years out. I shouldn't say a couple years, it's probably more than a year though. And that is to really get an integrated approach to the marketplace on the overall medical and drug lab, the whole spectrum of care brought together. And I know WellPoint is absolutely fixated on that, as well as we are, to change the way healthcare is delivered in this country, and really to start taking costs out of the equation in order to meet the needs of the country. So that's something we are continuously working on. We both have set up working groups to focus on that as we go forward, and it will stay one of our priorities. And once we get to the integration, we'll keep you updated on what we're doing here. And I think we're just going to have a great offering in the future."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","On Select Home Delivery, are you seeing any concentration of particular types of customers that are interested in that, ones that already have a lot a mail or don't, or employers versus health plans?",34,"On Select Home Delivery, are you seeing any concentration of particular types of customers that are interested in that, ones that already have a lot a mail or don't, or employers versus health plans?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","It's been mostly on the employer side, initially, but now we've got several health plan clients that have actually rolled it out this year. So we're seeing it on both sides. I would tell you that it's also across-the-board. We've had clients with very lit",137,"It's been mostly on the employer side, initially, but now we've got several health plan clients that have actually rolled it out this year. So we're seeing it on both sides. I would tell you that it's also across-the-board. We've had clients with very little mail penetration and has seen significant increases in mail penetration through the programs. We've also had clients that had high penetrations. But as you know, as with an aging population, more and more people are going into maintenance medications. And this is a good way to capture those new users of prescription drugs, and convert them over to mail in a timely fashion to continue to drive down costs. So we're seeing it across the spectrum. Probably still today, more on the employer side than anywhere else, but it is across-the-board."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","You've sort of looked at the Medicare PDP, your own Medicare PDP, a little bit differently than your competitors the last couple of years. And now with sort of the way reform looks, are you thinking about that any differently? Or how should we be thinking",60,"You've sort of looked at the Medicare PDP, your own Medicare PDP, a little bit differently than your competitors the last couple of years. And now with sort of the way reform looks, are you thinking about that any differently? Or how should we be thinking about what you're going to do with that over the next few years?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","From my perspective, and I think I've been saying this for quite some time, is that I don't think Express Scripts is a household name. So to compete in the individual market on our margins, I just don't think we have a very good offering. I don't have the",284,"From my perspective, and I think I've been saying this for quite some time, is that I don't think Express Scripts is a household name. So to compete in the individual market on our margins, I just don't think we have a very good offering. I don't have the money that Coca-Cola, Anheuser-Busch InBev, whatever, has these, Procter & Gamble, to spend to go after the consumer marketplace. Our best answer is, we've got great partners with WellPoint and many other brewers plants [ph] and clients that are household names in their marketplace. I would rather partner up with them and have an offering that's recognized in their given geographic area, and go in and try to sell the individual business through them, and give them the tools that they need to be successful. And we grow as they grow. That's always been our strategy. And I think it's a great strategy for them as they pick up the medical side, and it's a great strategy for us when we pick up the drug side. I think if, in fact, you see -- we will see a growth there with the 30 million people coming to the market. How many of those people want to carve out medical from drug at that point. That's a big question. But I think our clients are well positioned to gain their share of the overall comprehensive medical and drug side. And so when they lay in those clients, we'll pick up the drug side through them, which is the best of all answers. So I like where we're positioned. That didn't happen by accident. We focused on this approach, and I'm very pleased with where we sit."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","That question will come from the line of Ricky Goldwasser with Morgan Stanley.",13,"That question will come from the line of Ricky Goldwasser with Morgan Stanley."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","First, I think you said that 15% of lives were migrated by April 1. What percent of lives do you expect to migrate by the end of the second quarter? And then, if you can give us some more color on what percent of year-over-year change in gross profit is f",53,"First, I think you said that 15% of lives were migrated by April 1. What percent of lives do you expect to migrate by the end of the second quarter? And then, if you can give us some more color on what percent of year-over-year change in gross profit is from DoD reallocation?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, a couple of things. We're not going to get in to projecting migration, and it's not really all that relevant at the end of the day. The idea is we have to get the first one done. When you do the first one, you learn so much about the different opera",182,"Well, a couple of things. We're not going to get in to projecting migration, and it's not really all that relevant at the end of the day. The idea is we have to get the first one done. When you do the first one, you learn so much about the different operating platforms and the people. And so the idea is, you get the first one done, and then the other ones come in line. So we haven't laid out a schedule. We said we'd get this done in 12 to 18 months. We're still very comfortable with that approach, and that's what we're going to focus on. We'll give you updates each quarter as we progress. One of the things we have been focused on, though, is making sure that those areas that drive the highest level of synergies are first and foremost in our integration plans. So we're going after those as quickly as we can. Secondly, as far as client specifics, we don't discuss gross profits or profitability on any given client. So I really can't get into that."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","I mean, I guess the question is not really on profitability. There's just been a change, kind of like reallocating in that contract?",23,"I mean, I guess the question is not really on profitability. There's just been a change, kind of like reallocating in that contract?"
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, the contract changed. We now do a lot more things, which by definition, means it's more profitable for us. And we also, because we adjudicate the claims and do many other elements of it, we gross up the numbers into revenue. But I don't want to get",110,"Well, the contract changed. We now do a lot more things, which by definition, means it's more profitable for us. And we also, because we adjudicate the claims and do many other elements of it, we gross up the numbers into revenue. But I don't want to get into specific clients. We just don't do that.
Well, again, I thank everyone for listening in to our call today. We appreciate your confidence in us. And we look forward to the integration of NextRx. We think great things are ahead of us, and we look forward to talking to you again next quarter. Thank you very much. Have a great day."
317975,100362867,58487,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","With that, ladies and gentlemen, that does conclude our conference for today. Thank you very much for your participation, and for using AT&T Teleconferencing. You may now disconnect.",28,"With that, ladies and gentlemen, that does conclude our conference for today. Thank you very much for your participation, and for using AT&T Teleconferencing. You may now disconnect."
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the First Quarter 2010 Earnings Conference Call. [Operator Instructions] I now like to turn the call over to the Vice President of Investor Relations, David Myers.",37,"Ladies and gentlemen, thank you for standing by, and welcome to the First Quarter 2010 Earnings Conference Call. [Operator Instructions] I now like to turn the call over to the Vice President of Investor Relations, David Myers.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, and good morning, everyone. Welcome to our First Quarter Conference Call. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO.Before we begin, I need to read the following statement. Statements or comments made on this",186,"Thank you, and good morning, everyone. Welcome to our First Quarter Conference Call. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO.
Before we begin, I need to read the following statement. Statements or comments made on this conference call may be forward-looking statements and may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. 
These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors, which are discussed in detail in our SEC reports. 
For clarity purposes, all numbers we talk about today will be on an adjusted basis. Please refer to the tables on our press release for reconciliation of GAAP to the adjusted numbers we will be discussing. The reconciliation of EBITDA to net income can also be found in our earnings release. Earnings release is posted on our website.
Now at this point, I'll turn the call over to Jeff, who'll discuss our first quarter financial results.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, David. Yesterday, we reported solid first quarter EPS of $1.10, which represents an increase of 25% over last year. Other highlights in the quarter were EBITDA per Rx at $2.92, the high end of our guidance range for the quarter. Cash flows from",517,"Thank you, David. Yesterday, we reported solid first quarter EPS of $1.10, which represents an increase of 25% over last year. Other highlights in the quarter were EBITDA per Rx at $2.92, the high end of our guidance range for the quarter. Cash flows from operations was strong at $761 million, up 166% from the prior year. We made significant progress with the implementation of NextRx live and now have more than 15% integrated onto our system. And we raised the low end and midpoint of our EPS guidance range for the year.
Last year, we indicated that our focus for uses of cash in the first half of the year would be the $1.3 billion of 2010 debt maturity. This is still our primary focus. However, as a result of strong cash flow, which includes $25.7 million from our 338(h)(10) election for NextRx, we were able to repurchase 2.2 million shares and repay $180 million of debt in the quarter. We still expect cash from operations for the year to be more than $2 billion.
Our Q1 results reflected a full quarter of both NextRx, which closed on December 1, and the new DoD contract, which was implemented on November 4. As you know, we began recording DoD revenues on a gross basis which increased revenues and cost of revenues by $2 billion in the quarter. 
Gross profit dollars increased 35% from last year. However, as a result of the change in DoD revenue and the addition of the NextRx business, gross profit margin declined to 6.4% from 9.8%. As we continue to make progress executing our integration plan, we expect gross profit margin to increase sequentially.
During the quarter, our focus is on the successful start up of our new clients, including NextRx, which resulted in a higher level of spending charged to cost of goods sold. As a result of this focus, we also spent less on SG&A projects than we were in subsequent quarters. We continue to expect that SG&A, excluding charges and amortization, will be $865 million to $881 million for the year. 
As a result of our performance so far this year, we're now expecting earnings per share, excluding transaction-related charges and amortization, to be in the range of $4.85 to $5. This range represents a growth of 23% to 27% over 2009, excluding three closed financing costs last year. 
After our call last quarter, we realized that while EPS and EBITDA estimates were in line with our guidance, many of the details were not. As a result, mid-quarter, we provided specific guidance for several line items, including revenue and SG&A. We provide the details on our IR website. Please consider our detailed guidance as updated[ph], as you adjust your model for the remainder of the year.
As the year progresses, you will see us rationalize our footprint, eliminate redundancies, implement more eyes [ph] onto our system and realize synergies as we made progress towards delivering to more than $1 billion in incremental EBITDA we expect to achieve in the NextRx transaction. 
And with that, I'll turn it over to George.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, Jeff. Good morning, everyone. In addition to solid financial performance, we've been successful on a number of fronts this year. Earlier this month, we successfully integrated the first major group of NextRx slides onto our platforms. This migr",526,"Thank you, Jeff. Good morning, everyone. In addition to solid financial performance, we've been successful on a number of fronts this year. Earlier this month, we successfully integrated the first major group of NextRx slides onto our platforms. This migration represented over 15% of total membership. 
Our focus on integration is continuing. This will allow us to provide Express Scripts high level of services and tools to NextRx patients and clients. In turn, this will help WellPoint maintain and grow its business.
Last week, we held our outcomes conference in St. Louis and simultaneously released our industry-leading Drug Trend Report. The Drug Trend Report quantifies and analyzes the underlying factors that influence prescription spending patterns in the United States. 
Following several years of declines, overall drug trend increased to 6.4%. Traditional PBM trend was 4.8%, while specialty trend was 19.5%. These trends were mainly driven by branded-drug price inflation of 9.1% on the traditional side and 11.5% on the specialty side. 
Of course, those clients can actively take advantage of our tools, can drive their drug trends to zero or below. In order to come back to these increasing trends, we are pleased that healthcare reform legislation has empowered the FDA to establish a regulatory pathway for the approval of biogenerics. The availability of these lower cost drugs will significantly change the industry landscape and provide opportunities to leverage our expertise in innovative ways.
This year in our Drug Trend Report, we reported that a strong influence or a drug trend is patient behavior. As a result, our Drug Trend Report includes a first time analysis of pharmacy-related behaviors that if optimized, could eliminate $163 billion in annual pharmacy-related waste resulting from non-adherence, drug mix and distribution channel. Over the next 10 years, over $2 trillion could be saved by better management of prescription drug trend.
These findings could never be more timely or relevant. The message from our clients is loud and clear. In these economic times, they're willing to try new strategies to garner lower costs, optimize health outcomes and reduce member disruption. 
Fortunately, we have a solution for their dilemma. And that is the application of proven programs that leverage our behavior-centric approach. The power of these programs is that they are voluntary, at the member level, but effective in encouraging the optimum clinical behavior. This means driving greater therapy adherence, greater use of generics and clinically equivalent lower-cost brands and increasing usage of home delivery. 
Much of our success over the years has been attributable to our business model alignment. That is, if we save our clients and patients money, our performance improves. For example, last year, Express Scripts clients saved $1.4 billion from greater use of lower-cost brands and generics. The work with our clients in addressing patient behavior drove approximately $790 million of these savings over and above market factors, such as branded patent expirations.
Our world-class clinical tools powered by our behavior-centric approach is resonating in the marketplace. Since it is still early in the sales season, we will update you on our sales results later this year. 
At this point, we'll be happy to answer any questions. Operator?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","[Operator Instructions] And our first question today will come from the line of Larry Marsh with Barclays Capital.",18,"[Operator Instructions] And our first question today will come from the line of Larry Marsh with Barclays Capital.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","One is, it seems like a key part of the strategy besides integrating NextRx is to continue to drive value to your customers, extending [ph] base of business. I guess my question is, how would you and Ed and his team defend any sort of efforts of aggressiv",74,"One is, it seems like a key part of the strategy besides integrating NextRx is to continue to drive value to your customers, extending [ph] base of business. I guess my question is, how would you and Ed and his team defend any sort of efforts of aggressive pricing in the marketplace? And what are you guys hearing so far in your best and finals in terms of customer concerns or feedback around pricing?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","I think that every year, pricing is an issue for us, only because of the dynamics of our industry. When you think about what happens in our industry, is we just talk about high drug trends, inflation rates that are growing at very fast rates. So think abo",754,"I think that every year, pricing is an issue for us, only because of the dynamics of our industry. When you think about what happens in our industry, is we just talk about high drug trends, inflation rates that are growing at very fast rates. So think about a static situation. In a static situation, you don't have a lot of moving parts, and so price is easier to look at. But when you have drug prices that are growing at 9%, 10%, 11%, spending of your traditional or your specialties, and you got drugs losing patent protection, you got generics, some of which are steady, some which might have a slight increase, some of them are actually declining. This is a very dynamic pricing metric with thousands and thousands of price points. And then on top of all that, we got our pricing tools. As I tell Ed and I tell our sales team and when I have a chance to talk to our clients, pricing is clearly an important component of our business. It's important piece of any business. I really don't believe though that our business is commoditized. I think that there are -- at the end of the day, it's the relationships, similar to most of your businesses where you're dealing with investors. You have to show your rates of return and you have to have the relationships, the tool and everything that helps sell your business to your clients. We have to have the same thing in our business. We have to have good account managers. We have to have clinicians that are leading edge are going after the client and discussing changes that are taking place in the marketplace and giving them options to understand the market. Our account management team has to understand the predicament or the opportunities that sit in front of our clients to understand labor contracts, changing market dynamics, the financial straits of any given corporation to understand what opportunities may exist. And then all that, once we create the strategy, is that how do you implement that strategy. And that's where consumerology kicks in. So it's not just trying to push a step therapy onto a target bunch of individuals. But instead, try to get those individuals to resonate with the message to take control of their spend and become part of the solution, as opposed to part of the problem. So I think there's a lot more to our business than pricing. Also keep in mind that not all clients were going to resonate with any given PBM. Our whole approach is around the consumer-centric side. That resonates with a lot of companies. Some companies aren't necessarily going to take that approach, and they're going to go to one of my competitors. Obviously, some of my competitors have different approaches, that's going to resonate with other clients. So I do think that as we look at the pricing environment, and you've heard me say this since 1998, every year is a tough year. Every year, we have to look at what's taking place in the marketplace and meet the needs. I'm a very competitive person. I hate to lose. But also to be smart enough not to win, if it's not right for business. If, in fact, a client is looking to go a direction that our business isn't equipped to do, in other words they're not going to promote generics, they don't want to promote mail, they don't want to put in ant kind of programs. They want to put in programs that don't line up with our formulary. Those are not clients we need to win. And keep in mind, that clients are on static either. Clients have changes in their HR department. A new person comes income that came from a different company of a new approach, and they want to shake up the company. They want to put a different type of formulary. And if it doesn't line up with our programs, we may lose that client. At the end of the day, I don't like losing clients. But if we lose it for the right reasons, then you move on. And I think every time we win or lose a major account, we just don't sale, good or bad. We sit down and we analyze what took place and try to make sure we stay competitive in the market. Pricing is just one factor that goes into the overall decision on how wide a PBM is selected.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, and so is it -- from where you said here early in the selling season, it sounds like you're saying -- are you seeing any difference in pricing behavior in the marketplace? Or based on what you said, is pricing always a conversation in these meetin",47,"George, and so is it -- from where you said here early in the selling season, it sounds like you're saying -- are you seeing any difference in pricing behavior in the marketplace? Or based on what you said, is pricing always a conversation in these meetings?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, I wish I could go get the tape from 1998. I think I said the same thing. It's extremely competitive market, it's always been extremely competitive because we're not selling to individuals, we're selling to businesses. Businesses are sophisticated. T",278,"Well, I wish I could go get the tape from 1998. I think I said the same thing. It's extremely competitive market, it's always been extremely competitive because we're not selling to individuals, we're selling to businesses. Businesses are sophisticated. They're good purchasers. And so what we've got do is we got to resonate that our tools can drive down costs. I said this many time over the years, you can take an extra dime or quarter out of me, But that's a fraction of the savings. If you really want to save money, let's convert 10% from retail to mail. Let's convert a 3% increase in generics. Let's drive people to lower-cost brands if you have a high three-tier element. Let's start eliminating drugs off the formulary and getting it more focused, driving up rebates, driving up the use of low-cost brands. All those tools are going to dwarf whatever the price point is. Take my total profit and divide it by my total scripts, do the same thing for my other two biggest competitors and for the other players in the industry, there's not enough money there at the end of the day to make the big changes. The money to be made is in how you affect drug trends, and we do that through the behavioral approach. If I can go in, if the clients looking for another $0.50 of script off, but that I can drive a dollar off by influencing those behaviors with the right programs and the right outcomes, I'm a hero. And that's our job of our account management team is to be that hero for every one of those clients.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, you guys are, I guess, very aggressive in 2005 in getting in front of Zocor to really promote the brand savings into simvastatin. Are there other opportunities to be creative or innovative coming into the Lipitor cliff here at the end of 11? Or is",57,"George, you guys are, I guess, very aggressive in 2005 in getting in front of Zocor to really promote the brand savings into simvastatin. Are there other opportunities to be creative or innovative coming into the Lipitor cliff here at the end of 11? Or is this story still too early to communicate any kind of programs?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","No, I think that's a great question. As you know, Larry, what ends up happening as drug starts to lose their patent protection, typically, they're not supported by the manufacturers. So you see there's a whole lot of erosion in market share that can take",187,"No, I think that's a great question. As you know, Larry, what ends up happening as drug starts to lose their patent protection, typically, they're not supported by the manufacturers. So you see there's a whole lot of erosion in market share that can take place in the year leading up to the loss of the patent. So our job is to make sure the clients understand why that erosion is taking place. Sometimes other competing products can increase rebate offers to drive behavior or do more advertising and more detailing. Our job is to give the clients their alternatives and let them decide, do they one first year economic benefits of driving to a different position, or do they want to maintain their share and get a higher pull-through on the generic when it grows. I think, again, this isn't one-size-fits-all. We've got thousands and thousands of clients in our account management team working with Dr. Miller, our Chief Medical Officer, is to go out and design the programs that make the most sense for each and every client, to meet the needs of that client.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question will come from the line of Lisa Gill with JPMorgan.",13,"Our next question will come from the line of Lisa Gill with JPMorgan.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, I just had a couple of questions around Select Home Delivery. Can you just give us some thoughts around what you're hearing in the marketplace and what the opportunities are? I know you said that it's early for 2011, but my guess would be that you",110,"George, I just had a couple of questions around Select Home Delivery. Can you just give us some thoughts around what you're hearing in the marketplace and what the opportunities are? I know you said that it's early for 2011, but my guess would be that you're out and you're making presentations. And I'm just wondering, what you're seeing as far as interest and uptake around that program. And then secondly, on the specialty side, maybe can you quantify the opportunity in your book of business? Can you maybe give us a percentage of your PBM customers that are using your specialty business today, and what the potential opportunities are?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Sure. That's a very, very popular program. We're seeing -- if you look at same-store sales, we're up about 7%, thereabouts, in mission [ph]trends. And keep in mind, that a lot of these clients are just kicking off. So they're hitting their first block at",470,"Sure. That's a very, very popular program. We're seeing -- if you look at same-store sales, we're up about 7%, thereabouts, in mission [ph]trends. And keep in mind, that a lot of these clients are just kicking off. So they're hitting their first block at retail. Obviously, they can opt out of that block but this is -- so it's very early on. And we're seeing some very nice pull-through again on a same-store basis. We got over 200 clients that have selected the program and seeing some very strong results. Now keep in mind, that a client is already at 40%, the pick up is going to be not nearly as great as the client that's at 5%. So the results vary by client. But still the impact, the movement of 1% or 2% is still pretty significant, especially in tough economic times. So I think the program is working very well for us. And I think what the clients like most is when we come in and we put -- it's dependent, again, on a client. If a client has a tough situation and they need immediate savings fast, then they can put in exclusive home delivery. And then obviously, they get the bump right away. They may not have a choice, they may need to do that in order to garner the savings. But where there is a choice, they can, in fact, put in Select Home Delivery and get almost to the same level of results, not quite, but they can get fairly close by just letting our teams use consumerology to drive. What we see in a couple of clients is that they've actually put in Select Home Delivery, they've ran that for a while, they took a couple of cases, they took it from low teens, up to the high 30s percent penetration rates. And then they put in exclusive home delivery because at that point, they've converted so many [indiscernible] to mail, that the next step was then just to go ahead and get the rest of them, maximize the savings, and it was already a very widely accepted benefit inside the company. So it can be -- Select Home Delivery can either be a stand-alone product or it can be a stepping stone to exclusive home delivery. So it's what the client needs in their timing. As far as specialty goes, specialty has been one of our bright spots. We don't break it out any longer, because we really do believe it's just one of our tools to battle overall drug trends. But this year has been an incredible year for us, an exclusive in specialty. We've seen margin expansion. We've seen significant increase in the number of prescriptions in this area. And so we're really excited about our specialty offering today.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Can you give us an idea though of how penetrated your book is? And how big that opportunity remains around specialty to fully penetrate specialty and your PBM book of business? Do you have a number around that?",38,"Can you give us an idea though of how penetrated your book is? And how big that opportunity remains around specialty to fully penetrate specialty and your PBM book of business? Do you have a number around that?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","There's two pieces to this. One is, how much do we penetrate into our existing book. And then the other piece is, this is clearly the fastest-growing area of PBM. So those are two -- I'm not trying to avoid your question. I just don't have a number off th",80,"There's two pieces to this. One is, how much do we penetrate into our existing book. And then the other piece is, this is clearly the fastest-growing area of PBM. So those are two -- I'm not trying to avoid your question. I just don't have a number off the top of my head. I'm not exactly sure I know what the penetration rate on my clients is today. So I'll have to try to get that for you.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","But I think it would be fair to say, George, right, that there's still a lot of runway here, that there's still a lot of opportunity around Specialty?",28,"But I think it would be fair to say, George, right, that there's still a lot of runway here, that there's still a lot of opportunity around Specialty?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Absolutely.",1,"Absolutely.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Absolutely, Lisa. There's lots of room to run in this space where, as George said, we've seen very nice growth. And we think there's lots of opportunity over the coming years, to really grow this business and grow it nicely. This is a huge area spend for",83,"Absolutely, Lisa. There's lots of room to run in this space where, as George said, we've seen very nice growth. And we think there's lots of opportunity over the coming years, to really grow this business and grow it nicely. This is a huge area spend for our clients. This is an area where you can really help and save a lot of money. And we think we have unique offering in this space, and we're going to see this grow our business.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","The other side to that, just to pile on. I think that when you think about behaviors, this is an area that's ripe for this, and that we're going to see a massive opportunity when you think about Consumerology. The side effect profile, the results that the",147,"The other side to that, just to pile on. I think that when you think about behaviors, this is an area that's ripe for this, and that we're going to see a massive opportunity when you think about Consumerology. The side effect profile, the results that these disease have on a given family can be devastating. And so being able to message both the doctors, the patients, the nurses, all that's up and down in that ladder, are incredibly important. And as biogenerics come into this marketplace, it's going to be very important that we're out in front of that, because once somebody gets them that first fill, it's going to be hard to get them to change if they stabilize. So giving the information to the doctors, they know what the options are, are very, very important. So this is a big, big thing for us.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, you talked about gross profit and you talked about it improving throughout the year. Can you just help us understand this. Is it the incremental cost of employees that you had in COGS for implementation and integration that will go away? Or is there",59,"Jeff, you talked about gross profit and you talked about it improving throughout the year. Can you just help us understand this. Is it the incremental cost of employees that you had in COGS for implementation and integration that will go away? Or is there other key drivers that will drive gross profit as we move throughout the year?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes and yes, is the simple answer. Certainly, the implementation efforts have increased cost of goods sold in the first quarter, and that will trend down over time as we move through the year. But we've also got a lot of programs that's got a large acquis",137,"Yes and yes, is the simple answer. Certainly, the implementation efforts have increased cost of goods sold in the first quarter, and that will trend down over time as we move through the year. But we've also got a lot of programs that's got a large acquisition that we're in the process of implementing on. We've got an operations team here, which is focused on continuous improvement and they're going to keep driving down costs. And we're just going to keep executing. And I mean, you'd heard us say this time and time again, we are focused on alignment. We make money when our clients make money, and we are going to keep doing everything we can using all of our Consumerology tools to save our clients' money. And as we do that, we'd see margin grow.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Next, we'll go to line of Bob Willoughby with Bank of America.",12,"Next, we'll go to line of Bob Willoughby with Bank of America.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","How much did the base business grow? And can you remind us what you have for start-ups as of July 1, if anything? And then secondarily, is it possible to say in any way, shape or form, of the incremental billion you hope to generate from the WellPoint dea",67,"How much did the base business grow? And can you remind us what you have for start-ups as of July 1, if anything? And then secondarily, is it possible to say in any way, shape or form, of the incremental billion you hope to generate from the WellPoint deal? What you actually saw flow through, what percentage of that might have been apparent in the first quarter?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Bob, this is Jeff. Let me just say this just upfront. No, I'm not going to answer the second part of your question. And yes I can, and no I'm not going to. We're just not going to break it out. Actually, it's pretty hard to break it out, as it's integrate",138,"Bob, this is Jeff. Let me just say this just upfront. No, I'm not going to answer the second part of your question. And yes I can, and no I'm not going to. We're just not going to break it out. Actually, it's pretty hard to break it out, as it's integrated into the core business. As we think back to -- I'm sorry, I forgot the first part of -- in the core business on a Script basis, we obviously had a good selling season last year, we said. So I think we haven't been precise other than to say that, in the core business, year-over-year, we expect growth in Scripts. And so I'm not going to get a whole lot more detailed than that. But certainly, we think the core business, x WellPoint, certainly was growing.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Is there a July 1 start-up of any consequence or...",11,"Is there a July 1 start-up of any consequence or...
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","No meaningful July 1. I mean, it certainly doesn't move the numbers from that, I see one way or the other.",21,"No meaningful July 1. I mean, it certainly doesn't move the numbers from that, I see one way or the other.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","And we factored those already into our guidance, Bob.",9,"And we factored those already into our guidance, Bob.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And you've given us a number of line items for guidance, but nothing on your share base. Where do you expect that to be for the year?",28,"And you've given us a number of line items for guidance, but nothing on your share base. Where do you expect that to be for the year?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","It's really hard to predict share base, so we try to stay out of that game, because it's so dependent on where the share price goes, over the course of the year. When we gave our original guidance, we assumed some kind of de minimis impact from share buyb",95,"It's really hard to predict share base, so we try to stay out of that game, because it's so dependent on where the share price goes, over the course of the year. When we gave our original guidance, we assumed some kind of de minimis impact from share buybacks, 1% to 2%. We still think that we'll get about 1% to 2% of EPS gain from share buybacks. So I think you can model that in, but that would get you to a place that's probably not meaningfully different than where we are today.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is coming from John Kreger with William Blair.",11,"Our next question is coming from John Kreger with William Blair.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, if you think about the renewal discussions you're having today and maybe contrast them to a year ago, or clearly, in a different economic place broadly, how have those changed? And is your WellPoint combination influencing those discussions? How d",44,"George, if you think about the renewal discussions you're having today and maybe contrast them to a year ago, or clearly, in a different economic place broadly, how have those changed? And is your WellPoint combination influencing those discussions? How do clients perceive that?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","At the end of last year, throughout the third and fourth quarter and even into the first quarter, I think that many clients asked the question, how will WellPoint integration affect us? Will we lose our account manager? Will it change the timeliness of ou",275,"At the end of last year, throughout the third and fourth quarter and even into the first quarter, I think that many clients asked the question, how will WellPoint integration affect us? Will we lose our account manager? Will it change the timeliness of our reporting? Anytime a company goes through a major acquisition, from the client-side, there's always a little bit of noise. And the reason that noise exist, of course, is my competitors are up at their tone [ph]. The noise should exist. And as you know, we've done a lot of these things. And we've grown both organically -- we've grown organically through our acquisitions. So as we've added more and more lives into our business, we've always kept the discipline around selling and around growing the base. And that continues to be our focus. And the best thing that happened to us in the first quarter was the migration of the first tier. Because now the clients can, when they ask the question, ""How am I going to be affected?"" we say, ""Well, how are you affected in the first quarter?"" And most of them didn't sense a thing. None of them, to my knowledge, had any concerns, any issues, nothing. It's not only is it operations as normal, it's a continued focus on Consumerology and driving out the waste. And they didn't even know what occurred. And that's the best view of an integration. And I think if you reach out to the consultant community and ask that question, you'll hear that same comment that the integration is going extremely well and that there is not noise on the street.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Are you seeing client priorities change at all now that presumably, they are maybe a little less worried about the economic backdrop?",22,"Are you seeing client priorities change at all now that presumably, they are maybe a little less worried about the economic backdrop?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well,  I think CEOs and CFOs, at least the ones I know, and I know quite a few, are still very worried about the economic backdrop. A lot of the companies we deal with are global in nature, and you got some issues in Greece and Spain and on and on and on.",334,"Well,  I think CEOs and CFOs, at least the ones I know, and I know quite a few, are still very worried about the economic backdrop. A lot of the companies we deal with are global in nature, and you got some issues in Greece and Spain and on and on and on. And I think that companies have to make tough decisions back in the last year in reducing workforce and making cost-cutting moves. The last thing a CEO wants to do to his organization is to have a roller coaster ride. I think it's going to take a little while before employment comes back. I think companies are going to want to make sure that, that light at the end of the tunnel isn't a train, and they're going to make sure that they, in fact, can see their way. So I think the focus today is every business is focused on cost reduction as possible. Keep in mind, that really plays into our sweet spot. We've been out there for 15 years talking about cost constraints around these things that were really better for health outcomes. And we only got so much noise. Over the last couple of years, it's resonated with companies. And now what companies realize is, in fact, they were able to get those cost savings. We didn't impact members unfavorably. We actually improved clients and member satisfaction, and at the same time, reduced cost. So once we got that training in place, with the clients understand they can take out the cost, while not adversely affecting their relationship with their members, that sets the driveway into the coming years. Even as the economy turns, I think the work we did during this last couple of years paves the way, especially to the earlier question about Lipitor, and other drugs that are coming off patent, to really position us nicely to take advantage of those opportunities. And I have to worry about member disruption to the same level.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Next, we'll go to the line of Ross Muken with Deutsche Bank.",12,"Next, we'll go to the line of Ross Muken with Deutsche Bank.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Given sort of the renewed focus on sort of attracting larger clients and what you'd call kind of the marquee accounts, can you talk a bit about the strategy there for this selling season? And what sort have you learned from WellPoint? And how you're using",70,"Given sort of the renewed focus on sort of attracting larger clients and what you'd call kind of the marquee accounts, can you talk a bit about the strategy there for this selling season? And what sort have you learned from WellPoint? And how you're using some of the newer parts of the Consumerology offering to kind of use as a differentiator as you attempt to attract those accounts?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","When we go into this year, we're looking at opportunities again. The opportunities -- there's a lot of opportunities out there, just to be clear. And we would need to find opportunities that resonate with our book of business, as I said earlier. So that's",256,"When we go into this year, we're looking at opportunities again. The opportunities -- there's a lot of opportunities out there, just to be clear. And we would need to find opportunities that resonate with our book of business, as I said earlier. So that's always the first call, is to make sure we can find those clients that want our offerings, that has to accept our approach, and then we can stay focused on the core things we do. So once that occurs and we find them, then I think it goes back to Consumerology and our approach. We love going into a client, and not only signing off on day one, but then selling them Select Home Delivery. In addition to that, our teams are working very hard on other programs, such as step therapies and other similar-type programs, in order to -- limited networks and curtailing are shrinking the size of the formularies. We're doing a lot of different things in using the Consumerology approach to attack those situations. Also, adherence is a major, major driver. As I said in my prepared comments, there's $163 billion, the majority of which is attributable to adherence. That's an opportunity for us to drive down overall healthcare costs. And so that's our approach to the marketplace. That's what we try to get to resonate, not just with marquee clients but any client. We're looking at opportunities in all of the different segments we operate in. And we're trying to drive better cost outcomes for our clients.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And Jeff, on the balance sheet, you have a lot of cash flow that's being generated this year. You're obviously paying down some debt and buying back some shares. But from an M&A standpoint, how are you thinking about sort of the environment? There's a lot",85,"And Jeff, on the balance sheet, you have a lot of cash flow that's being generated this year. You're obviously paying down some debt and buying back some shares. But from an M&A standpoint, how are you thinking about sort of the environment? There's a lot of assets right now in the private market. And also, potentially, with the financing environment still being attractive, people are looking at other types of deals. How would you sort of characterize the activity you're seeing on that front?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Obviously, I'm not going to comment on specific deals. But I think our position, my position, hasn't really changed over the years here. It's pretty simple. We look at opportunities for our cash. And I mean, absolutely you're right, we certainly got a ver",226,"Obviously, I'm not going to comment on specific deals. But I think our position, my position, hasn't really changed over the years here. It's pretty simple. We look at opportunities for our cash. And I mean, absolutely you're right, we certainly got a very strong cash flow year, and we have a very strong cash balance. So certainly, as I said in my prepared remarks, first goal is to pay down, pay off the debt that's coming due here in 2010. But even after that, we're left with a very strong cash position. And as we look at that cash position, we say, first off, we want to invest in the projects that are driving this company. We've got a bunch of great people here. They always have great ideas, and we want to invest in those ideas and keep driving our return on invested capital with new ideas. After that comes M&A. Certainly, we've had great experience with good accretive M&A over the life of this business. We're happy with the M&A. We're integrating at the moment with NextRx. And to the extent there are more opportunities out there that we think have the same kind of positive returns, we're anxious and interested at getting them done at the right price and the right terms. But other than that, it's hard to comment on specifics.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is coming from the line of Tom Gallucci with Lazard Capital Markets.",15,"Our next question is coming from the line of Tom Gallucci with Lazard Capital Markets.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","I guess on the selling season, as it pertains to WellPoint, you sort of talked about customers wondering how it was going to impact that negatively. What about from a positive standpoint, do you feel like you're positioned any different this year in the s",71,"I guess on the selling season, as it pertains to WellPoint, you sort of talked about customers wondering how it was going to impact that negatively. What about from a positive standpoint, do you feel like you're positioned any different this year in the selling season for different types of customers, given the bigger scale that you've got? And is there any sort of tangible evidence of that at this point?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Ed Ignaczak and his team is really focused on integrating our approach and our sales into the WellPoint approach. I think when you look at our website, when you look at our tools and what we can do, it's significantly better than what NextRx has to offer",298,"Ed Ignaczak and his team is really focused on integrating our approach and our sales into the WellPoint approach. I think when you look at our website, when you look at our tools and what we can do, it's significantly better than what NextRx has to offer today. So we're trying to integrate our sales approaches and we're holding sessions with the NextRx people to update them on how to sell PBM, and how to approach the marketplace, how to be better at it. As I've told my counterpart over at WellPoint, our view is, I would prefer to grow through them as to grow directly. It's a tremendous opportunity for us to combine our forces in order to grow our joint book of business. And we are absolutely fixated on that, and it's a great approach to the marketplace. So yes, I think the real value, though, is still a couple of years out. I shouldn't say a couple years, it's probably more than a year though. And that is to really get an integrated approach to the marketplace on the overall medical and drug lab, the whole spectrum of care brought together. And I know WellPoint is absolutely fixated on that, as well as we are, to change the way healthcare is delivered in this country, and really to start taking costs out of the equation in order to meet the needs of the country. So that's something we are continuously working on. We both have set up working groups to focus on that as we go forward, and it will stay one of our priorities. And once we get to the integration, we'll keep you updated on what we're doing here. And I think we're just going to have a great offering in the future.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","On Select Home Delivery, are you seeing any concentration of particular types of customers that are interested in that, ones that already have a lot a mail or don't, or employers versus health plans?",34,"On Select Home Delivery, are you seeing any concentration of particular types of customers that are interested in that, ones that already have a lot a mail or don't, or employers versus health plans?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","It's been mostly on the employer side, initially, but now we've got several health plan clients that have actually rolled it out this year. So we're seeing it on both sides. I would tell you that it's also across-the-board. We've had clients with very lit",137,"It's been mostly on the employer side, initially, but now we've got several health plan clients that have actually rolled it out this year. So we're seeing it on both sides. I would tell you that it's also across-the-board. We've had clients with very little mail penetration and has seen significant increases in mail penetration through the programs. We've also had clients that had high penetrations. But as you know, as with an aging population, more and more people are going into maintenance medications. And this is a good way to capture those new users of prescription drugs, and convert them over to mail in a timely fashion to continue to drive down costs. So we're seeing it across the spectrum. Probably still today, more on the employer side than anywhere else, but it is across-the-board.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","You've sort of looked at the Medicare PDP, your own Medicare PDP, a little bit differently than your competitors the last couple of years. And now with sort of the way reform looks, are you thinking about that any differently? Or how should we be thinking",60,"You've sort of looked at the Medicare PDP, your own Medicare PDP, a little bit differently than your competitors the last couple of years. And now with sort of the way reform looks, are you thinking about that any differently? Or how should we be thinking about what you're going to do with that over the next few years?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","From my perspective, and I think I've been saying this for quite some time, is that I don't think Express Scripts is a household name. So to compete in the individual market on our margins, I just don't think we have a very good offering. I don't have the",284,"From my perspective, and I think I've been saying this for quite some time, is that I don't think Express Scripts is a household name. So to compete in the individual market on our margins, I just don't think we have a very good offering. I don't have the money that Coca-Cola, Anheuser-Busch InBev, whatever, has these, Procter & Gamble, to spend to go after the consumer marketplace. Our best answer is, we've got great partners with WellPoint and many other brewers plants [ph] and clients that are household names in their marketplace. I would rather partner up with them and have an offering that's recognized in their given geographic area, and go in and try to sell the individual business through them, and give them the tools that they need to be successful. And we grow as they grow. That's always been our strategy. And I think it's a great strategy for them as they pick up the medical side, and it's a great strategy for us when we pick up the drug side. I think if, in fact, you see -- we will see a growth there with the 30 million people coming to the market. How many of those people want to carve out medical from drug at that point. That's a big question. But I think our clients are well positioned to gain their share of the overall comprehensive medical and drug side. And so when they lay in those clients, we'll pick up the drug side through them, which is the best of all answers. So I like where we're positioned. That didn't happen by accident. We focused on this approach, and I'm very pleased with where we sit.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","That question will come from the line of Ricky Goldwasser with Morgan Stanley.",13,"That question will come from the line of Ricky Goldwasser with Morgan Stanley.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","First, I think you said that 15% of lives were migrated by April 1. What percent of lives do you expect to migrate by the end of the second quarter? And then, if you can give us some more color on what percent of year-over-year change in gross profit is f",53,"First, I think you said that 15% of lives were migrated by April 1. What percent of lives do you expect to migrate by the end of the second quarter? And then, if you can give us some more color on what percent of year-over-year change in gross profit is from DoD reallocation?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, a couple of things. We're not going to get in to projecting migration, and it's not really all that relevant at the end of the day. The idea is we have to get the first one done. When you do the first one, you learn so much about the different opera",182,"Well, a couple of things. We're not going to get in to projecting migration, and it's not really all that relevant at the end of the day. The idea is we have to get the first one done. When you do the first one, you learn so much about the different operating platforms and the people. And so the idea is, you get the first one done, and then the other ones come in line. So we haven't laid out a schedule. We said we'd get this done in 12 to 18 months. We're still very comfortable with that approach, and that's what we're going to focus on. We'll give you updates each quarter as we progress. One of the things we have been focused on, though, is making sure that those areas that drive the highest level of synergies are first and foremost in our integration plans. So we're going after those as quickly as we can. Secondly, as far as client specifics, we don't discuss gross profits or profitability on any given client. So I really can't get into that.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","I mean, I guess the question is not really on profitability. There's just been a change, kind of like reallocating in that contract?",23,"I mean, I guess the question is not really on profitability. There's just been a change, kind of like reallocating in that contract?
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, the contract changed. We now do a lot more things, which by definition, means it's more profitable for us. And we also, because we adjudicate the claims and do many other elements of it, we gross up the numbers into revenue. But I don't want to get",110,"Well, the contract changed. We now do a lot more things, which by definition, means it's more profitable for us. And we also, because we adjudicate the claims and do many other elements of it, we gross up the numbers into revenue. But I don't want to get into specific clients. We just don't do that.
Well, again, I thank everyone for listening in to our call today. We appreciate your confidence in us. And we look forward to the integration of NextRx. We think great things are ahead of us, and we look forward to talking to you again next quarter. Thank you very much. Have a great day.
"
317975,100362867,58493,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","With that, ladies and gentlemen, that does conclude our conference for today. Thank you very much for your participation, and for using AT&T Teleconferencing. You may now disconnect.",28,"With that, ladies and gentlemen, that does conclude our conference for today. Thank you very much for your participation, and for using AT&T Teleconferencing. You may now disconnect.

"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the First Quarter 2010 Earnings Conference Call. [Operator Instructions] I now like to turn the call over to the Vice President of Investor Relations, David Myers.",37,"Ladies and gentlemen, thank you for standing by, and welcome to the First Quarter 2010 Earnings Conference Call. [Operator Instructions] I now like to turn the call over to the Vice President of Investor Relations, David Myers."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, and good morning, everyone. Welcome to our First Quarter Conference Call. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO.Before we begin, I need to read the following statement. Statements or comments made on this",186,"Thank you, and good morning, everyone. Welcome to our First Quarter Conference Call. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO.
Before we begin, I need to read the following statement. Statements or comments made on this conference call may be forward-looking statements and may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. 
These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors, which are discussed in detail in our SEC reports. 
For clarity purposes, all numbers we talk about today will be on an adjusted basis. Please refer to the tables on our press release for reconciliation of GAAP to the adjusted numbers we will be discussing. The reconciliation of EBITDA to net income can also be found in our earnings release. Earnings release is posted on our website.
Now at this point, I'll turn the call over to Jeff, who'll discuss our first quarter financial results."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, David. Yesterday, we reported solid first quarter EPS of $1.10, which represents an increase of 25% over last year. Other highlights in the quarter were EBITDA per Rx at $2.92, the high end of our guidance range for the quarter. Cash flows from",518,"Thank you, David. Yesterday, we reported solid first quarter EPS of $1.10, which represents an increase of 25% over last year. Other highlights in the quarter were EBITDA per Rx at $2.92, the high end of our guidance range for the quarter. Cash flows from operations was strong at $761 million, up 166% from the prior year. We made significant progress with the implementation of NextRx live and now have more than 15% integrated onto our system. And we raised the low end and midpoint of our EPS guidance range for the year.
Last year, we indicated that our focus for uses of cash in the first half of the year would be the $1.3 billion of 2010 debt maturity. This is still our primary focus. However, as a result of strong cash flow, which includes $25.7 million from our 338(h)(10) election for NextRx, we were able to repurchase 2.2 million shares and repay $180 million of debt in the quarter. We still expect cash from operations for the year to be more than $2 billion.
Our Q1 results reflected a full quarter of both NextRx, which closed on December 1, and the new DoD contract, which was implemented on November 4. As you know, we began recording DoD revenues on a gross basis which increased revenues and cost of revenues by $2 billion in the quarter. 
Gross profit dollars increased 35% from last year. However, as a result of the change in DoD revenue and the addition of the NextRx business, gross profit margin declined to 6.4% from 9.8%. As we continue to make progress executing our integration plan, we expect gross profit margin to increase sequentially.
During the quarter, our focus is on the successful start up of our new clients, including NextRx, which resulted in a higher level of spending charged to cost of goods sold. As a result of this focus, we also spent less on SG&A projects than we were in subsequent quarters. We continue to expect that SG&A, excluding charges and amortization, will be $865 million to $881 million for the year. 
As a result of our performance so far this year, we're now expecting earnings per share, excluding transaction-related charges and amortization, to be in the range of $4.85 to $5. This range represents a growth of 23% to 27% over 2009, excluding three pre-close financing costs last year. 
After our call last quarter, we realized that while EPS and EBITDA estimates were in line with our guidance, many of the details were not. As a result, mid-quarter, we provided specific guidance for several line items, including revenue and SG&A. We provide the details on our IR website. Please consider our detailed guidance as updated [ph], as you adjust your model for the remainder of the year.
As the year progresses, you will see us rationalize our footprint, eliminate redundancies, implement more eyes [ph] onto our system and realize synergies as we made progress towards delivering to more than $1 billion in incremental EBITDA we expect to achieve in the NextRx transaction. 
And with that, I'll turn it over to George."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, Jeff. Good morning, everyone. In addition to solid financial performance, we've been successful on a number of fronts this year. Earlier this month, we successfully integrated the first major group of NextRx slides onto our platforms. This migr",525,"Thank you, Jeff. Good morning, everyone. In addition to solid financial performance, we've been successful on a number of fronts this year. Earlier this month, we successfully integrated the first major group of NextRx slides onto our platforms. This migration represented over 15% of total membership. 
Our focus on integration is continuing. This will allow us to provide Express Scripts high level of services and tools to NextRx patients and clients. In turn, this will help WellPoint maintain and grow its business.
Last week, we held our outcomes conference in St. Louis and simultaneously released our industry-leading Drug Trend Report. The Drug Trend Report quantifies and analyzes the underlying factors that influence prescription spending patterns in the United States. 
Following several years of declines, overall drug trend increased to 6.4%. Traditional PBM trend was 4.8%, while specialty trend was 19.5%. These trends were mainly driven by branded-drug price inflation of 9.1% on the traditional side and 11.5% on the specialty side. 
Of course, those clients that can actively take advantage of our tools can drive their drug trends to zero or below. In order to combat these increasing trends, we are pleased that healthcare reform legislation has empowered the FDA to establish a regulatory pathway for the approval of biogenerics. The availability of these lower cost drugs will significantly change the industry landscape and provide opportunities to leverage our expertise in innovative ways.
This year in our Drug Trend Report, we reported that a strong influence of a drug trend is patient behavior. As a result, our Drug Trend Report includes a first time analysis of pharmacy-related behaviors that if optimized, could eliminate $163 billion in annual pharmacy-related waste resulting from non-adherence, drug mix and distribution channel. Over the next 10 years, over $2 trillion could be saved by better management of prescription drug trend.
These findings could never be more timely or relevant. The message from our clients is loud and clear. In these economic times, they're willing to try new strategies to garner lower costs, optimize health outcomes and reduce member disruption. 
Fortunately, we have a solution for their dilemma. And that is the application of proven programs that leverage our behavior-centric approach. The power of these programs is that they are voluntary, at the member level, but effective in encouraging the optimum clinical behavior. This means driving greater therapy adherence, greater use of generics and clinically equivalent lower-cost brands and increasing usage of home delivery. 
Much of our success over the years has been attributable to our business model alignment. That is, if we save our clients' and patients' money, our performance improves. For example, last year, Express Scripts clients saved $1.4 billion from greater use of lower-cost brands and generics. The work with our clients in addressing patient behavior drove approximately $790 million of these savings over and above market factors, such as branded patent expirations.
Our world-class clinical tools powered by our behavior-centric approach is resonating in the marketplace. Since it is still early in the sales season, we will update you on our sales results later this year. 
At this point, we'll be happy to answer any questions. Operator?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","[Operator Instructions] And our first question today will come from the line of Larry Marsh with Barclays Capital.",18,"[Operator Instructions] And our first question today will come from the line of Larry Marsh with Barclays Capital."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","One is, it seems like a key part of the strategy besides integrating NextRx is to continue to drive value to your customers, extending [ph] base of business. I guess my question is, how would you and Ed and his team defend any sort of efforts of aggressiv",74,"One is, it seems like a key part of the strategy besides integrating NextRx is to continue to drive value to your customers, extending [ph] base of business. I guess my question is, how would you and Ed and his team defend any sort of efforts of aggressive pricing in the marketplace? And what are you guys hearing so far in your best and finals in terms of customer concerns or feedback around pricing?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","I think that every year, pricing is an issue for us, only because of the dynamics of our industry. When you think about what happens in our industry, is we just talk about high drug trends, inflation rates that are growing at very fast rates. So think abo",758,"I think that every year, pricing is an issue for us, only because of the dynamics of our industry. When you think about what happens in our industry, is we just talk about high drug trends, inflation rates that are growing at very fast rates. So think about a static situation. In a static situation, you don't have a lot of moving parts, and so price is easier to look at. But when you have drug prices that are growing at 9%, 10%, 11%, spending of your traditional or your specialties, and you got drugs losing patent protection, you got generics, some of which are steady, some which might have a slight increase, some of them are actually declining. This is a very dynamic pricing metric with thousands and thousands of price points. And then on top of all that, we got our pricing tools. As I tell Ed and I tell our sales team and when I have a chance to talk to our clients, pricing is clearly an important component of our business. It's important piece of any business. I really don't believe though that our business is commoditized. I think that there are -- at the end of the day, it's the relationships, similar to most of your businesses where you're dealing with investors. You have to show your rates of return and you have to have the relationships, the tool and everything that helps sell your business to your clients. We have to have the same thing in our business. We have to have good account managers. We have to have clinicians that are leading edge are going after the client and discussing changes that are taking place in the marketplace and giving them options to understand the market. Our account management team has to understand the predicament or the opportunities that sit in front of our clients to understand labor contracts, changing market dynamics, the financial straits of any given corporation to understand what opportunities may exist. And then all that, once we create the strategy, is that how do you implement that strategy. And that's where Consumerology kicks in. So it's not just trying to push a step therapy onto a target bunch of individuals. But instead, try to get those individuals to resonate with the message to take control of their spend and become part of the solution, as opposed to part of the problem. So I think there's a lot more to our business than pricing. Also keep in mind that not all clients were going to resonate with any given PBM. Our whole approach is around the consumer-centric side. That resonates with a lot of companies. Some companies aren't necessarily going to take that approach, and they're going to go to one of my competitors. Obviously, some of my competitors have different approaches, that's going to resonate with other clients. So I do think that as we look at the pricing environment, and you've heard me say this since 1998, every year is a tough year. Every year, we have to look at what's taking place in the marketplace and meet the needs. I'm a very competitive person. I hate to lose, but also to be smart enough not to win, if it's not right for our business. If, in fact, a client is looking to go a direction that our business isn't equipped to do, in other words, they're not going to promote generics, they don't want to promote mail, they don't want to put in any kind of programs. They want to put in programs that don't line up with our formulary. Those are not clients we need to win. And keep in mind, that clients are on static either. Clients have changes in their HR department. A new person comes income, they came from a different client, they have a new approach and they want to shake up the company. They want to put a different type of formulary. And if it doesn't line up with our programs, we may lose that client. At the end of the day, I don't like losing clients. But if we lose it for the right reasons, then you move on. And I think every time we win or lose a major account, we just don't say, ""Oh, good"" or, ""Oh, bad."" We sit down and we analyze what took place and try to make sure we stay competitive in the market. Pricing is just one factor that goes into the overall decision on how wide a PBM is selected."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, and so is it -- from where you said here early in the selling season, it sounds like you're saying -- are you seeing any difference in pricing behavior in the marketplace? Or based on what you said, is pricing always a conversation in these meetin",47,"George, and so is it -- from where you said here early in the selling season, it sounds like you're saying -- are you seeing any difference in pricing behavior in the marketplace? Or based on what you said, is pricing always a conversation in these meetings?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, I wish I could go get the tape from 1998. I think I said the same thing. It's extremely competitive market, it's always been extremely competitive because we're not selling to individuals, we're selling to businesses. Businesses are sophisticated. T",278,"Well, I wish I could go get the tape from 1998. I think I said the same thing. It's extremely competitive market, it's always been extremely competitive because we're not selling to individuals, we're selling to businesses. Businesses are sophisticated. They're good purchasers. And so what we've got do is we got to resonate that our tools can drive down costs. I said this many time over the years, you can take an extra dime or quarter out of me, But that's a fraction of the savings. If you really want to save money, let's convert 10% from retail to mail. Let's convert a 3% increase in generics. Let's drive people to lower-cost brands if you have a high three-tier element. Let's start eliminating drugs off the formulary and getting it more focused, driving up rebates, driving up the use of low-cost brands. All those tools are going to dwarf whatever the price point is. Take my total profit and divide it by my total scripts, do the same thing for my other two biggest competitors and for the other players in the industry, there's not enough money there at the end of the day to make the big changes. The money to be made is in how you affect drug trends, and we do that through the behavioral approach. If I can go in, if the clients looking for another $0.50 of script off, but that I can drive a dollar off by influencing those behaviors with the right programs and the right outcomes, I'm a hero. And that's our job of our account management team is to be that hero for every one of those clients."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, you guys are, I guess, very aggressive in 2005 in getting in front of Zocor to really promote the brand savings into simvastatin. Are there other opportunities to be creative or innovative coming into the Lipitor cliff here at the end of 11? Or is",57,"George, you guys are, I guess, very aggressive in 2005 in getting in front of Zocor to really promote the brand savings into simvastatin. Are there other opportunities to be creative or innovative coming into the Lipitor cliff here at the end of 11? Or is this story still too early to communicate any kind of programs?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","No, I think that's a great question. As you know, Larry, what ends up happening as drug starts to lose their patent protection, typically, they're not supported by the manufacturers. So you see there's a whole lot of erosion in market share that can take",187,"No, I think that's a great question. As you know, Larry, what ends up happening as drug starts to lose their patent protection, typically, they're not supported by the manufacturers. So you see there's a whole lot of erosion in market share that can take place in the year leading up to the loss of the patent. So our job is to make sure the clients understand why that erosion is taking place. Sometimes other competing products can increase rebate offers to drive behavior or do more advertising and more detailing. Our job is to give the clients their alternatives and let them decide, do they one first year economic benefits of driving to a different position, or do they want to maintain their share and get a higher pull-through on the generic when it grows. I think, again, this isn't one-size-fits-all. We've got thousands and thousands of clients in our account management team working with Dr. Miller, our Chief Medical Officer, is to go out and design the programs that make the most sense for each and every client, to meet the needs of that client."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question will come from the line of Lisa Gill with JPMorgan.",13,"Our next question will come from the line of Lisa Gill with JPMorgan."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, I just had a couple of questions around Select Home Delivery. Can you just give us some thoughts around what you're hearing in the marketplace and what the opportunities are? I know you said that it's early for 2011, but my guess would be that you",110,"George, I just had a couple of questions around Select Home Delivery. Can you just give us some thoughts around what you're hearing in the marketplace and what the opportunities are? I know you said that it's early for 2011, but my guess would be that you're out and you're making presentations. And I'm just wondering, what you're seeing as far as interest and uptake around that program. And then secondly, on the specialty side, maybe can you quantify the opportunity in your book of business? Can you maybe give us a percentage of your PBM customers that are using your specialty business today, and what the potential opportunities are?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Sure. That's a very, very popular program. We're seeing -- if you look at same-store sales, we're up about 7%, thereabouts, in mission [ph]trends. And keep in mind, that a lot of these clients are just kicking off. So they're hitting their first block at",470,"Sure. That's a very, very popular program. We're seeing -- if you look at same-store sales, we're up about 7%, thereabouts, in mission [ph]trends. And keep in mind, that a lot of these clients are just kicking off. So they're hitting their first block at retail. Obviously, they can opt out of that block but this is -- so it's very early on. And we're seeing some very nice pull-through again on a same-store basis. We got over 200 clients that have selected the program and seeing some very strong results. Now keep in mind, that a client is already at 40%, the pick up is going to be not nearly as great as the client that's at 5%. So the results vary by client. But still the impact, the movement of 1% or 2% is still pretty significant, especially in tough economic times. So I think the program is working very well for us. And I think what the clients like most is when we come in and we put -- it's dependent, again, on a client. If a client has a tough situation and they need immediate savings fast, then they can put in exclusive home delivery. And then obviously, they get the bump right away. They may not have a choice, they may need to do that in order to garner the savings. But where there is a choice, they can, in fact, put in Select Home Delivery and get almost to the same level of results, not quite, but they can get fairly close by just letting our teams use consumerology to drive. What we see in a couple of clients is that they've actually put in Select Home Delivery, they've ran that for a while, they took a couple of cases, they took it from low teens, up to the high 30s percent penetration rates. And then they put in exclusive home delivery because at that point, they've converted so many [indiscernible] to mail, that the next step was then just to go ahead and get the rest of them, maximize the savings, and it was already a very widely accepted benefit inside the company. So it can be -- Select Home Delivery can either be a stand-alone product or it can be a stepping stone to exclusive home delivery. So it's what the client needs in their timing. As far as specialty goes, specialty has been one of our bright spots. We don't break it out any longer, because we really do believe it's just one of our tools to battle overall drug trends. But this year has been an incredible year for us, an exclusive in specialty. We've seen margin expansion. We've seen significant increase in the number of prescriptions in this area. And so we're really excited about our specialty offering today."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Can you give us an idea though of how penetrated your book is? And how big that opportunity remains around specialty to fully penetrate specialty and your PBM book of business? Do you have a number around that?",38,"Can you give us an idea though of how penetrated your book is? And how big that opportunity remains around specialty to fully penetrate specialty and your PBM book of business? Do you have a number around that?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","There's two pieces to this. One is, how much do we penetrate into our existing book. And then the other piece is, this is clearly the fastest-growing area of PBM. So those are two -- I'm not trying to avoid your question. I just don't have a number off th",80,"There's two pieces to this. One is, how much do we penetrate into our existing book. And then the other piece is, this is clearly the fastest-growing area of PBM. So those are two -- I'm not trying to avoid your question. I just don't have a number off the top of my head. I'm not exactly sure I know what the penetration rate on my clients is today. So I'll have to try to get that for you."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","But I think it would be fair to say, George, right, that there's still a lot of runway here, that there's still a lot of opportunity around Specialty?",28,"But I think it would be fair to say, George, right, that there's still a lot of runway here, that there's still a lot of opportunity around Specialty?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Absolutely.",1,"Absolutely."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Absolutely, Lisa. There's lots of room to run in this space where, as George said, we've seen very nice growth. And we think there's lots of opportunity over the coming years, to really grow this business and grow it nicely. This is a huge area spend for",83,"Absolutely, Lisa. There's lots of room to run in this space where, as George said, we've seen very nice growth. And we think there's lots of opportunity over the coming years, to really grow this business and grow it nicely. This is a huge area spend for our clients. This is an area where you can really help them save a lot of money. And we think we have unique offering in this space, and we're going to see this grow our business."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","The other side to that, just to pile on. I think that when you think about behaviors, this is an area that's ripe for this, and that we're going to see a massive opportunity when you think about Consumerology. The side effect profile, the results that thi",146,"The other side to that, just to pile on. I think that when you think about behaviors, this is an area that's ripe for this, and that we're going to see a massive opportunity when you think about Consumerology. The side effect profile, the results that this disease have on a given family can be devastating. And so being able to message both the doctors, the patients, the nurses, all that's up and down that ladder, are incredibly important. And as biogenerics come into this marketplace, it's going to be very important that we're out in front of that, because once somebody gets them that first fill, it's going to be hard to get them to change if they stabilize. So giving the information to the doctors, they know what the options are, are very, very important. So this is a big, big thing for us."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, you talked about gross profit and you talked about it improving throughout the year. Can you just help us understand this. Is it the incremental cost of employees that you had in COGS for implementation and integration that will go away? Or is there",59,"Jeff, you talked about gross profit and you talked about it improving throughout the year. Can you just help us understand this. Is it the incremental cost of employees that you had in COGS for implementation and integration that will go away? Or is there other key drivers that will drive gross profit as we move throughout the year?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes and yes, is the simple answer. Certainly, the implementation efforts have increased cost of goods sold in the first quarter, and that will trend down over time as we move through the year. But we've also got a lot of programs. We've got a large acquis",137,"Yes and yes, is the simple answer. Certainly, the implementation efforts have increased cost of goods sold in the first quarter, and that will trend down over time as we move through the year. But we've also got a lot of programs. We've got a large acquisition that we're in the process of implementing on. We've got an operations team here, which is focused on continuous improvement and they're going to keep driving down costs. And we're just going to keep executing. And I mean, you'd heard us say this time and time again, we are focused on alignment. We make money when our clients make money, and we are going to keep doing everything we can using all of our Consumerology tools to save our clients' money. And as we do that, we'd see margin grow."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Next, we'll go to line of Bob Willoughby with Bank of America.",12,"Next, we'll go to line of Bob Willoughby with Bank of America."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","How much did the base business grow? And can you remind us what you have for start-ups as of July 1, if anything? And then secondarily, is it possible to say in any way, shape or form, of the incremental billion you hope to generate from the WellPoint dea",67,"How much did the base business grow? And can you remind us what you have for start-ups as of July 1, if anything? And then secondarily, is it possible to say in any way, shape or form, of the incremental billion you hope to generate from the WellPoint deal? What you actually saw flow through, what percentage of that might have been apparent in the first quarter?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Bob, this is Jeff, I'll try to take that. Let me just say this just upfront. No, I'm not going to answer the second part of your question. And yes I can, and no I'm not going to. We're just not going to break it out. Actually, it's pretty hard to break it",143,"Bob, this is Jeff, I'll try to take that. Let me just say this just upfront. No, I'm not going to answer the second part of your question. And yes I can, and no I'm not going to. We're just not going to break it out. Actually, it's pretty hard to break it out, as it's integrated into the core business. As we think back to -- I'm sorry, I forgot the first part of -- in the core business on a Script basis, we obviously had a good selling season last year, we said. So I think we haven't been precise other than to say that, in the core business, year-over-year, we expect growth in Scripts. And so I'm not going to get a whole lot more detailed than that. But certainly, we think the core business, x WellPoint, certainly was growing."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Is there a July 1 start-up of any consequence or...",11,"Is there a July 1 start-up of any consequence or..."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","No meaningful July 1. I mean, it certainly doesn't move the numbers from that, I see one way or the other.",21,"No meaningful July 1. I mean, it certainly doesn't move the numbers from that, I see one way or the other."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","And we factored those already into our guidance, Robert.",9,"And we factored those already into our guidance, Robert."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And you've given us a number of line items for guidance, but nothing on your share base. Where do you expect that to be for the year?",28,"And you've given us a number of line items for guidance, but nothing on your share base. Where do you expect that to be for the year?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","It's really hard to predict share base, so we try to stay out of that game, because it's so dependent on where the share price goes over the course of the year. When we gave our original guidance, we assumed some kind of de minimis impact from share buyba",95,"It's really hard to predict share base, so we try to stay out of that game, because it's so dependent on where the share price goes over the course of the year. When we gave our original guidance, we assumed some kind of de minimis impact from share buybacks, 1% to 2%. We still think that we'll get about 1% to 2% of EPS gain from share buybacks. So I think you can model that in, but that would get you to a place that's probably not meaningfully different than where we are today."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is coming from John Kreger with William Blair.",11,"Our next question is coming from John Kreger with William Blair."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, if you think about the renewal discussions you're having today and maybe contrast them to a year ago or clearly in a different economic place broadly, how have those changed? And is your WellPoint combination influencing those discussions? How do",44,"George, if you think about the renewal discussions you're having today and maybe contrast them to a year ago or clearly in a different economic place broadly, how have those changed? And is your WellPoint combination influencing those discussions? How do clients perceive that?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","At the end of last year, throughout the third and fourth quarter and even into the first quarter, I think that many clients asked the question, how will WellPoint integration affect us? Will we lose our account manager? Will it change the timeliness of ou",275,"At the end of last year, throughout the third and fourth quarter and even into the first quarter, I think that many clients asked the question, how will WellPoint integration affect us? Will we lose our account manager? Will it change the timeliness of our reporting? Anytime a company goes through a major acquisition, from the client-side, there's always a little bit of noise. And the reason that noise exist, of course, is my competitors are up at their tone [ph]. The noise should exist. And as you know, we've done a lot of these things. And we've grown both organically -- we've grown organically through our acquisitions. So as we've added more and more lives into our business, we've always kept the discipline around selling and around growing the base. And that continues to be our focus. And the best thing that happened to us in the first quarter was the migration of the first tier. Because now the clients can, when they ask the question, ""How am I going to be affected?"" we say, ""Well, how are you affected in the first quarter?"" And most of them didn't sense a thing. None of them, to my knowledge, had any concerns, any issues, nothing. It's not only is it operations as normal, it's a continued focus on Consumerology and driving out the waste. And they didn't even know what occurred. And that's the best view of an integration. And I think if you reach out to the consultant community and ask that question, you'll hear that same comment that the integration is going extremely well and that there is not noise on the street."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Are you seeing client priorities change at all now that presumably, they are maybe a little less worried about the economic backdrop?",22,"Are you seeing client priorities change at all now that presumably, they are maybe a little less worried about the economic backdrop?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well,  I think CEOs and CFOs, at least the ones I know, and I know quite a few, are still very worried about the economic backdrop. A lot of the companies we deal with are global in nature, and you got some issues in Greece and Spain and on and on and on.",334,"Well,  I think CEOs and CFOs, at least the ones I know, and I know quite a few, are still very worried about the economic backdrop. A lot of the companies we deal with are global in nature, and you got some issues in Greece and Spain and on and on and on. And I think that companies have to make tough decisions back in the last year in reducing workforce and making cost-cutting moves. The last thing a CEO wants to do to his organization is to have a roller coaster ride. I think it's going to take a little while before employment comes back. I think companies are going to want to make sure that, that light at the end of the tunnel isn't a train, and they're going to make sure that they, in fact, can see their way. So I think the focus today is every business is focused on cost reduction as possible. Keep in mind, that really plays into our sweet spot. We've been out there for 15 years talking about cost constraints around these things that were really better for health outcomes. And we only got so much noise. Over the last couple of years, it's resonated with companies. And now what companies realize is, in fact, they were able to get those cost savings. We didn't impact members unfavorably. We actually improved clients and member satisfaction, and at the same time, reduced cost. So once we got that training in place, with the clients understand they can take out the cost, while not adversely affecting their relationship with their members, that sets the driveway into the coming years. Even as the economy turns, I think the work we did during this last couple of years paves the way, especially to the earlier question about Lipitor, and other drugs that are coming off patent, to really position us nicely to take advantage of those opportunities. And I have to worry about member disruption to the same level."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Next, we'll go to the line of Ross Muken with Deutsche Bank.",12,"Next, we'll go to the line of Ross Muken with Deutsche Bank."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Given sort of the renewed focus on sort of attracting larger clients and what you'd call kind of the marquee accounts, can you talk a bit about the strategy there for this selling season? And what sort have you learned from WellPoint? And how you're using",70,"Given sort of the renewed focus on sort of attracting larger clients and what you'd call kind of the marquee accounts, can you talk a bit about the strategy there for this selling season? And what sort have you learned from WellPoint? And how you're using some of the newer parts of the Consumerology offering to kind of use as a differentiator as you attempt to attract those accounts?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","When we go into this year, we're looking at opportunities again. The opportunities -- there's a lot of opportunities out there, just to be clear. And we would need to find opportunities that resonate with our book of business, as I said earlier. So that's",256,"When we go into this year, we're looking at opportunities again. The opportunities -- there's a lot of opportunities out there, just to be clear. And we would need to find opportunities that resonate with our book of business, as I said earlier. So that's always the first call, is to make sure we can find those clients that want our offerings, that has to accept our approach, and then we can stay focused on the core things we do. So once that occurs and we find them, then I think it goes back to Consumerology and our approach. We love going into a client, and not only signing off on day one, but then selling them Select Home Delivery. In addition to that, our teams are working very hard on other programs, such as step therapies and other similar-type programs, in order to -- limited networks and curtailing are shrinking the size of the formularies. We're doing a lot of different things in using the Consumerology approach to attack those situations. Also, adherence is a major, major driver. As I said in my prepared comments, there's $163 billion, the majority of which is attributable to adherence. That's an opportunity for us to drive down overall healthcare costs. And so that's our approach to the marketplace. That's what we try to get to resonate, not just with marquee clients but any client. We're looking at opportunities in all of the different segments we operate in. And we're trying to drive better cost outcomes for our clients."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And Jeff, on the balance sheet, you have a lot of cash flow that's being generated this year. You're obviously paying down some debt and buying back some shares. But from an M&A standpoint, how are you thinking about sort of the environment? There's a lot",85,"And Jeff, on the balance sheet, you have a lot of cash flow that's being generated this year. You're obviously paying down some debt and buying back some shares. But from an M&A standpoint, how are you thinking about sort of the environment? There's a lot of assets right now in the private market. And also, potentially, with the financing environment still being attractive, people are looking at other types of deals. How would you sort of characterize the activity you're seeing on that front?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Obviously, I'm not going to comment on specific deals. But I think our position, my position, hasn't really changed over the years here. It's pretty simple. We look at opportunities for our cash. And I mean, absolutely you're right, we certainly got a ver",226,"Obviously, I'm not going to comment on specific deals. But I think our position, my position, hasn't really changed over the years here. It's pretty simple. We look at opportunities for our cash. And I mean, absolutely you're right, we certainly got a very strong cash flow year, and we have a very strong cash balance. So certainly, as I said in my prepared remarks, first goal is to pay down, pay off the debt that's coming due here in 2010. But even after that, we're left with a very strong cash position. And as we look at that cash position, we say, first off, we want to invest in the projects that are driving this company. We've got a bunch of great people here. They always have great ideas, and we want to invest in those ideas and keep driving our return on invested capital with new ideas. After that comes M&A. Certainly, we've had great experience with good accretive M&A over the life of this business. We're happy with the M&A. We're integrating at the moment with NextRx. And to the extent there are more opportunities out there that we think have the same kind of positive returns, we're anxious and interested at getting them done at the right price and the right terms. But other than that, it's hard to comment on specifics."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is coming from the line of Tom Gallucci with Lazard Capital Markets.",15,"Our next question is coming from the line of Tom Gallucci with Lazard Capital Markets."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","I guess on the selling season, as it pertains to WellPoint, you sort of talked about customers wondering how it was going to impact that negatively. What about from a positive standpoint, do you feel like you're positioned any different this year in the s",71,"I guess on the selling season, as it pertains to WellPoint, you sort of talked about customers wondering how it was going to impact that negatively. What about from a positive standpoint, do you feel like you're positioned any different this year in the selling season for different types of customers, given the bigger scale that you've got? And is there any sort of tangible evidence of that at this point?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Ed Ignaczak and his team is really focused on integrating our approach and our sales into the WellPoint approach. I think when you look at our website, when you look at our tools and what we can do, it's significantly better than what NextRx has to offer",298,"Ed Ignaczak and his team is really focused on integrating our approach and our sales into the WellPoint approach. I think when you look at our website, when you look at our tools and what we can do, it's significantly better than what NextRx has to offer today. So we're trying to integrate our sales approaches and we're holding sessions with the NextRx people to update them on how to sell PBM, and how to approach the marketplace, how to be better at it. As I've told my counterpart over at WellPoint, our view is, I would prefer to grow through them as to grow directly. It's a tremendous opportunity for us to combine our forces in order to grow our joint book of business. And we are absolutely fixated on that, and it's a great approach to the marketplace. So yes, I think the real value, though, is still a couple of years out. I shouldn't say a couple years, it's probably more than a year though. And that is to really get an integrated approach to the marketplace on the overall medical and drug lab, the whole spectrum of care brought together. And I know WellPoint is absolutely fixated on that, as well as we are, to change the way healthcare is delivered in this country, and really to start taking costs out of the equation in order to meet the needs of the country. So that's something we are continuously working on. We both have set up working groups to focus on that as we go forward, and it will stay one of our priorities. And once we get to the integration, we'll keep you updated on what we're doing here. And I think we're just going to have a great offering in the future."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","On Select Home Delivery, are you seeing any concentration of particular types of customers that are interested in that, ones that already have a lot a mail or don't, or employers versus health plans?",34,"On Select Home Delivery, are you seeing any concentration of particular types of customers that are interested in that, ones that already have a lot a mail or don't, or employers versus health plans?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","It's been mostly on the employer side, initially, but now we've got several health plan clients that have actually rolled it out this year. So we're seeing it on both sides. I would tell you that it's also across-the-board. We've had clients with very lit",137,"It's been mostly on the employer side, initially, but now we've got several health plan clients that have actually rolled it out this year. So we're seeing it on both sides. I would tell you that it's also across-the-board. We've had clients with very little mail penetration and has seen significant increases in mail penetration through the programs. We've also had clients that had high penetrations. But as you know, as with an aging population, more and more people are going into maintenance medications. And this is a good way to capture those new users of prescription drugs and convert them over to mail in a timely fashion to continue to drive down costs. So we're seeing it across the spectrum. Probably still today, more on the employer side than anywhere else, but it is across-the-board."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","You've sort of looked at the Medicare PDP, your own Medicare PDP, a little bit differently than your competitors in the last couple of years. And now with sort of the way reform looks, are you thinking about that any differently? Or how should we be think",61,"You've sort of looked at the Medicare PDP, your own Medicare PDP, a little bit differently than your competitors in the last couple of years. And now with sort of the way reform looks, are you thinking about that any differently? Or how should we be thinking about what you're going to do with that over the next few years?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, from my perspective, and I think I've been saying this for quite some time, is that I don't think Express Scripts is a household name. So to compete in the individual market on our margins, I just don't think we have a very good offering. I don't ha",285,"Well, from my perspective, and I think I've been saying this for quite some time, is that I don't think Express Scripts is a household name. So to compete in the individual market on our margins, I just don't think we have a very good offering. I don't have the money that Coca-Cola, Anheuser-Busch InBev, whatever, has these, Procter & Gamble, to spend to go after the consumer marketplace. Our best answer is, we've got great partners with WellPoint and many other brewers plants [ph] and clients that are household names in their marketplace. I would rather partner up with them and have an offering that's recognized in their given geographic area, and go in and try to sell the individual business through them and give them the tools that they need to be successful, and we grow as they grow. That's always been our strategy. And I think it's a great strategy for them as they pick up the medical side, and it's a great strategy for us when we pick up the drug side. I think if, in fact, you see -- we will see a growth there with the 30 million people coming to the market. How many of those people want to carve out medical from drug at that point. That's a big question. But I think our clients are well positioned to gain their share of the overall comprehensive medical and drug side. And so when they lay in those clients, we'll pick up the drug side through them, which is the best of all answers. So I like where we're positioned. That didn't happen by accident. We focused on this approach, and I'm very pleased with where we sit."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","That question will come from the line of Ricky Goldwasser with Morgan Stanley.",13,"That question will come from the line of Ricky Goldwasser with Morgan Stanley."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","First, I think you said that 15% of lives were migrated by April 1. What percent of lives do you expect to migrate by the end of the second quarter? And then, if you can give us some more color on what percent of year-over-year change in gross profit is f",53,"First, I think you said that 15% of lives were migrated by April 1. What percent of lives do you expect to migrate by the end of the second quarter? And then, if you can give us some more color on what percent of year-over-year change in gross profit is from DoD reallocation?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, a couple of things. We're not going to get into projecting migration, and it's not really all that relevant at the end of the day. The idea is we have to get the first one done. When you do the first one, you learn so much about the different operat",181,"Well, a couple of things. We're not going to get into projecting migration, and it's not really all that relevant at the end of the day. The idea is we have to get the first one done. When you do the first one, you learn so much about the different operating platforms and the people. And so the idea is, you get the first one done, and then the other ones come in line. So we haven't laid out a schedule. We said we'd get this done in 12 to 18 months. We're still very comfortable with that approach, and that's what we're going to focus on. We'll give you updates each quarter as we progress. One of the things we have been focused on, though, is making sure that those areas that drive the highest level of synergies are first and foremost in our integration plans. So we're going after those as quickly as we can. Secondly, as far as client specifics, we don't discuss gross profits or profitability on any given client. So I really can't get into that."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","I mean, I guess the question is not really on profitability. There's just been a change, kind of like reallocating in that contract?",23,"I mean, I guess the question is not really on profitability. There's just been a change, kind of like reallocating in that contract?"
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, the contract changed. We now do a lot more things, which by definition, means it's more profitable for us. And we also, because we adjudicate the claims and do many other elements of it, we gross up the numbers into revenue. But I don't want to get",110,"Well, the contract changed. We now do a lot more things, which by definition, means it's more profitable for us. And we also, because we adjudicate the claims and do many other elements of it, we gross up the numbers into revenue. But I don't want to get into specific clients. We just don't do that.
Well, again, I thank everyone for listening in to our call today. We appreciate your confidence in us. And we look forward to the integration of NextRx. We think great things are ahead of us, and we look forward to talking to you again next quarter. Thank you very much. Have a great day."
317975,100362867,60840,"Express Scripts Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Evernorth Health, Inc.","Operator","With that, ladies and gentlemen, that does conclude our conference for today. Thank you very much for your participation, and for using AT&T Teleconferencing. You may now disconnect.",28,"With that, ladies and gentlemen, that does conclude our conference for today. Thank you very much for your participation, and for using AT&T Teleconferencing. You may now disconnect."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter 2010 Earnings Call. [Operator Instructions] I'd now like to turn the conference over to David Myers, Vice President of Investor Relations. Please go ahead.",37,"Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter 2010 Earnings Call. [Operator Instructions] I'd now like to turn the conference over to David Myers, Vice President of Investor Relations. Please go ahead."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, and welcome, everyone to our second quarter conference call. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. Before we begin, I need to read the following Safe Harbor statement. Statements or comments made on this",197,"Thank you, and welcome, everyone to our second quarter conference call. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. 
Before we begin, I need to read the following Safe Harbor statement. Statements or comments made on this conference call may be forward-looking statements and may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors, which are discussed in detail in the company's filings with the Security (sic) [Securities] and Exchange Commission. 
For clarity purposes, all numbers we talk about today will be on an adjusted basis. Please refer to the tables in our press release for the reconciliation of GAAP to the adjusted numbers we will be discussing. The reconciliation of EBITDA to net income can also be found in our earnings release. The earnings release is posted on our website at express-scripts.com 
At this point, I'll turn the call over to Jeff, who will discuss our second quarter results."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thanks, David. We plan to keep our prepared comment brief as we've already published a lot of data, and we believe the question-and-answer session provides a better opportunity to address your questions and our thoughts and strategies. In summary, we ha",481,"Thanks, David. We plan to keep our prepared comment brief as we've already published a lot of data, and we believe the question-and-answer session provides a better opportunity to address your questions and our thoughts and strategies. 
In summary, we had another strong quarter. All of our metrics are positive and moving in the right direction. Earnings and margins were up, cash flows were strong, we're raising the bottom end of our guidance, and we now have more than 50% of the WellPoint live migrated on to our system. Given this strong performance, we remain confident in both the short- and long-term prospects for our core PBM business and our ability to realize more than $1 billion of incremental EBITDA from NextRx. 
Moving on to a few more details in the quarter. We reported second quarter adjusted earnings per share of $0.60, an increase of 33% over last year. This increase was driven by EBITDA, which grew 46% from the prior year and 6% sequentially as a result of strong operating performance in the core business and the NextRx acquisition. 
Metrics for the quarter were solid across the board. Adjusted claims grew over 51%, reaching $189 million, mainly reflecting the addition of NextRx, but also the results of a successful selling season. Gross profit was up 31% over last year and gross profit for Rx increased 7% sequentially to $4.11. Going forward, we expect our strong performance in the core business and the realization of synergy will result in improving gross margins for the remainder of the year and into 2011.
As expected, SG&A spending increased from Q1 levels, as we continue to invest in our future. We continue to expect that SG&A, excluding amortization and nonrecurring items, will be between $865 million that $881 million for 2010. EBITDA for adjusted Rx reached $3.10, up sequentially from $2.92 last quarter. Cash flow from operations was up 197% from last year to $688 million. Cash flow was in line with our forecast and is on track to exceed $2 billion for the year. 
As a result of our strong operating fundamentals and positive outlook, we are raising the low end of our EPS guidance range for the year. 2010 EPS is now expected to be in the range of $2.45 to $2.50, representing growth of 25% to 27% on an adjusted basis. 
We expect to give initial 2011 guidance with the release of Q3 earnings later this fall. Until then, let me reiterate what I said at the beginning of the call. Given our strong performance year-to-date and the market factors we are seeing today, we remain confident in both the short- and long-term prospects for our business, our ability to grow margins throughout the year and into 2011, and that we will realize more than $1 billion of incremental EBITDA from NextRx. 
And with that, I'll turn it over to George."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, Jeff, and good morning, everyone. Our second quarter financial results reflect the strong fundamental performance of our core PBM business. We remain on track to complete the integration of NextRx in the lower end of 12 to 18 months with over 5",734,"Thank you, Jeff, and good morning, everyone. Our second quarter financial results reflect the strong fundamental performance of our core PBM business. We remain on track to complete the integration of NextRx in the lower end of 12 to 18 months with over 50% of our members already migrated on to our system. In addition to our integration activity, we have begun working with WellPoint on cultivating our alliance and deploying next-generation strategies and innovative programs to enhance the healthcare value we deliver to our members. 
Although the selling season is not yet complete, I will give you a preliminary indication of our progress. In 2010, we have seen high retention rates by incumbent PBMs for signature accounts. We define signature accounts as those with 1 million or more adjusted prescriptions per year. However, we also see significant opportunities that gain share in the smaller to middle market. 
Consistent with previous years, we have made decisions not to bid or renew certain accounts. We focused our efforts towards those clients that share our commitment to take the waste out of healthcare, while improving health outcomes for their members. 
With our unique tools and aligned business model, we can significantly reduce client expense, improve patient healthcare and create value for our shareholders. We accomplished this with our clients when we are aligned, both clinically and economically.
For example, we chose not to renew a few NextRx direct clients, including a major retailer. Because of their preference for management and the pharmacy benefit was not consistent with our approach, we made this decision. Our past experience have taught us that these types of arrangements do not deliver value for our client. It can also hinder our ability to leverage economies of scale and dilute the value of our overall offerings to the rest of our book of business. 
I should point out in the early 2000s, this retailer was a client of Express Scripts. When they came up for renewal back then, we also elected not to renew it. When we perform due diligence on NextRx, we specifically evaluated all the direct contracts. We knew a few of these contracts were managed in a manner that did not align with our approach and philosophy. As such, we assume these clients would terminate them. And when we calculated our purchase price and run rate EBITDA, we calculated those terminations in those numbers.
Although we decided not to renew certain clients, to date, we made substantial progress with our overall renewal efforts. At this point, we are more than halfway complete with our 2011 renewals. We anticipate by the end of the year, we will have client retention consistent with our historical norms of about 95%. 
Today, we're having another strong sales year. We're ahead of last year's pace and have added over 140 clients, including two new signature wins. As a result of the strong selling season so far and strong operating performance in all aspects of our business, we currently expect 2011 claims to be flat to slightly up compared to the 2010 claims. We also expect EBITDA per claim to increase through 2011. We will continue to update you as the selling season progresses.
In the midst of a tough economy and the effect of high drug trends, our tools are more in demand than ever before. Throughout our history, we have identified and tackled inefficiencies in healthcare. From the early days, where our primary tools were rebates and retail network management, we evolved with innovative tools to drive greater use of generics and low-cost brands and increase the use of home delivery. We will continually evolve by focusing on those issues which are driving up the healthcare costs for our clients, both today and in the future. Namely adherence and specialty management are the focus of their needs today and our focus of our clinical programs. 
Our ability to manage trend, coupled with our expertise in Consumerology, provides us with the ability to drive outlays for our clients, improve outcomes for patients and deliver increased earnings to our shareholders. As Jeff stated earlier, we remain positive on the underlying trends and opportunities in our space and remain confident in our ability to improve health outcomes and drive outlays, meeting the needs of our clients, lowering costs and generating exceptional value for our shareholders. 
At this point, I'd like to open it up to questions."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","[Operator Instructions] And we will begin with the line of Lisa Gill with JPMorgan.",14,"[Operator Instructions] And we will begin with the line of Lisa Gill with JPMorgan."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, as you talked about last quarter around pricing, can you maybe just give us an update if anything has changed in your mind over the last couple of months on the pricing front? Number one. And then number two, as you talk about the new clients that",100,"George, as you talked about last quarter around pricing, can you maybe just give us an update if anything has changed in your mind over the last couple of months on the pricing front? Number one. And then number two, as you talk about the new clients that you've signed, maybe can you just give us some indication as to what plan design looks like, if we're looking at scripts roughly flattish, but you're saying EBITDA per script is going to up? Are you seeing people do more step therapy, more mail, et cetera, in your new book of business?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","From a pricing perspective, and we did talk about this last quarter. You know I've been at this business since I came in at the end of 1997 then here to '98 and forward, pricing has always been extremely aggressive. And I remember back in 1998 addressing",847,"From a pricing perspective, and we did talk about this last quarter. You know I've been at this business since I came in at the end of 1997 then here to '98 and forward, pricing has always been extremely aggressive. And I remember back in 1998 addressing this question, I think in those days our EBITDA per script was about $0.70. And when you think about where he sat then and clients need to take cost out of the equation, there's two ways you can go about it. If you have a business model, which is ineffectual, that doesn't deliver needs to the clients, then effectively what you have to do is you have to give up your price because you don't have the clinical tools and the expertise to take out costs. On the other side of that equation, though, if in fact, you have clinical tools and you have the ability to drive out costs to a much better item, is it safe, is to keep people in the generics and to home delivery and to lower-cost brand, where we can share rebates back with our clients to drive down their costs, and everybody wins in that equation. The clients save money, the patients save money and we make more money. And that's again, around our model of alignment. We put our profits into those second-tier branded products that save money for our clients are more most efficacious. We put our profits and greater levels of our profits into the generic products. And of course, mail, which is the winner for everybody in the equation as you get better health outcomes and lower costs is also our highest profit margin items. So as long as we keep that model strong, the best way we can take out cost is not to focus on our pricing, but instead to focus on the clinical programs that drive those prices. We've got over 95% retention with our book of business. The reason I believe that exists is because we can win year in and year out and effectively show our clients that we hold ourselves accountable to a scorecard, where we show what overall drug trends are doing across the industry, what drug trends are in their specific industry and then what it is for them. And when we're doing our job right, their trends are lower than other companies in their industry and are lower than the overall PBM industry. So I do believe that approaching pricing properly does not mean it's a win-lose situation, the client versus the PBM. It's a win-win. When you have an effective model, such as ours, that focuses on the economic behaviors of our members and behavioral economics to save more appropriately, we can drive out those costs and we can have it a win-win for all three constituents: the members, the plan sponsors and for us. As far as our wins, keep in mind, we're saying that we're going to be flat to slightly up on claims next year. But that takes into consideration the loss of a major retailer and another client, another direct client that was part of the deal that came over with us that we also knew. The way they approach it was not in line with us. Just talking about the retailer for a moment. Keep in mind, the way that one works. It's adjudication only, and 95% of the volume only goes to their stores. With that situation, where's the leverage? What value do you get in signing up a client like that? Obviously, they don't want clinical programs, they want everything dirt cheap, they don't want any intrusion by us in driving better health outcomes. That's not the way our company is put together. That's not the way we manage, and that's not the way we train our employees. So to try to carve-out and do one-offs for clients like that creates tremendous, tremendous inefficiency inside of our operations and technology components of our business and it's just not worth it, especially just to adjudicate a client. So what we do is we are willing to jettison those types of clients and sign on clients that looking at either to have strong three-tier systems, that have a passion for trying to drive out costs, we sent up clients that have two tiers. But the management team is dealing with a tough labor situation where they're confined by a labor contract, which doesn't allow them to go to three-tier or make big differentials between generics and brand. Well, we have the tools to Consumerology to go in and without changing claim designs to drive higher generic bill rates, to drive higher mail penetration and the unions buy in to that. And they allow us to take costs out for our clients and meet their need, and therefore, drive our profit. When we get clients lined up like that, our scale grows. Scale, in and of itself doesn't matter, unless it's a lined scale going after the right metric in order to drive overall profitability."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","So what you're saying is that it's just more of the same for 2011, you're not really seeing much as far as changes go, George, and what people are looking for from plan design? So that they're basically looking to Express Scripts for all the things you ju",58,"So what you're saying is that it's just more of the same for 2011, you're not really seeing much as far as changes go, George, and what people are looking for from plan design? So that they're basically looking to Express Scripts for all the things you just talked about, rather than making big plan design changes?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","I would say, every client is different, Lisa, so what we see in some situation is the client will have -- that's taken on a step therapy program. And once we get huge utilization in the preferred product, then what a client may do in the following year is",269,"I would say, every client is different, Lisa, so what we see in some situation is the client will have -- that's taken on a step therapy program. And once we get huge utilization in the preferred product, then what a client may do in the following year is eliminate a drug off the tier in order to get even better economics. So we see people constantly, and that's our job, is for our account management team and our clinical pharmacists to sit down with those clients and help them work with their book of business in a situation they're in and tweak it. So hopefully, for all of our clients, we are constantly tweaking plan design with them in order to drive the desired benefits and minimize employee disruption. Especially in today's environment where HR departments have been cut back, they don't want employee noise. And so I think our tools are designed to get into those results while minimizing that noise. And I think that's the reason that works. And again, if drug trends are running 7%, 8%, and we can deliver 0% to minus 1%, we've done a pretty effective job. And therefore, price concessions are nearly as important. Having said all that, keep in mind, no client has ever called me on the phone and offered me more money the following year. The increase, to walk away from discount. So our job is to figure out how do we drive those discounts and drive those costs and still do what we do each and every quarter for our shareholders, which is drive up our profitability."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then just one follow-on, Jeff, did I hear you correctly that now you expect free cash flow for the year to be north of $2 billion?",28,"And then just one follow-on, Jeff, did I hear you correctly that now you expect free cash flow for the year to be north of $2 billion?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, that's correct. We expect cash flow to be above $2 billion. But to be fair, I think we say, it's definitely the same thing last quarter.",27,"Yes, that's correct. We expect cash flow to be above $2 billion. But to be fair, I think we say, it's definitely the same thing last quarter."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Next, we will go to the line of Robert Willoughby with Bank of America.",14,"Next, we will go to the line of Robert Willoughby with Bank of America."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, on some of those NextRx clients that you've walked away from, how does this jive with the guaranteed claims number that you have with WellPoint? Have these clients been excluded from day one?",34,"George, on some of those NextRx clients that you've walked away from, how does this jive with the guaranteed claims number that you have with WellPoint? Have these clients been excluded from day one?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Obviously, we're looking for strong relationships with our partners, and we believe that WellPoint is a great partner. And so when we went in, we knew this would go away. So we never wanted to include them in the calculation. That wouldn't be fair to them",59,"Obviously, we're looking for strong relationships with our partners, and we believe that WellPoint is a great partner. And so when we went in, we knew this would go away. So we never wanted to include them in the calculation. That wouldn't be fair to them and it wouldn't be fair to do in general. So we excluded them."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And just you've obviously bought stock back at some higher levels here than where the stock is today, might share repurchases going forward take a different form, more front-end loaded or overnight repurchases of some sort or any changes on how you're goi",46,"And just you've obviously bought stock back at some higher levels here than where the stock is today, might share repurchases going forward take a different form, more front-end loaded or overnight repurchases of some sort or any changes on how you're going about that?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","We've always had the same philosophy towards the use of our cash flow, strategic opportunities will always come first, but we weigh those against the options. So once we look at those, we then look at investing in ourself. But as you know, our business is",77,"We've always had the same philosophy towards the use of our cash flow, strategic opportunities will always come first, but we weigh those against the options. So once we look at those, we then look at investing in ourself. But as you know, our business is not all that capital intensive. And then the third option is share repurchase and you've seen our behavior for the last 12 years. So I think that speaks for itself."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","And next, we will go to the line of Tom Gallucci with Lazard Capital Market.",15,"And next, we will go to the line of Tom Gallucci with Lazard Capital Market."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","So just to be clear, George, when you're talking about not renewing, obviously, these are things that you didn't even bid on, is that right?",25,"So just to be clear, George, when you're talking about not renewing, obviously, these are things that you didn't even bid on, is that right?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes. Well, the one big retailer, we didn't bid on that. There was no sense in bidding on that. I think, I don't know if you've ever been a part of a PBM or seen what a proposal looks like, but we're talking thousands of drugs and a lot of the plans have m",108,"Yes. Well, the one big retailer, we didn't bid on that. There was no sense in bidding on that. I think, I don't know if you've ever been a part of a PBM or seen what a proposal looks like, but we're talking thousands of drugs and a lot of the plans have multiple divisions and so you have different claim designs for different division. It's a lot of work. And I don't believe in spending money that doesn't make sense. So in that situation, we could see the pricing. We knew where it was at. We knew the client well, and we elected not to bid it."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Maybe just changing gears, your volume for the year is sort of in line with what you've talked about in the past so far. But obviously, there's been issues that have been discussed out there about physician office visits and pressures on an overall indust",80,"Maybe just changing gears, your volume for the year is sort of in line with what you've talked about in the past so far. But obviously, there's been issues that have been discussed out there about physician office visits and pressures on an overall industry script volume, or maybe some shifts in mix versus what people are looking for. Can you just maybe make a comment toward the macro environment and how it's shaping up versus what you've been expecting?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Jeff, may want to chime in here as well, but our focus is not just what the environment evolved. We had to be a major player in the environment. So when we see members, diabetic, people on look to lowering drugs, hypertensive, hence, hypertensive drugs, w",209,"Jeff, may want to chime in here as well, but our focus is not just what the environment evolved. We had to be a major player in the environment. So when we see members, diabetic, people on look to lowering drugs, hypertensive, hence, hypertensive drugs, we see that they're not filling their scripts. We don't just say, ""Okay, it's a bad economy."" We reach out to those members and with our clinicians and our pharmacists, and we try to make sure they understand the impact of non-adherence and we do a pretty good job. Year-to-date, we're actually seeing trends close to 3% to slightly under that in our book of business. Utilization trends, we see it both in new prescriptions being filled, as well as in renewals. I can't speak to some of the comments made by others and why they're not seeing the same thing we are, but maybe because our Consumerology or because probably, because our Consumerology approach really does work and our messaging to our members really is effective. And it does drive behaviors, and we are getting those better clinical outcomes. And I 100% believe it that it's working and we're seeing the numbers come through. Jeff, do you have anything you'd like to add?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","I think that's exactly right. We look in detail at our utilization yesterday again, after our comments were made and our utilization is exactly where we forecasted it for the year and adherence remains very strong in our book.",40,"I think that's exactly right. We look in detail at our utilization yesterday again, after our comments were made and our utilization is exactly where we forecasted it for the year and adherence remains very strong in our book."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Any differences in mix, retail, mail, et cetera?",8,"Any differences in mix, retail, mail, et cetera?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, mail is always stronger. And again, I think, it only make sense, right, if you're an Express Scripts' mail user, a call comes into your house or a text message comes to your phone or whatever your appropriate means of communication is and its got Exp",208,"Yes, mail is always stronger. And again, I think, it only make sense, right, if you're an Express Scripts' mail user, a call comes into your house or a text message comes to your phone or whatever your appropriate means of communication is and its got Express Scripts on. If you're a mail user and you're using our pharmacy on a regular basis, chances are you're going to open it and read it and see what we have to say. And so we reach out to the individuals when they -- in the scripts, if we see that their renewal is due and they haven't refilled it yet, we'd send out a reminder notice to them. They can sign up for automatic renewals if they would -- so it could just show up automatically, if they want. So we give them a lot of tools and a lot of opportunities. We got our pilots going with our ball caps. So that's giving us some very positive results as well. So we constantly look for ways to evolve our programs to make sure our member use the first sign of defense, which is prescription drug to maintain their better healthcare outcomes. And I think we're very effective at it."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Next, we will go to the line of Glen Santangelo with Crdit Suisse.",13,"Next, we will go to the line of Glen Santangelo with Crdit Suisse."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","One of the questions I think that's been on a lot of people's minds, post reform, is maybe whether the insurance companies might decide to claw their PBM businesses back in house based on the new MLR rules or ultimately decide to outsource those businesse",101,"One of the questions I think that's been on a lot of people's minds, post reform, is maybe whether the insurance companies might decide to claw their PBM businesses back in house based on the new MLR rules or ultimately decide to outsource those businesses. We obviously had the WellPoint data point last year. And then this week, we had Aetna. George, I don't know if you kind of have a view on potentially the direction of those captive PBMs? And maybe if you think there's more opportunity down the road potentially what you see given within the reform rules?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Quite frankly, I think it works to our advantage. When you have pressure and you got to figure out how do I maximize profits, keep in mind, that a health plan selling an insured product, when that drug costs comes in to them, that drug is going to be incl",249,"Quite frankly, I think it works to our advantage. When you have pressure and you got to figure out how do I maximize profits, keep in mind, that a health plan selling an insured product, when that drug costs comes in to them, that drug is going to be included in that premium costs so it's already in the number. When we pay the drug on their behalf, it becomes part of their cost of goods sold. So the drug cost is embedded into their MLR. So that's in there, whether they do it internally or externally. Now the question becomes how do you make profits of this? And how do you get the best outcomes? So our job is to make sure that we are better than the alternative in-sourcing and I think it speaks for ourselves. WellPoint saw our expertise in this area. They have a tremendous expertise on the medical side, by them allowing us to manage the drug side for them, their focus on the medical side. I believe they can drive their overall loss ratios to the right level to meet their clients' needs and allow them to maximize their profit levels within their book of business. And I think that's what it's all about. So our focus on the drug side, they're focused on the medical. And then our joint focus on overall health outcomes, I think, is a winning combination that you'll see in both of our results as we go forward."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","So with kind of that being said, you would expect to see that trend towards outsourcing continue. Is that a fair way to characterize that?",25,"So with kind of that being said, you would expect to see that trend towards outsourcing continue. Is that a fair way to characterize that?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","I'm pretty biased with this, obviously. So you're asking me, I would think it's the right answer. We provide outsource benefits to many, many Blues claims around the country, plus other managed care organizations. I think we are considered by most, if not",150,"I'm pretty biased with this, obviously. So you're asking me, I would think it's the right answer. We provide outsource benefits to many, many Blues claims around the country, plus other managed care organizations. I think we are considered by most, if not all of them, as their right hand in helping them manage their overall cost. I think it's the right answer. I think it's transparent. From their perspective, they're getting the best of all worlds. They're getting the value of a $40-plus billion revenue company that can make the investments in the drug side that they need to be competitive. And at the same time, they're getting very good pricing in the proper clinical outcomes for their members. It's a great combination for all the parties, I mean, while we can create value for our shareholders. So I think it works and I think it works great."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, maybe if I could just ask one other follow up. If I listen to kind of your call and then CVS and then ultimately Medco, it kind of sounds like each quarter you guys are sounding more and more different from each other and your models are kind of e",108,"George, maybe if I could just ask one other follow up. If I listen to kind of your call and then CVS and then ultimately Medco, it kind of sounds like each quarter you guys are sounding more and more different from each other and your models are kind of evolving further and further away from each other. How is that being perceived with the client base out there? Do you think the bigger clients are starting to view you guys more and more differently over time? And will that ultimately impact pricing in either direction as maybe you're viewed potentially less as a commoditized business over time?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","I've always believed that. I've always believed that we were different and our approach was different. We have a very strong focus on that number. Pat and Gary, operations and IT, Ed from sales to account management, their whole mission is to treat each o",309,"I've always believed that. I've always believed that we were different and our approach was different. We have a very strong focus on that number. Pat and Gary, operations and IT, Ed from sales to account management, their whole mission is to treat each of those 65 million members as an individual and to give the right tools and the right offering to not just worry about the 5% of the patients we spend 80% of the drug costs, but instead to focus on every member. Because if you're one of those other people that just have episodic care, you don't care. If you know that you're taking really good care of that other 10% or 15%, you want to know that you're taking care of, and that's our approach. We treat each member with a tremendous amount of respect and a passion for their situation and try to solve it. I do think that makes us different in at least at my view. I can't speak to Medco or Caremark view. You got to ask their CEOs. Their approaches and what their doing. But I do think that each of us have a different approach to the marketplace. I like the things that they are all different. Again, as I started in my prepared comments, I don't believe that the answer is just the drop price. If you just got to drop price to get business, that speaks for the quality of your service and your offering. I think you got to be able to just go in there and show that you can drive better health outcomes, while lowering costs. And if you can do that, you can maintain your profitability. If you don't have a model that can deliver that, then you can only deliver on costs, and that's not what we're going to be."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","And next, we will go to the line of Ann Hynes with Caris & Company.",15,"And next, we will go to the line of Ann Hynes with Caris & Company."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Have you ever disclosed how much of the $1 billion incremental synergies you have included in guidance for 2010? And if you haven't, will you do that?",27,"Have you ever disclosed how much of the $1 billion incremental synergies you have included in guidance for 2010? And if you haven't, will you do that?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","I'll let Jeff answer this. But from my perspective, I think, you also have to understand that WellPoint has many, many, what we call, dope [ph], and that's different plain designs by -- they have 14 different Blues plans in each of those fill a myriad of",202,"I'll let Jeff answer this. But from my perspective, I think, you also have to understand that WellPoint has many, many, what we call, dope [ph], and that's different plain designs by -- they have 14 different Blues plans in each of those fill a myriad of different products. They have come on to our systems. We can calculate the synergies that we're going to gain from where we stood a year ago when we closed the deal or before we close the deal. Once you put all the companies together, it all gets commingled. We buy drugs at mail order. We negotiate discounts from the retail drugstore chain. We don't negotiate discounts and rebate. That's why it's so important that we have a homogeneous approach to the marketplace, and we no longer focus. I know many of you look and try to focus on how much is coming out of WellPoint and how much is coming out of this. For us, it's a lot of allocation, and we feel very, very confident in the numbers and the trends that we have. But we just don't break those out. We don't talk about client-specific economics, and we're not about to now."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And just a follow-up, Jeff, you made a comment that SG&A will be going up to invest in the future. Can you discuss some of the projects that you're working on?",32,"And just a follow-up, Jeff, you made a comment that SG&A will be going up to invest in the future. Can you discuss some of the projects that you're working on?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Sure. We've spent a lot of effort here. As George was just talking about, building out better and better systems to make sure that we're well serving every individual client out there, and providing just absolutely flawless care for our clients, for our m",112,"Sure. We've spent a lot of effort here. As George was just talking about, building out better and better systems to make sure that we're well serving every individual client out there, and providing just absolutely flawless care for our clients, for our members and along those lines. You'll also hear us talk a lot about behavioral economics, and we're spending a lot of time and effort there in building out new programs, new systems that really led us continue to build our lead there, continue to build our intellectual property. So that we can continue to deliver better health outcomes and lower cost to our clients and members along those fronts."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","And next, we will go to the line of John Kreger with William Blair.",14,"And next, we will go to the line of John Kreger with William Blair."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Another question about the progress around the WellPoint integration. It seems like you gained some speed recently. Given that, are you starting to feel comfortable that perhaps in 2011 you could start transitioning to the next phase where you can drive m",62,"Another question about the progress around the WellPoint integration. It seems like you gained some speed recently. Given that, are you starting to feel comfortable that perhaps in 2011 you could start transitioning to the next phase where you can drive more mails, specialty and some of your more clinical programs? Or should we view that more as an opportunity for 2012?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","The first thing we want to do is get everybody on the same platform, and that's appropriate. As they come on to our platforms, we now have the tool in our operations centers to actually start effectuating and driving, especially from the generic side. Tha",134,"The first thing we want to do is get everybody on the same platform, and that's appropriate. As they come on to our platforms, we now have the tool in our operations centers to actually start effectuating and driving, especially from the generic side. That's already starting to happen. It becomes full force though with a real drive behind it in 2011. So we're not waiting for 2012. What I'd hope what we're doing in 2011 is try driving their generic penetration. We are where it is today, as well as the mail order. And we also, simultaneously, through Dr. Miller, we have a focus on what is that next-generation. Those groups already meeting, and we hope to start delivering on some combined new approaches to the delivery of healthcare throughout 2012 and '13."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then George, just a follow-up question on health care reform, based on what you know now, when do you think you might start to see some additional competition within the Specialty business through biosimilars?",35,"And then George, just a follow-up question on health care reform, based on what you know now, when do you think you might start to see some additional competition within the Specialty business through biosimilars?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","We've been meeting, both Jeff and myself and many of my senior management team have been meeting with several representatives and senators. It's great we got in what we got in. We fought hard for that, but we're still fall far short of where we need to be",209,"We've been meeting, both Jeff and myself and many of my senior management team have been meeting with several representatives and senators. It's great we got in what we got in. We fought hard for that, but we're still fall far short of where we need to be. I think the big question for pharma today is they try to use the pipeline and the pathway or did they just go about it in the new -- just try to introduce new products. And I think that you're going to start seeing some come into the market because of the receptivity. But I think that congress, as they look at new ways to drive down healthcare costs, because keep in mind, through this bill, what we've done is were given coverage, but we really haven't tackled the tough problems of costs. And as we start tackling those problems, I think there's room for that component of the bill to be amended and made more easier for pharma to introduce products. So I think under the current rate, a couple of years out, we should see some biosimilars. We really like to see some biogenerics coming in the market, and we're going to need some more legislation for that."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","And next, we will go to the line of Ross Muken with Deutsche Bank.",14,"And next, we will go to the line of Ross Muken with Deutsche Bank."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","I want to build off of something that one of the earlier callers talked about. And there's been a lot of you who recently kind of on the healthcare reform front, but really across the service complex on sort of core growth and the sustainability of earnin",133,"I want to build off of something that one of the earlier callers talked about. And there's been a lot of you who recently kind of on the healthcare reform front, but really across the service complex on sort of core growth and the sustainability of earnings, and the sustainability of capital returns. As you look at your business and then you look at the next several years, which we've known for sometime, we're going to be quite good and think about the various threats on the horizon. I mean, is there anything different today than versus six months ago or 12 months ago or even before in terms of how you thought about things that you could even perceive as a potential threat to any of those metrics as we go forward?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, of course. There's always threats, right? I mean, anybody that's a business man is going to be looking for threats. My job is not just to look for threats, though, it's how do you mitigate those threats and then take advantage of the opportunity. Wh",384,"Well, of course. There's always threats, right? I mean, anybody that's a business man is going to be looking for threats. My job is not just to look for threats, though, it's how do you mitigate those threats and then take advantage of the opportunity. When I look out through 2017, I see a tremendous amount of Blue Sky. Think about what we were about to embark on. The government has just opened up coverage to over 30 million more, and it's probably more than that based on the state of economy today. It's more than 30-plus million people are going to now have access to coverage. In addition to that, who's got the tools that work? The PBMs have a proven pathway and track record of showing that we can reduce costs, while improving health outcomes. Think about all the statements that were made by the administration about what they needed to have in health outcomes, and it's a blue print for the way the PBM was designed. So you got millions and millions of individuals come into the market. You've got a proven model that does what it needs to do to take costs out. I think we're sitting at an incredibly good space right now. I think we have -- sure, there's pricing pressures. But keep in mind, we have tremendous inflationary impact of drug costs. When drugs are going up at 7% to 10% a year, you got specialty products that arise, going up at double digits 14%, utilization trends and specialty that are driving overall specialty drug trends at 20% or more. Those things are all opportunities for us. So when you have those kinds of increases, you can actually give part of it back to your clients as price concession and still have profit for yourself, especially if you can show that you're driving people to the cheaper alternatives. With all of the headwinds that we have as a nation and healthcare inefficiencies, I see the PBMs as a great, great tool to continue to grow, to innovate and to change the way healthcare is delivered and take advantage of the opportunities that are out there. I think we are part of the solution. And being part of that solution provides us runway for better years to come."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","I certainly tend to agree with you there, George. Maybe one for Jeff, we have the maturities coming due, I believe in October on one of the term loans, you have the interest rate you're paying there is pretty de minimis. As you sort of think about where l",134,"I certainly tend to agree with you there, George. Maybe one for Jeff, we have the maturities coming due, I believe in October on one of the term loans, you have the interest rate you're paying there is pretty de minimis. As you sort of think about where leverages is today on the balance sheet and putting that in the context of the interest rate environment, you sort of appetite for maybe rolling that over or maybe keeping more leverage, I guess, would be the way I'd put it on the business, and then to a degree that you might do that. You obviously have a pretty attractive stock price. I think someone hinted earlier to kind of the desire and appetite for that. What sorts of things would be possible in that context?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Certainly, there are lots of possibilities. I mean, you're exactly right. We've got about $980 million of debt that's due in October. Our expectations, same thing we said last quarter, expectation remain the same at this point that we will pay that off wh",261,"Certainly, there are lots of possibilities. I mean, you're exactly right. We've got about $980 million of debt that's due in October. Our expectations, same thing we said last quarter, expectation remain the same at this point that we will pay that off when it indeed come due. When we do that, we're going to beat about 1x EBITDA, debt to EBITDA. And we've said many times in the past that our goal for -- or the correct range for us to leverage is 1x to 2x EBITDA. So we're certainly going to be at the low end of that range. So being at the low end of the range, along with the strong cash flows that the business is producing, really opens us up to a lot of different opportunity. And our view of how we want to use that cash hasn't changed over time. We still think the best use is reinvesting in our business. And second is solid, accretive acquisitions like the NextRx acquisition. And to the extent that we still see offered excess cash beyond that, then we use it to do share buybacks. And George said earlier on the call we're buying stock back at higher prices earlier in the year. So certainly if the stock stays at a level it has been recently, that's certainly in a very attractive price to us as well. So I'm not really ready to give any more detailed guidance than that today. But certainly, we have lots of opportunities and have historically done the right thing for our shareholders."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","And next, we will go to the line of Lawrence Marsh with Barclays Capital.",14,"And next, we will go to the line of Lawrence Marsh with Barclays Capital."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","First, a clarification for Jeff. I'm assuming a little over 1% script growth in '11. I know back in February, you guided to, I think, $740 million to $760 million adjusted claims. It seems to me you're on a run rate to do kind of a higher end of that. Is",68,"First, a clarification for Jeff. I'm assuming a little over 1% script growth in '11. I know back in February, you guided to, I think, $740 million to $760 million adjusted claims. It seems to me you're on a run rate to do kind of a higher end of that. Is there any way to clarify that? Is it fair to say that's kind of the right base?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, I don't think we want to tighten up that range at this point. We still think that $740 million to $750 million is the right range for scripts for the year.",32,"Yes, I don't think we want to tighten up that range at this point. We still think that $740 million to $750 million is the right range for scripts for the year."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, you've mentioned another direct client from WellPoint that you assume was leaving, it is. I know you don't talk about specific customers, but can you give us any clarification even via industry group?",34,"George, you've mentioned another direct client from WellPoint that you assume was leaving, it is. I know you don't talk about specific customers, but can you give us any clarification even via industry group?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","No, I prefer not to. The only thing I mentioned the retailers is because that's been in the press release that somebody else put out. I don't take a greater pride in jealousing a client. I mean, you do it because it's the right economic answer. But I woul",133,"No, I prefer not to. The only thing I mentioned the retailers is because that's been in the press release that somebody else put out. I don't take a greater pride in jealousing a client. I mean, you do it because it's the right economic answer. But I would rather have them conform. I would rather have them look for more than just adjudication. For me, purely adjudicating a claim for a couple of pennies a script, that doesn't do anything for me. Unless it's adding scale and size, as we've talked about earlier, and doing things that are benefiting the entire book. It just doesn't make sense. So singling clients out to talk about, it's not something whether we win them or lose them. It's something I've ever really wanted to do."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","I guess to that point, George, you make an interesting observation at some customers, understanding your system and some not, and we step back and say Aetna. They used to be a customer of yours. They chose some years ago to go on their own way, and start",102,"I guess to that point, George, you make an interesting observation at some customers, understanding your system and some not, and we step back and say Aetna. They used to be a customer of yours. They chose some years ago to go on their own way, and start their own PBM, build on facilities. Obviously, they've chosen to partner with another competitor. So in terms of that, is it fair to say you are not necessarily in agreement with how they're thinking about running their business relative to your customer? Or are you not in a position to comment on their strategy?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","I'd rather not talk about other people's strategy because that's their business, and what they've elected to do to get a deal done. But I would tell you again, from my perspective, if a big company comes to us, and let's say it's a health plan and they ow",386,"I'd rather not talk about other people's strategy because that's their business, and what they've elected to do to get a deal done. But I would tell you again, from my perspective, if a big company comes to us, and let's say it's a health plan and they own their own PBM and they want to carve out that PBM and partner with Express Scripts, we are going to be -- there's two ways to be competitive on that deal. One is we can do it for no value, i.e., no shareholder value, give all the economics to the client and have them do whatever they want to do, whether manage their own formularies, whether they manage their own networks, whether they want to take in all the back office stuff. We can do that, but the value just isn't there. If we can convince them, which is what we do, that they should align their formularies with ours. At the end of the day, we have a P&T Committee. Most health plans have a P&T Committee. Yet when you look at our formularies, sales were at lapped 99% of the time, or somewhere in that range, because we can get them to understand how we make our selections. We can show them the economics of it. So we can find clients that want to conform to our ways, and I believe it's the right clinical answers. And they want to go after the things we want to go after. They want to drive generics. They want to pay me more for my generics, and maybe lose money on my brands or make money on my generics. As I can drive more, they win, I win. Those are the clients we want. Those are the clients we line up with. Same thing with getting the rebates on the branded products. Again, going back to conformity of formularies. So if a client comes to us and none of those things are lined up, they just don't line up well, we, quite frankly, don't waste our time even bidding the account. It's not worth it. We can spends thousands, thousands of dollars, a lot of man hours, kill a lot of trees. At the end of the day, we're not going to get it anyway. So why?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","Finally, back for Jeff and maybe George, I know you've been very consistent in suggesting $1 billion of incremental EBITDA to enterprise when integrated. I know you've communicated, you've just paid the integration, being completed the low end of 12 to 18",85,"Finally, back for Jeff and maybe George, I know you've been very consistent in suggesting $1 billion of incremental EBITDA to enterprise when integrated. I know you've communicated, you've just paid the integration, being completed the low end of 12 to 18 months. I know your partner suggested yesterday and just made integration to be completed by the end of 2010. Is there reason to think then that $1 billion of incremental value should accrue fully into 2011 or you're not willing to say that?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","I think it's a -- I think we haven't really gone there. I would say that if you'd assume that everything -- if we are indeed completely done by the end of the year, then I think it's reasonable to assume that $1 billion would all accrue in 2011.",50,"I think it's a -- I think we haven't really gone there. I would say that if you'd assume that everything -- if we are indeed completely done by the end of the year, then I think it's reasonable to assume that $1 billion would all accrue in 2011."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Larry, what we'd like to do is at the end of the third quarter, we will have, for the most part, keep in mind the small employer comp, the TPA business, a lot of the small Brokerage business, it's still out there, a very profitable business by the way. So",101,"Larry, what we'd like to do is at the end of the third quarter, we will have, for the most part, keep in mind the small employer comp, the TPA business, a lot of the small Brokerage business, it's still out there, a very profitable business by the way. So it's something that we really do focus on. But having said all that, the majority of the big accounts have been selected. Retention was pretty much done. And so when we disclose our third quarter earnings, as Jeff said earlier, we will give full year guidance for 2011 at that time."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Next, we will go to the line of Randall Stanicky with Goldman Sachs.",13,"Next, we will go to the line of Randall Stanicky with Goldman Sachs."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","George, first, a follow up, a lot of cash flow being generated. As you think about the longer-term picture, what's your strategic appetite to add businesses or diversify away from the core PBM offering or add tangential businesses to what you currently ha",43,"George, first, a follow up, a lot of cash flow being generated. As you think about the longer-term picture, what's your strategic appetite to add businesses or diversify away from the core PBM offering or add tangential businesses to what you currently have?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","I looked at our business, and I see growth rates. I think Jeff talked about 25% to 27% growth for this year. We've got the value of NextRx coming in. I have a lot of confidence in the WellPoint management team and where they're headed. I have a lot of con",216,"I looked at our business, and I see growth rates. I think Jeff talked about 25% to 27% growth for this year. We've got the value of NextRx coming in. I have a lot of confidence in the WellPoint management team and where they're headed. I have a lot of confidence from either Blues plans and managed care partners that they want to do, what we want to do in driving out the waste of costs. And we've got hundreds and thousands of clients that are aligned with us. And I looked and I asked, what are the industries do you own or do you have that since 1992 have grown in excess of 20% in each and every year. And then I have to ask myself what would I diversify out of that? What do I add into that mix that can supplement that growth rate and not be a drain on the ROIC, which, I'm the x-CFO here. Jeff is 100% behind it. The management team believes in ROIC. I can't think of why we would want to diversify, when we got a business model that's in demand, that's needed by America, and we can deliver exceptional value for our patients, clients and shareholders. It just doesn't make a lot of sense to me."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","As you look forward to 2015 plus, I mean, do you think that growth rate that you're putting up right now, which is obviously significant, do you think you can sustain that growth rate through that period?",37,"As you look forward to 2015 plus, I mean, do you think that growth rate that you're putting up right now, which is obviously significant, do you think you can sustain that growth rate through that period?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","You're talking 2015, its 2010. We do three-year plans. The third year is always a bit of a challenge because what's going to happen in three years? I can't speak unequivocally that 2015 is going to continue on the same path. But I think the answer to that",268,"You're talking 2015, its 2010. We do three-year plans. The third year is always a bit of a challenge because what's going to happen in three years? I can't speak unequivocally that 2015 is going to continue on the same path. But I think the answer to that question resides in the management team that you entrusted to run your capital here at Express Scripts. Our job is to make sure we don't give up on that growth rate. My people, my management team is absolutely focused on maximizing our growth rate, and we don't take that lightly. And I don't think -- it's not like we come to work every day and we just switch somebody to a generic. Our whole idea is to innovate, improve and change the way we administer. If you were to walk into Express Scripts in 1998, if you were to walk in 2002, 2005 and now in 2010, our approaches, our reporting, what we do for our clients, is far different than each one of those different intervals. We don't want to sit still and wait to get commoditized. We innovate, change and come up with new ideas and new approaches to tackle the myriad of problems and inefficiencies that existed in healthcare. Our job is to stay on top of that. 2015 is a long way out. I feel really good about where we sit today. We talked about what healthcare reform can do for us. I think there's a lot of Blue Sky out there. Our job is to make sure we capture our share of the value."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","With the line of Garen Sarafian with Citigroup.",8,"With the line of Garen Sarafian with Citigroup."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","First, on the selling season and your two new signature wins. Can you just elaborate a little bit more as to what in particular resonated with these two new clients that their current vendor wasn't providing?",36,"First, on the selling season and your two new signature wins. Can you just elaborate a little bit more as to what in particular resonated with these two new clients that their current vendor wasn't providing?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","He sent me an e-mail yesterday which was a debrief. Every time we renew a client or we win a client, I think, we have a very high track record of winning in a jump ball situation. But quite frankly, there's times when the client renews with the existing,",217,"He sent me an e-mail yesterday which was a debrief. Every time we renew a client or we win a client, I think, we have a very high track record of winning in a jump ball situation. But quite frankly, there's times when the client renews with the existing, incumbent. And so what we do is we just say, okay, we take that apart and understand, could have done something different. Was it merely the client trying to get a better price from their existing vendor or was it just effectively doing a market check or they actually going to change hands? So we take it apart. Rod sent me an e-mail yesterday, and look at three major wins we've had this year and what was the driver. And I would tell you, Consumerology was a very important component in all three of those wins, two of those signature wins, where in fact, they pointed to the fact that we were addressing their need and hitting the market with opportunities that they don't otherwise have access to get the best pull-through without massive planned design changes, which could cause employee disruption. Our approach here is resonating, it's working and it's good for us and our clients and our members. So I think that is the driver."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then in your prepared remarks, you made some comments about you seeing some opportunities in the small to mid markets, which I thought was interesting because I would have thought that with the acquisition of NextRx, using your jump ball analogy, you'",79,"And then in your prepared remarks, you made some comments about you seeing some opportunities in the small to mid markets, which I thought was interesting because I would have thought that with the acquisition of NextRx, using your jump ball analogy, you're totally, probably going over it in a more formidable competitor with the Fortune 100. So is the small to mid market more of a focus this year? Or am I just reading too much into it?"
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","No, its been a focus every year since we went public in 1992. It's always been an area that we really go after. Let me make sure I'm clear, though. In those states where NextRx has a dominant position and there's a small client opportunity, we would rathe",182,"No, its been a focus every year since we went public in 1992. It's always been an area that we really go after. Let me make sure I'm clear, though. In those states where NextRx has a dominant position and there's a small client opportunity, we would rather work through them than go direct. So we want to partner with our Blues plans. We have Blues plans throughout the country. We have managed care organizations throughout the country. And so we were actually caught our sales to people on our clinicians into their shops to help them secure clients and growth. So we do it in two different ways. We do it either through our existing managed care book of business or we do it direct in those areas where we don't have a managed care partner, or if a client wants to carve out and no longer offer an insured benefit. And they just want to go purely ASO, and they want us to bid, and we would bid on those two. But that's always been a big focus of ours."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then just lastly, it's clear that we can see our progress in migrating the NextRx lives onto the Express Scripts' IT platform. But can you maybe discuss a little bit as to what you've started to do with these lives and now that they've migrated? Are t",69,"And then just lastly, it's clear that we can see our progress in migrating the NextRx lives onto the Express Scripts' IT platform. But can you maybe discuss a little bit as to what you've started to do with these lives and now that they've migrated? Are there any metrics you can share those very low mail penetration, for example? Anything you could share on that would be great."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","The focus, as we said earlier, the focus this year is really getting all the lives migrated. While we started to explore potential ways to increase mail and generic bill rates and those things, we are spending a lot of effort on that this year. The primar",162,"The focus, as we said earlier, the focus this year is really getting all the lives migrated. While we started to explore potential ways to increase mail and generic bill rates and those things, we are spending a lot of effort on that this year. The primary effort is to get the lives migrated. And then just to be clear, integration doesn't end with migration. There's a lot of other things we have to do that are also related to integration. But as we go through the integration, once that's complete in early next year, we would expect them to spend a lot of effort mapping out new mail plans, new generic plans and really starting to second order drive the integration and the synergy. Certainly, both WellPoint and Express Scripts, in keeping with our model of alignment, are both very highly motivated to increase mail and increase generics, and we're confident were going to be able to do that over time."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, again, I thank everyone for joining us this morning. We do have tremendous confidence in our space, and we feel very good about our position in the marketplace. We believe our clinical tools are second to none. Our Consumerology approach, coupled wi",90,"Well, again, I thank everyone for joining us this morning. We do have tremendous confidence in our space, and we feel very good about our position in the marketplace. We believe our clinical tools are second to none. Our Consumerology approach, coupled with those clinical tools, allows us to compete extremely effectively in the market to maximize shareholder value while delivering value to our clients and our patients. So again, we appreciate your attendance on our call this morning. We look forward to talking with you all soon. Thank you."
317975,109364373,70448,"Express Scripts Inc., Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, that does conclude our conference call for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect.",26,"Ladies and gentlemen, that does conclude our conference call for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Express Scripts Third Quarter 2010 Earnings Call. [Operator Instructions] Now with that being said, I'll turn the conference now to the Vice President of Investor Relations, Mr. David Myers.",40,"Ladies and gentlemen, thank you for standing by. Welcome to the Express Scripts Third Quarter 2010 Earnings Call. [Operator Instructions] Now with that being said, I'll turn the conference now to the Vice President of Investor Relations, Mr. David Myers."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, and good morning, everyone. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. Before we begin, I need to read the following Safe Harbor statement.Statements or comments made on this conference call may be forward-loo",184,"Thank you, and good morning, everyone. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. Before we begin, I need to read the following Safe Harbor statement.
Statements or comments made on this conference call may be forward-looking statements and may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors, which are discussed in detail in our filings with the SEC.
For clarity purposes, all numbers we talk about today will be on an adjusted basis. Please refer to the tables in our press release for reconciliation of GAAP to the adjusted numbers we will be discussing. The reconciliation of EBITDA to net income can also be found in our earnings release. The earnings release is posted on our website. 
At this point, I'll turn the call over to Jeff, who will talk about our third quarter results."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, David. Today, we are pleased to report another record quarter and provide guidance for 2011. Our strong results and outlook for the future are the result of our differentiated strategy. Our business model of alignment, enabled by our behavior-c",523,"Thank you, David. Today, we are pleased to report another record quarter and provide guidance for 2011. Our strong results and outlook for the future are the result of our differentiated strategy. Our business model of alignment, enabled by our behavior-centric approach, supported by market-leading technology and service levels. Our execution of this strategy helps our clients and patients drive out wasteful spending, which in turn helps us continue to deliver superior returns to our stockholders. 
Third quarter earnings per share reached a record of $0.65, up 55% over last year. The majority of these growth came from EBITDA, which grew at 45% over last year and 5% sequentially. During the quarter, we made significant progress executing our integration plans. We have now transitioned 90% of the WellPoint Live to our IT platform, and expect to complete the final migration of Live at year end. This will position us to finish the integration, retire the NextRx system and rationalize our operational footprint in the first quarter. 
Metrics for the quarter were strong and reflect our integration progress. Adjusted claims grew at 48% to $186.9 million. Total operating expenses were in line with our expectations, although the mix of expenses is weighted more towards cost of goods sold and forecasted through the excess capacity that remains in the system today. Despite this excess capacity, gross profit improved to 7.2%, up 30 basis points sequentially. We expect gross profit margin will continue to improve as the underlying fundamentals of our business continue to improve, the completion of the integration and the optimization of capacity.
EBITDA for adjusted Rx reached $3.30, up sequentially from $3.10 last quarter, and year-to-date cash flow from operations increased 99% to $1.8 billion. During the quarter, we repurchased 16.4 million shares and repaid the remaining balance of our term loan. Based on these results and our positive outlook for the remainder of the year, we have narrowed our 2010 EPS guidance range to $2.48 to $2.50. This represents growth of 26% to 27% over 2009 on an adjusted basis. 
Moving on to 2011 guidance, we expect that 2011 EPS will be in the range of $3.15 to $3.25, representing growth of 27% to 31% over 2010. We are confident we will complete the integration and achieve our synergy targets in the year. And as a result, our 2011 guidance include $1 billion of incremental EBITDA. 
Since the acquisition will be fully integrated next year and our guidance includes the achievement of synergy targets, and keeping with our long-standing practice of not commenting on specific clients, we will no longer discuss WellPoint-specific results. 
Cash flow from operations is expected to be between $2.2 billion and $2.4 billion. We see a lot of exciting opportunities, and our EPS guidance include significant investments in 2011. In addition to these significant investments flowing through our P&L, we also expect to spend $140 million to $170 million in capital investments in the year.
We are pleased with how our team has executed in 2010 and look forward to continuing to deliver strong performance in 2011 and beyond. 
And with that, I'll turn it over to George."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, Jeff, and good morning, everyone. Since our inception, we have been focused on alignment and our ability to innovate and execute. These qualities are as strong as ever, and we are now deploying new capabilities enabled by our groundbreaking wor",577,"Thank you, Jeff, and good morning, everyone. Since our inception, we have been focused on alignment and our ability to innovate and execute. These qualities are as strong as ever, and we are now deploying new capabilities enabled by our groundbreaking work in Consumerology. This week, we had our National Accounts Advisory Board meeting. Annually, we hold this meeting to bring in our diverse set of our National Account clients to get input on market conditions, medical trends and our pipeline of new products. At this meeting, I gathered feedback from many of our clients. They are overwhelmingly pleased with our ability to drive out wasteful spending while improving health outcomes, with high levels of member satisfaction. 
The NextRx acquisition is another good example of innovation and execution at work. We closed the transaction just 11 months ago. And through the focused effort of both companies, the migration of Live is nearing completion. The transition of Live was seamless and efficient with very little noise or disruption. As Jeff mentioned, we now consider NextRx part of our core business. Completing the critical migration so quickly is important so that we can focus on the potential of this strategic alliance. It will open new horizons for improving outcomes for members while driving all [ph] down our overall health care costs.
As the selling season winds down, let me summarize the results. As we pointed out last quarter, we saw high retention rates for signature accounts. Notwithstanding the stickiness in the marketplace, we won three signature accounts and again, grew our share in the middle market. Even with the client losses discussed last quarter, we expect the retention to exceed 95%. Based on our new sales activities and retention rate, we expect claims to be flat to up 4% for 2011. Our 2011 guidance not only provides strong earnings growth, it also provides for significant investments designed to keep us ahead of the competition in the evolving healthcare landscape. These projects include preparation for EBIT changes, Medicare regulations and healthcare reform. We are investing in opportunities to continue to differentiate ourselves in the marketplace by creating new products and services that meet and exceed the needs of tomorrow's marketplace.
In addition to the investments in our Consumerology platform, I'm particularly excited about two specific initiatives. First, we are investing heavily in our next-generation specialty offering that will be rolled out next year. This offering will enhance our ability manage the cost and quality, especially drug care. Part of the programs in this area had been enthusiastically endorsed by clients for their ability to drive out significant ways to the specially drug spend, the fastest-growing area of pharmaceutical costs. Second, we're tackling the issue of non-adherence by making significant investments in our predictive modeling capabilities. Through these efforts, we are able to identify in advance, those patients that are unlikely to adhere to medication therapies. We then intervene and customize ways to improve adherence. Although early, we are seeing significant improvements in medication adherence in our pilot programs. 
Our core business is strong, and we are positive on the underlying trends and opportunities in our space. This is why we are investing to position ourselves for a long-term growth. Our ability to manage trend, coupled with our behavior-centric approach, will drive out ways for clients, improve health outcomes for patients and deliver strong earnings growth for our stockholders. 
At this point, I'd like to open it up to questions. Operator?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","[Operator Instructions] First in line is Tom Gallucci with Lazard Capital Markets.",12,"[Operator Instructions] First in line is Tom Gallucci with Lazard Capital Markets."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","First, just wondering, you sort of mentioned significant investments within the 2011 expectations. Is there any way you can frame or quantify the magnitude of what we're looking at here?",30,"First, just wondering, you sort of mentioned significant investments within the 2011 expectations. Is there any way you can frame or quantify the magnitude of what we're looking at here?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","I can let Jeff chime in on that as well, but as you probably know, CMS, before healthcare reform was ultimately passed, and certainly, quickly thereafter, continued to issue more and more guidance. There was a lot of uncertainty and ambiguity in the Medic",451,"I can let Jeff chime in on that as well, but as you probably know, CMS, before healthcare reform was ultimately passed, and certainly, quickly thereafter, continued to issue more and more guidance. There was a lot of uncertainty and ambiguity in the Medicare provisions that exist. And so CMS has been very proactive in trying to get guidance out to the providers and to the insurance companies. And so as that guidance has come down, there's two ways you can approach this. We can do the minimum and make sure we hit that guidance so we can think about how we want to position ourselves in an evolving world and make sure that we can, not only meet the guidance requirements, but be ahead of the game with respect to new product innovation and meet the needs of that guidance may imply with respect to the needs of our clients and patients. So our IT and operational departments and our sales and comm management product development all work in unison to both meet the guidance requirements, as well as drive new product innovation. That, coupled with all the requirements from HIPAA, HITECH, we had DIDAD coming through, which is the new standard by which everyone has to be geared up for by 2012, in order to handle the ingredient components of compounds and expands fields. There's a tremendous amount of work that has to take place. Again, it's not just meeting those needs, but making sure that we meet them better than the competition and use it for new product innovation. Those have to go hand-in-hand. And of course, there's healthcare reform. So quite frankly, I don't want to get into the specifics but we don't want to give guidance by line items on our financials. But I will tell you that our investments in technology and operations and product development have significantly improved. They were quite a bit higher in 2010 as the year ramped out. And then in 2011, we expect continued increases. When we give our -- you often asked us how we feel about the deployment of our capital. And one of the things we say is we always like to invest in ourself first. I think that's critically important because I don't know what else gets better returns than investing in our own business. And as we look at this, that's exactly what we're doing. We're investing in ourself. Well, we invest in ourself, either it has to come through to two places, either it has to come through expenses or it has come through capital investments, depending on the type of project it is, and that's what you're seeing in the guidance we're giving."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","And next with Larry Marsh with Barclays Capital.",8,"And next with Larry Marsh with Barclays Capital."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","First on new business, George, your model's a little bit different. You're really focused on driving value to your customers and shareholders, you're focused on EBITDA and earnings, not necessarily winning new business. But obviously, over time, you got t",94,"First on new business, George, your model's a little bit different. You're really focused on driving value to your customers and shareholders, you're focused on EBITDA and earnings, not necessarily winning new business. But obviously, over time, you got to balance the two. As we think about the next couple of years, how do we think about the opportunity for you to take share? Do you think of it that way, where would you gain share? And then how do you think of Medi in that sort of balance between margin and new business?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Only challenged a little bit, Larry, first of all. I think if it was a stagnant world and you are selling just automobiles. You have to always worry about how do I sell the next car. Keep in mind that we have a totally different dynamic that's occurring i",538,"Only challenged a little bit, Larry, first of all. I think if it was a stagnant world and you are selling just automobiles. You have to always worry about how do I sell the next car. Keep in mind that we have a totally different dynamic that's occurring in our market spot. We have an under-penetration of mail, we have people that aren't fully utilizing specialty drugs, the fastest-growing part of healthcare cost in the drug space, not being properly utilized and not being properly adhere to. And then we've got members aging, the baby booms getting older, people are moving through that pipeline and becoming older. And as they do, they take more prescriptions. We see in 2014, 30 plus million more people entering into the market. So there's a whole lot of things going on. So the question you have to ask yourself is where should the company's focus be? Should it be coming up with innovative product to drive mail, generic utilization, to drive specialty cost out that all these things add value to our clients, improve health outcomes for our members and drive shareholder value, or do you want to grow new business for the sake of new business growth? What gives you the biggest returns? I've said on many, many, many calls that part of a great client-company relationship has to have built into it a common desire to meet the needs of the marketplace. There are certain clients that want to do things that don't align with our model. Those aren't good clients for us. Adding those clients would be a detraction of our call center associates, our operational associates, our account management as they're trying to conform a square peg into a round hole. Our focus has to be around growing share value and you do that through ROIC. That doesn't mean we can shrink the business over time, but what it means is we have to be disciplined about that business. We need clients that are concerned about their drug costs and spend and the improvement of health outcomes for their individuals. When we align those desires and needs with the products we have to offer and our approach, we have a marriage that works quite happily. And that's what we look for, Larry. So I think we can continue to grow EBITDA, we can continue to grow our profits without getting crazy in the marketplace by just competing on the clients that make sense. And by the way, when you're offering the client something they want and you're aligned with them, then the price is always important. But the prices points doesn't match up what they're looking for and our messaging and our pricing resonates with them and we get a sale. And guess what, even though I might make more money over some period of time with that client, they're happy because we're taking far more costs out of their equation than they expected or that they originally anticipated or they've gotten in the past. And so we got a very high, happy camper. I got happy patients as they got better health outcomes and I'm driving shareholder value to all of my valuable shareholders. That's our focus."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And I guess a follow up and a couple of things in on overall script growth you now see is a little bit stronger than you would have said six months ago for '11. Do we assume that mail script growth is kind of consistent with that overall 0% to 4% trend? A",112,"And I guess a follow up and a couple of things in on overall script growth you now see is a little bit stronger than you would have said six months ago for '11. Do we assume that mail script growth is kind of consistent with that overall 0% to 4% trend? And then just on WellPoint, I know Jeff and I are talking anymore specifically about that customer going forward, but you talked about integration costs that are to be determined. How do we framework that for '11? What kind of things could there be and can you give us any guidance as to how big or small that might be?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","You're right, we did end up with three signature accounts this year. And we did -- we're having a very successful selling season in the small to middle market area. And those things aren't finished yet, and the latter one isn't finished yet. Sometimes we",407,"You're right, we did end up with three signature accounts this year. And we did -- we're having a very successful selling season in the small to middle market area. And those things aren't finished yet, and the latter one isn't finished yet. Sometimes we don't know we got a new client win until January 15 and those are usually very small. But that last piece kind of rolls out towards the end of the year. So based on our best guess is in the pipeline and where we sit today, our selling season and success is better than we had anticipated earlier in the year. Having said all that, I don't want to get into client-specific situations, but we are pleased with where we sit. As far as mail is concerned, mail is a very important focus to us. We believe mail is important because it does drive better economics for our members, we show better adherence, better health outcomes for mail. By the same token, with certain clients, when you're going through an integration, the integration has to go first. So we got to get through this year. Finish that often. So starting next year, we're absolutely focused on mail and generic programs with WellPoint. I guess, I am talking about the clients specifically, but in this situation, we will address that. For the rest of our clients, keep in mind that one of the things that we're facing is a tough economic environment. And when a member has to pay two or three copays, upfront versus paying one at the Connery retailer in an uncertain tough environment, that's a little harder to do. And so the members struggle a little bit with that, and we do see some of our membership moving from mail into retail for that reason. But we fight hard. We try to make sure that we get them back. It's good for the client, ultimately, it's good for the member. And of course, it's very good for their healthcare outcomes. So it's going to continue to be a focus for us. I would say that you going into next year because we're just getting underway with the WellPoint situation, we expect modest to low growth in mail. But keep in mind, that's based on our current economic situation. There's a lot of things that can change over next year. And we'll obviously keep you posted quarter-by-quarter on that progress."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then any range of integration costs?",7,"And then any range of integration costs?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","So Larry, the range really hasn't changed. We've been saying from the beginning that we expect about $120 million to $150 million in integration costs. I think the difference that you're picking up now on is that now that we've got guidance into 2011. We",110,"So Larry, the range really hasn't changed. We've been saying from the beginning that we expect about $120 million to $150 million in integration costs. I think the difference that you're picking up now on is that now that we've got guidance into 2011. We still think it's going to be $120 million to $150 million. But what we don't know what the great clarity at the moment is how much of that is going to hit into 2010 how much of that is going to hit in 2011. But if some of it does push over into 2011, we still expect the same range, $120 million to $150 million."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Lisa Gill with JPMorgan.",9,"Our next question is from Lisa Gill with JPMorgan."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, I know that you just commented -- George commented around mail for 2011 as it pertains to WellPoint. Can you comment as to if there's anything in your current expectations in the current guidance or will this just be the beginning stages of trying t",52,"Jeff, I know that you just commented -- George commented around mail for 2011 as it pertains to WellPoint. Can you comment as to if there's anything in your current expectations in the current guidance or will this just be the beginning stages of trying to sell through some of these programs?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well as I said, as we said we, I said about [ph] WellPoint kicking off their programs in 2011. The overall growth in our mail, I believe, will be slightly up year-over-year. So that encompasses the whole book.",38,"Well as I said, as we said we, I said about [ph] WellPoint kicking off their programs in 2011. The overall growth in our mail, I believe, will be slightly up year-over-year. So that encompasses the whole book."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","I think that a lot of investors have been focused on how quickly you can up sell, George, to that new book of business. And I was just curious if anything was in your expectations or if this is a [indiscernible] that we're getting the integration as we'll",69,"I think that a lot of investors have been focused on how quickly you can up sell, George, to that new book of business. And I was just curious if anything was in your expectations or if this is a [indiscernible] that we're getting the integration as we'll now have the opportunity to go out and start talking about the programs rather than having something built within your expectations?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, clearly, it will be a focus of ours, Lisa. And it's certainly a focus of WellPoint. I think the reason they chose us was because they liked our approach to mail or liked our approach to generics. As we said that throughout this year though, this yea",175,"Well, clearly, it will be a focus of ours, Lisa. And it's certainly a focus of WellPoint. I think the reason they chose us was because they liked our approach to mail or liked our approach to generics. As we said that throughout this year though, this year had to be a focus on integration. So if we're finished on '11, then we change our focus next year to up-selling clinical programs and working, trying to work with them as a client. So as you might suspect, when you start that, January is all about planned design changes and making sure the book of business is stable and you're meeting all your service requirements. So these things don't start to look end of the first quarter to the second quarter and then you got to up-sell them, you got to work them through, you got to go out and talk to the clients. We got to put our people out on the street to go talk to them. So next year is the kick-off year."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then maybe could you just comment on, are you seeing any acquisition opportunities in the marketplace? This has clearly been a very successful transaction for you. What are some of your thoughts on some of the other things that are maybe out there tod",45,"And then maybe could you just comment on, are you seeing any acquisition opportunities in the marketplace? This has clearly been a very successful transaction for you. What are some of your thoughts on some of the other things that are maybe out there today?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Our position has been pretty consistent over the last several quarters. We say the same thing every time. Certainly, there are other PBMs that we think would be very attractive acquisitions for us, but we always caveat that with at the right price and the",128,"Our position has been pretty consistent over the last several quarters. We say the same thing every time. Certainly, there are other PBMs that we think would be very attractive acquisitions for us, but we always caveat that with at the right price and the right term. And so there are lots of rumors out in the market. We're not going to comment on individual specifics or individual rumors, but our position remains the same. There are PBMs we'd like to own at the right price and the right terms. We think we've proven that we can do this, integrate them better and faster than anybody else and we've proven that can create great shareholder value by doing this. And when the opportunities are right, we will execute."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then just finally, Jeff, I missed some of your prepared comments. But did you talk at all about the progression and how we should be thinking about 2011 from a quarterly progression standpoint?",34,"And then just finally, Jeff, I missed some of your prepared comments. But did you talk at all about the progression and how we should be thinking about 2011 from a quarterly progression standpoint?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Let me just back that up a little bit and talk just a little bit about how I see guidance and I think my position maybe slightly different than some of my other peers out there. But my view on guidance is actually relatively simple, which is do a really a",256,"Let me just back that up a little bit and talk just a little bit about how I see guidance and I think my position maybe slightly different than some of my other peers out there. But my view on guidance is actually relatively simple, which is do a really accurate forecast then tell investors what we really think we can do and then just hit those numbers. And certainly, since my arrival here, we have significantly improved our forecasting ability in order to execute on that vision. I also think there are only a few numbers that really matter, claims, EPS, EBITDA, cash flow. As a result, we try to only guide to those numbers because we think guiding in more detail just dilutes the focus on those metrics, the metrics that matter. We also want to stay focused on the long term so we don't guide the quarters either, again, making sure that we don't dilute our focus on hit and what matters. That said, I understand that everybody out there, all the sell-side people have models to put together. So from time to time, we give a little bit more color on different things to help you out a little bit. As we think about EPS progression for next year, I'd say it looks about like 2010 right now, a little bit more back-end loaded, quite frankly, than 2011. But just to be clear, we're not focused on hitting individual quarters. We're focused on delivering long-term shareholder value and the metrics that matter."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Robert Willoughby with Bank of America Merrill Lynch.",13,"Our next question is from Robert Willoughby with Bank of America Merrill Lynch."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","George or Jeff, you've been saying [ph] of floating rates in the past, but forgive me if someone has asked already. But you've been saying that the floating rates, when you guys moved to lock in some rates here, either turn up a bit or just take advantage",55,"George or Jeff, you've been saying [ph] of floating rates in the past, but forgive me if someone has asked already. But you've been saying that the floating rates, when you guys moved to lock in some rates here, either turn up a bit or just take advantage of the rates you're seeing out there?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Certainly, we think over long periods of time in history, being floating has certainly paid off. As we look at our current debt structure, we're clearly at the low end of our range, saying that we're comfortable at 1x to 2x EBITDA, if you look at our EPS",132,"Certainly, we think over long periods of time in history, being floating has certainly paid off. As we look at our current debt structure, we're clearly at the low end of our range, saying that we're comfortable at 1x to 2x EBITDA, if you look at our EPS guidance for '11, we're probably a little bit below 1x now. So we certainly think that for the right opportunities, we could those debt levels could come up a little bit. If we did make that change, we would certainly be looking at the potential to float things out there. Although we're also in a really unique interest rate environment where long-term debt has very low fixed rates and certainly that's all got to come into the calculates of what we end up doing."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","So the numbers for 2011, you've basically assumed status quo here? No refinancing and what in the way [ph] share repurchase then?",22,"So the numbers for 2011, you've basically assumed status quo here? No refinancing and what in the way [ph] share repurchase then?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, that's right. We assume status quo. As you think about share repurchase, obviously, our guidance range does include some share repurchase. How much cash we actually use to do that share repurchase really depends on two factors: When we're going to bu",172,"Yes, that's right. We assume status quo. As you think about share repurchase, obviously, our guidance range does include some share repurchase. How much cash we actually use to do that share repurchase really depends on two factors: When we're going to buy the shares back; and what price we're going to buy them at. Obviously, when you look at a share count as a weighted average basis based on when you buy them back, I think if you look back in our history of share repurchases, we generally do very few share repurchases in the first quarter because of the timing of our earnings release and our 10-K filing. So certainly, when you think about how much cash we may use, you'd have to consider the fact that probably not a lot of repurchases come in the first quarter. And then as I said, what price you're going to do to math with. It's hard for us to forecast stock prices going forward. So we try not to guide to that."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","But you'd have a rough idea in terms of the cash going out the door, if it's closer to $500 million versus a $1 billion?",26,"But you'd have a rough idea in terms of the cash going out the door, if it's closer to $500 million versus a $1 billion?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, at this point, it's certainly a larger number -- a large portion of our cash flow.",17,"Yes, at this point, it's certainly a larger number -- a large portion of our cash flow."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Ricky Goldwasser with Morgan Stanley.",10,"Our next question is from Ricky Goldwasser with Morgan Stanley."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, I have a couple of follow-up questions here. First of all, are the 2011 investments similar in magnitude to what you've done in 2009?",25,"Jeff, I have a couple of follow-up questions here. First of all, are the 2011 investments similar in magnitude to what you've done in 2009?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","I think I tried to answer that earlier. This is George, Ricky. We've actually increased significantly -- even on the third quarter results and our fourth quarter guidance includes an ascending amount of investment in those investments. We think we're in a",136,"I think I tried to answer that earlier. This is George, Ricky. We've actually increased significantly -- even on the third quarter results and our fourth quarter guidance includes an ascending amount of investment in those investments. We think we're in a unique opportunity right now. When change is about to occur, those companies are most nimble and can take advantage of that change and meet the marketplace, we're going to do the best. And we think we are very nimble. We think we're very innovative and creative. And so we're positioning ourselves to take advantage of the tremendous amount of flock sets occurring in our space today. So those enhancements are up each and every year since I've taken over CEO. And certainly, there are higher -- it's of an accelerating rate at this point."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","So accelerated rates from the $62 million, I think it was about $62 million that you've done in 2009.",19,"So accelerated rates from the $62 million, I think it was about $62 million that you've done in 2009."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","You're talking about CapEx. And there's two pieces to this. There's CapEx and SG&A spend and some parts, that may go through GPC. So you've got all those pieces come together. And so it's not just the investments in CapEx.",41,"You're talking about CapEx. And there's two pieces to this. There's CapEx and SG&A spend and some parts, that may go through GPC. So you've got all those pieces come together. And so it's not just the investments in CapEx."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then just one question on the third quarter, or did you forget cost in the third quarter all related to NextRx or did you also see some impact from the ramping up of the new mail facility?",38,"And then just one question on the third quarter, or did you forget cost in the third quarter all related to NextRx or did you also see some impact from the ramping up of the new mail facility?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, and I would say those things are both and those things are related. As we look at -- talking about in my prepared remarks about having a little bit of excess capacity in the system today, and we're working on optimizing that capacity. We're excited a",104,"Yes, and I would say those things are both and those things are related. As we look at -- talking about in my prepared remarks about having a little bit of excess capacity in the system today, and we're working on optimizing that capacity. We're excited about our new pharmacy here in St. Louis. It's got just unbelievable accuracy and great efficiency, and it's really, we think, a competitive advantage for us long term. But we do have a little bit of excess capacity and we've got to rationalize that in time. We're moving through all the WellPoint activity. So I would say both."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Just to add on a little bit there, the site we built in St. Louis is exceeding our expectations on capacity and accuracy. We've got a program in place with zero defects. Obviously, that's pretty hard to do. But we're down to one to two defects per million",114,"Just to add on a little bit there, the site we built in St. Louis is exceeding our expectations on capacity and accuracy. We've got a program in place with zero defects. Obviously, that's pretty hard to do. But we're down to one to two defects per million and the filling [ph]. And we are truly excited about that. No other site do we have to meet those type of numbers. So we are absolutely excited about what we do. And then on a capacity side, we have significant excess capacity to meet today's needs and tomorrow's needs. So we have to go through that in the first quarter and rationalize our overall footprint."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Ross Muken with Deutsche Bank.",10,"Our next question is from Ross Muken with Deutsche Bank."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","You talked, George, a lot about sort of the specialty opportunity longer term. In the last quarter, we did see what could we call kind of the first biosimilar of sorts to kind of come to market in terms of medroxy [ph] pairing. I mean as you think about t",115,"You talked, George, a lot about sort of the specialty opportunity longer term. In the last quarter, we did see what could we call kind of the first biosimilar of sorts to kind of come to market in terms of medroxy [ph] pairing. I mean as you think about that as maybe hopefully a catalyst event for FDA to get more constructive on biosimilars, how do you think about that in that kind of context of your business and as an opportunity going forward? And do you feel like this may be something that could be a bit more hopeful in terms of this being a more near-term opportunity or maybe a two, three-year basis?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Absolutely. The biggest disappointment, as you know, that I had in healthcare reform is the fact that we put to this significant piece of legislation and didn't address with the way we needed to address the specialty market. We gave it lip service, if you",340,"Absolutely. The biggest disappointment, as you know, that I had in healthcare reform is the fact that we put to this significant piece of legislation and didn't address with the way we needed to address the specialty market. We gave it lip service, if you will, by the biosimilars. And as you also know, and when you're talking about biosimilars instead of biogenerics, these products are probably going to be priced not nearly as advantageously as they would be priced from a client perspective as a generic. So we're facing a little bit of a two edged sword here. But to your point, having introduction of these products and having many of the generic manufacturers excited about this, the administration and Congress both know that there's a tremendous opportunity here. They're one of the largest users of the biotech drugs out there, and they know what this is costing the country. They know that they were facing deficits and have a tremendous issue, and I am excited about where this can go. Now we do still need some legislative changes to ultimately get to where we need to be. But our team, we've got a fairly large lobbying group in Washington, as well as Dr. Miller, my Chief Medical Officer, also spends a lot of time on the Hill. I spend time on the Hill. And our job is to make sure that we can try to get that legislation through. I think notwithstanding all of that, there's a real issue around adherence, proper channel and the use of biosimilars. So we're talking about rolling out -- I think we can get our arms around the trend and improve the health outcomes in the world we live today. And to your point, if we can actually tip the scale over and start getting better competition and better products, especially for those where patent protection is expired, I think there's such a great, great, great opportunity out there to continue to win in this space. And that truly is our focus."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And maybe, Jeff, I just want to touch on one thing, in terms of thinking about the profit growth here and the EBIT growth that we've seen, the guidance sort of implies roughly call it 30% type EPS growth this year. Your EPS growth CAGR over the last five",157,"And maybe, Jeff, I just want to touch on one thing, in terms of thinking about the profit growth here and the EBIT growth that we've seen, the guidance sort of implies roughly call it 30% type EPS growth this year. Your EPS growth CAGR over the last five years has been slightly below that. As you think about sort of going forward, I mean, and particularly given all the focus and sort from the investment community on margins and return on capital during this last three to six months where there was a bit of trepidation. And as you kind of go forward, maybe just in broad terms, I'm not asking for a forward guidance, but do you see any sort of change in your business or anything that would make you think that on a go-forward basis the trajectory is going to be meaningfully different than we've been used to seeing from Express Scripts historically?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, unfortunately, Ross, as much as I'd like to answer that question, I think any way I would answer that, would essentially be multiyear forward guidance. So certainly, I'm going to add -- I think we said last quarter on the call that we're excited abou",85,"Yes, unfortunately, Ross, as much as I'd like to answer that question, I think any way I would answer that, would essentially be multiyear forward guidance. So certainly, I'm going to add -- I think we said last quarter on the call that we're excited about the long-term prospects for this business. We are making significant investments as we said because we believe so strongly in our business and how our team can execute. But it's hard for me to get into any more detail."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Bust just in terms of like, given the assumptions for the core business from a margin perspective, et cetera. There was nothing that occurred during this last season or even next year that meant to you that all of a sudden, the profit trajectory of the bu",55,"Bust just in terms of like, given the assumptions for the core business from a margin perspective, et cetera. There was nothing that occurred during this last season or even next year that meant to you that all of a sudden, the profit trajectory of the business was anything meaningfully different than what we've seen."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Let me try something here then Jeff can certainly add on. We always get a question about price pressure in the marketplace. And I've said for the last three years, I saw the proof's in the pudding. I said you look at the script counts and you look at what",275,"Let me try something here then Jeff can certainly add on. We always get a question about price pressure in the marketplace. And I've said for the last three years, I saw the proof's in the pudding. I said you look at the script counts and you look at what's happened on to EBITDA per script. If we couldn't compete, then those metrics would not increase. And I think what you've seen from us, is we've grown our scripts significantly over the last five years. Our EBITDA per script overall is up. Obviously, there's been acquisitions and other things that may temporarily bring them down, but then they start to ascend again. And those things point to the health, from a historical perspective, of how the business is performing. Keeping in mind, we got three-year contracts for the most part, although we with 30% of our business have seven and 10 years or effectively seven years with two option years with the DoD. Seven and 10-year business. So those things stay very strong, obviously, over those periods of time. And so, I don't know, I mean, you look at the underlying trends in the business, and we're not going to give guidance to 2012 or '13 or '14. But I will tell you, you got an aging population, you got 30 million people coming into the market, you got a need by a country and by companies to figure how to control healthcare costs, and we have answers. So you throw all those things into the hopper, you shake it up, and I like our prospects. But again, we don't want to get into specifics."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","And next we'll go to Steve Valiquette with UBS.",10,"And next we'll go to Steve Valiquette with UBS."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","You just kind of touched on this is a little bit but I thought the 2011 EBITDA for plain [ph] guidance was pretty strong. I thought it put the rest on the concerns about PBM pricing. So I was just curious, just sort of your general  comments or thoughts a",74,"You just kind of touched on this is a little bit but I thought the 2011 EBITDA for plain [ph] guidance was pretty strong. I thought it put the rest on the concerns about PBM pricing. So I was just curious, just sort of your general  comments or thoughts about the puts and takes of the projected EBIT up for claim in 2011 as any other insights you might want to add to that?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, I think, obviously, as I said earlier, we're focused on a couple of things. And we think there a couple of things that really drive this business, that's certainly one of them. I think the team here has done just a phenomenal job getting the integrat",196,"Yes, I think, obviously, as I said earlier, we're focused on a couple of things. And we think there a couple of things that really drive this business, that's certainly one of them. I think the team here has done just a phenomenal job getting the integration done, getting our efficiencies up, bringing in new programs. There's a lot of things that we've talked to before that generics is of slightly lower year. But thankfully for Express Scripts, we've got a lot of other leverage we can pull. We've got a great team of people that are pulling them, and we've got -- we're firing at all cylinders here, we're driving EBITDA up for Rx as we continue to execute. And we're delivering products that, as George was saying, clients want to buy. And our model of alignment works at the end of the day. The more money we can save our clients, the more money we can make. And in this environment, our clients want to save money with Consumerology, we've got the tools that can help them save money with minimal member impact and the net result is the results that we're putting out."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","That's particularly true, Jeff, when you think about a year where there are low generic utilization. One or two things can happen. We consider slow generic utilization, so we can go to our clients and say sorry, but you guys all better get prepared for ba",404,"That's particularly true, Jeff, when you think about a year where there are low generic utilization. One or two things can happen. We consider slow generic utilization, so we can go to our clients and say sorry, but you guys all better get prepared for bad cost trends. Well, we probably wouldn't have any clients after that conversation. So our job is not to sit on our laurels and wait for a generic launch. Our job is to be creative and equip our account managers with products and innovation that go out and make sure they can manage those trends down. And when we do that, when we execute on that, what you see is we grow our EBITDA per script. We also, by the way, meet the clients' needs that take the cost out of the equation. If you remember a couple of years back, we had a bad generic year and we grew EBITDA per script significantly during that period. And the reason was is because we see these things three years out. So we don't sit and wait until the sky's going to fall or win anything else. We actually go out with a product portfolio to meet the needs of those clients. No CFO wants to sit there with the volatility in their cost going all over the place. Our job is to control that trend on a level of basis over the life of that contract, hopefully, over more than a couple of those contract terms. And that's our job. That's what we pay our account managers, and do in bonus [ph] them to do, and they've got to do it. So we're excited about the business and what we can do. As Jeff's pointed out, we got a lot of levers. And if it's not generics in a given year, then it's something else. But we just can't sit back and be complacent. We've got to drive those numbers and that's got to be our focus. Again, going back to Larry's question, it's not a question of just going out and trying to sell. It's a question of going out and making sure we're doing what our clients need to control their cost in very volatile markets. And when we do those things well, we can grow our business and grow our EBITDA, grow our business and meet the clients' needs, and that remains our singular focus."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Any chance of having that, just generally speaking, as far as your overall wins for next year, just generally,  would you say they were skewed towards higher margin customers that already have decent mail pen rates or lower or that's not really one you wa",51,"Any chance of having that, just generally speaking, as far as your overall wins for next year, just generally,  would you say they were skewed towards higher margin customers that already have decent mail pen rates or lower or that's not really one you want to comment on at this stage?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, we don't really like to talk about clients specifically. I think there's a lot of noise going on in our numbers only because as you know, we have the big retailer lost unintentionally halfway through the year. And then we had -- so that's a bunch of",90,"Well, we don't really like to talk about clients specifically. I think there's a lot of noise going on in our numbers only because as you know, we have the big retailer lost unintentionally halfway through the year. And then we had -- so that's a bunch of no-mail claims out. So  that's in the numbers. But as far as the winds, I think they're fairly common. I mean it's our job. I think they come to us because they have a need, and we're going to meet those needs."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","That would be from the line of Garen Sarafian with Citi Investment Research.",13,"That would be from the line of Garen Sarafian with Citi Investment Research."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","In terms of reinvesting in your business and market opportunities, I'm curious to hear your thoughts on Medicaid. State continues to have severe budget shortfalls. Would you think PMBs with skills as yours really could help lower their costs and especiall",60,"In terms of reinvesting in your business and market opportunities, I'm curious to hear your thoughts on Medicaid. State continues to have severe budget shortfalls. Would you think PMBs with skills as yours really could help lower their costs and especially with the sophisticated tools. So what really needs to change for the market to become really appealing for you?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","We're looking at that and obviously, with 40% more individuals going to be pushed into the Medicaid space, something's got to give here. States are -- if you go back, four and five and six years ago, even two years ago, many of the platforms like governor",360,"We're looking at that and obviously, with 40% more individuals going to be pushed into the Medicaid space, something's got to give here. States are -- if you go back, four and five and six years ago, even two years ago, many of the platforms like governors running for office was to trying to control the budget of the states, even before the economic downturn. Medicaid was costing the states tremendous amounts of money. Many states cut-slashed Medicaid spending and cut Medicaid enrollment by changing the qualifications, and we've seen a lot of that activity. Well, now we're going to put 40% of people on top of it. And we're going to fund it in the early years and then defund it over a period of time. The states are going to have a tremendously difficult time meeting that need. And you're exactly right, there's a tremendous opportunity for us to utilize our tools, to meet the needs of that marketplace. Today, those are being met through managed Medicaid plans. We have clients who manage Medicaid. So we picked up our share through the managed Medicaid plans, but there's an awful lot of fee-for-service out there. And to the extent that you start ratcheting down spending or you need to get control of the spend, managed Medicaids probably going to play a higher and higher role. I think we've got to figure out -- that's why we're making these investments is to figure how do we play in that space to make sure we can bring our tools and expertise to an area that truly needs to be managed and worked. And s you know, the Medicaid is far different than the other plans people are transient. Most pay close to nothing if nothing for their care. So getting adherence, getting incentives, making things work is very difficult for traditional businesses. For us though, where we use Consumerology, understand the drivers of the person, who we think were in a unique position where we can use those tools to help the states manage their business. So this is truly a focus of ours over the next couple of years."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Any reason why upcoming elections next week would impact anything for next year as to the progress you make of the Medicaid front?",23,"Any reason why upcoming elections next week would impact anything for next year as to the progress you make of the Medicaid front?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, I think -- really kind of depends on everything that happens, and that goes back to being fluid and flexible because I do believe that things have to change. I'm a citizen first and a CEO second. And we are facing tremendous deficits. We've got to a",277,"Well, I think -- really kind of depends on everything that happens, and that goes back to being fluid and flexible because I do believe that things have to change. I'm a citizen first and a CEO second. And we are facing tremendous deficits. We've got to address that issue. We've got to get our costs as a country under control. Whether it's the Democrats or the Republicans, we can't continue to spend the way we're spending. We got to do something about taxation. We've got to do something about competitive strength of our companies to be able to compete globally. There's an awful lot out there. All those things could have an impact on what happens. If the Republicans win the house and they decide not to procreate money to the healthcare bill, where does that take us? What happens if the Federal government has the right to establish the exchanges, will the states have the right to put them in? What if states don't do it, would the Federal government do it? What if there's money not appropriated? There's a lot of uncertainty out there. At the end of the day though, all those uncertainties, I view as a wonderful thing. Because the company that can change and the company that can meet the market needs and can be first to market is the one that can win. And I don't think there's anybody out there than at Express Scripts. So I love where we sit. We know that these things are at some way or form, these things are going to happen. And I think we're very well-positioned to take advantage of those opportunities."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Just switching channels a bit. I know you don't speak about specific clients coming up, but overall, how do you see the 2011 selling season as it gets underway? Maybe if you could offer just some broad color as to how it compares to 2010 in terms of size",65,"Just switching channels a bit. I know you don't speak about specific clients coming up, but overall, how do you see the 2011 selling season as it gets underway? Maybe if you could offer just some broad color as to how it compares to 2010 in terms of size and just the types of clients that are going to market next year versus this year?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Sure, I think you've heard us say this many times before. We've got two large clients that make up half of our book that are on longer term renewal cycles, which on average means that we've got 15% to 20% of our book up to renewal in any given year. And a",80,"Sure, I think you've heard us say this many times before. We've got two large clients that make up half of our book that are on longer term renewal cycles, which on average means that we've got 15% to 20% of our book up to renewal in any given year. And as we look at 2011 right now to the lower end of that range, certainly, clients up for renewal are slightly lower in '11 than it was in 2010."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Overall, is there opportunities in -- I mean, is the overall opportunity larger than 2010, or there might be some opportunities to bring on additional clients?",26,"Overall, is there opportunities in -- I mean, is the overall opportunity larger than 2010, or there might be some opportunities to bring on additional clients?"
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","We're always excited about the opportunities out there. I think we've got unique products that can really help clients save money. And we're excited about what we have to offer and certainly the sales team is out there to close every opportunity we can cl",70,"We're always excited about the opportunities out there. I think we've got unique products that can really help clients save money. And we're excited about what we have to offer and certainly the sales team is out there to close every opportunity we can close as long as the client we want to work with, the client is focused on taking out ways where we can add significant value."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, thank you all very much. I appreciate your attentiveness this morning, and look forward to bringing you up-to-date with our fourth quarter results early next year. Thank you very much.",31,"Well, thank you all very much. I appreciate your attentiveness this morning, and look forward to bringing you up-to-date with our fourth quarter results early next year. Thank you very much."
317975,114404734,82741,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation. You may now disconnect.",19,"Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation. You may now disconnect."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Express Scripts Third Quarter 2010 Earnings Call. [Operator Instructions] Now with that being said, I'll turn the conference now to the Vice President of Investor Relations, Mr. David Myers.",40,"Ladies and gentlemen, thank you for standing by. Welcome to the Express Scripts Third Quarter 2010 Earnings Call. [Operator Instructions] Now with that being said, I'll turn the conference now to the Vice President of Investor Relations, Mr. David Myers."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, and good morning, everyone. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. Before we begin, I need to read the following Safe Harbor statement.Statements or comments made on this conference call may be forward-loo",184,"Thank you, and good morning, everyone. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. Before we begin, I need to read the following Safe Harbor statement.
Statements or comments made on this conference call may be forward-looking statements and may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors, which are discussed in detail in our filings with the SEC.
For clarity purposes, all numbers we talk about today will be on an adjusted basis. Please refer to the tables in our press release for reconciliation of GAAP to the adjusted numbers we will be discussing. The reconciliation of EBITDA to net income can also be found in our earnings release. The earnings release is posted on our website. 
At this point, I'll turn the call over to Jeff, who will talk about our third quarter results."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, David. Today, we are pleased to report another record quarter and provide guidance for 2011. Our strong results and outlook for the future are the result of our differentiated strategy. Our business model of alignment, enabled by our behavior-c",523,"Thank you, David. Today, we are pleased to report another record quarter and provide guidance for 2011. Our strong results and outlook for the future are the result of our differentiated strategy. Our business model of alignment, enabled by our behavior-centric approach, supported by market-leading technology and service levels. Our execution of this strategy helps our clients and patients drive out wasteful spending, which in turn helps us continue to deliver superior returns to our stockholders. 
Third quarter earnings per share reached a record of $0.65, up 55% over last year. The majority of these growth came from EBITDA, which grew at 45% over last year and 5% sequentially. During the quarter, we made significant progress executing our integration plans. We have now transitioned 90% of the WellPoint Live to our IT platform, and expect to complete the final migration of Live at year end. This will position us to finish the integration, retire the NextRx system and rationalize our operational footprint in the first quarter. 
Metrics for the quarter were strong and reflect our integration progress. Adjusted claims grew at 48% to $186.9 million. Total operating expenses were in line with our expectations, although the mix of expenses is weighted more towards cost of goods sold and forecasted through the excess capacity that remains in the system today. Despite this excess capacity, gross profit improved to 7.2%, up 30 basis points sequentially. We expect gross profit margin will continue to improve as the underlying fundamentals of our business continue to improve, the completion of the integration and the optimization of capacity.
EBITDA for adjusted Rx reached $3.30, up sequentially from $3.10 last quarter, and year-to-date cash flow from operations increased 99% to $1.8 billion. During the quarter, we repurchased 16.4 million shares and repaid the remaining balance of our term loan. Based on these results and our positive outlook for the remainder of the year, we have narrowed our 2010 EPS guidance range to $2.48 to $2.50. This represents growth of 26% to 27% over 2009 on an adjusted basis. 
Moving on to 2011 guidance, we expect that 2011 EPS will be in the range of $3.15 to $3.25, representing growth of 27% to 31% over 2010. We are confident we will complete the integration and achieve our synergy targets in the year. And as a result, our 2011 guidance include $1 billion of incremental EBITDA. 
Since the acquisition will be fully integrated next year and our guidance includes the achievement of synergy targets, and keeping with our long-standing practice of not commenting on specific clients, we will no longer discuss WellPoint-specific results. 
Cash flow from operations is expected to be between $2.2 billion and $2.4 billion. We see a lot of exciting opportunities, and our EPS guidance include significant investments in 2011. In addition to these significant investments flowing through our P&L, we also expect to spend $140 million to $170 million in capital investments in the year.
We are pleased with how our team has executed in 2010 and look forward to continuing to deliver strong performance in 2011 and beyond. 
And with that, I'll turn it over to George."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, Jeff, and good morning, everyone. Since our inception, we have been focused on alignment and our ability to innovate and execute. These qualities are as strong as ever, and we are now deploying new capabilities enabled by our groundbreaking wor",577,"Thank you, Jeff, and good morning, everyone. Since our inception, we have been focused on alignment and our ability to innovate and execute. These qualities are as strong as ever, and we are now deploying new capabilities enabled by our groundbreaking work in Consumerology. This week, we had our National Accounts Advisory Board meeting. Annually, we hold this meeting to bring in our diverse set of our National Account clients to get input on market conditions, medical trends and our pipeline of new products. At this meeting, I gathered feedback from many of our clients. They are overwhelmingly pleased with our ability to drive out wasteful spending while improving health outcomes, with high levels of member satisfaction. 
The NextRx acquisition is another good example of innovation and execution at work. We closed the transaction just 11 months ago. And through the focused effort of both companies, the migration of Live is nearing completion. The transition of Live was seamless and efficient with very little noise or disruption. As Jeff mentioned, we now consider NextRx part of our core business. Completing the critical migration so quickly is important so that we can focus on the potential of this strategic alliance. It will open new horizons for improving outcomes for members while driving all [ph] down our overall health care costs.
As the selling season winds down, let me summarize the results. As we pointed out last quarter, we saw high retention rates for signature accounts. Notwithstanding the stickiness in the marketplace, we won three signature accounts and again, grew our share in the middle market. Even with the client losses discussed last quarter, we expect the retention to exceed 95%. Based on our new sales activities and retention rate, we expect claims to be flat to up 4% for 2011. Our 2011 guidance not only provides strong earnings growth, it also provides for significant investments designed to keep us ahead of the competition in the evolving healthcare landscape. These projects include preparation for EBIT changes, Medicare regulations and healthcare reform. We are investing in opportunities to continue to differentiate ourselves in the marketplace by creating new products and services that meet and exceed the needs of tomorrow's marketplace.
In addition to the investments in our Consumerology platform, I'm particularly excited about two specific initiatives. First, we are investing heavily in our next-generation specialty offering that will be rolled out next year. This offering will enhance our ability manage the cost and quality, especially drug care. Part of the programs in this area had been enthusiastically endorsed by clients for their ability to drive out significant ways to the specially drug spend, the fastest-growing area of pharmaceutical costs. Second, we're tackling the issue of non-adherence by making significant investments in our predictive modeling capabilities. Through these efforts, we are able to identify in advance, those patients that are unlikely to adhere to medication therapies. We then intervene and customize ways to improve adherence. Although early, we are seeing significant improvements in medication adherence in our pilot programs. 
Our core business is strong, and we are positive on the underlying trends and opportunities in our space. This is why we are investing to position ourselves for a long-term growth. Our ability to manage trend, coupled with our behavior-centric approach, will drive out ways for clients, improve health outcomes for patients and deliver strong earnings growth for our stockholders. 
At this point, I'd like to open it up to questions. Operator?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","[Operator Instructions] First in line is Tom Gallucci with Lazard Capital Markets.",12,"[Operator Instructions] First in line is Tom Gallucci with Lazard Capital Markets."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","First, just wondering, you sort of mentioned significant investments within the 2011 expectations. Is there any way you can frame or quantify the magnitude of what we're looking at here?",30,"First, just wondering, you sort of mentioned significant investments within the 2011 expectations. Is there any way you can frame or quantify the magnitude of what we're looking at here?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","I can let Jeff chime in on that as well, but as you probably know, CMS, before healthcare reform was ultimately passed, and certainly, quickly thereafter, continued to issue more and more guidance. There was a lot of uncertainty and ambiguity in the Medic",451,"I can let Jeff chime in on that as well, but as you probably know, CMS, before healthcare reform was ultimately passed, and certainly, quickly thereafter, continued to issue more and more guidance. There was a lot of uncertainty and ambiguity in the Medicare provisions that exist. And so CMS has been very proactive in trying to get guidance out to the providers and to the insurance companies. And so as that guidance has come down, there's two ways you can approach this. We can do the minimum and make sure we hit that guidance so we can think about how we want to position ourselves in an evolving world and make sure that we can, not only meet the guidance requirements, but be ahead of the game with respect to new product innovation and meet the needs of that guidance may imply with respect to the needs of our clients and patients. So our IT and operational departments and our sales and comm management product development all work in unison to both meet the guidance requirements, as well as drive new product innovation. That, coupled with all the requirements from HIPAA, HITECH, we had DIDAD coming through, which is the new standard by which everyone has to be geared up for by 2012, in order to handle the ingredient components of compounds and expands fields. There's a tremendous amount of work that has to take place. Again, it's not just meeting those needs, but making sure that we meet them better than the competition and use it for new product innovation. Those have to go hand-in-hand. And of course, there's healthcare reform. So quite frankly, I don't want to get into the specifics but we don't want to give guidance by line items on our financials. But I will tell you that our investments in technology and operations and product development have significantly improved. They were quite a bit higher in 2010 as the year ramped out. And then in 2011, we expect continued increases. When we give our -- you often asked us how we feel about the deployment of our capital. And one of the things we say is we always like to invest in ourself first. I think that's critically important because I don't know what else gets better returns than investing in our own business. And as we look at this, that's exactly what we're doing. We're investing in ourself. Well, we invest in ourself, either it has to come through to two places, either it has to come through expenses or it has come through capital investments, depending on the type of project it is, and that's what you're seeing in the guidance we're giving."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","And next with Larry Marsh with Barclays Capital.",8,"And next with Larry Marsh with Barclays Capital."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","First on new business, George, your model's a little bit different. You're really focused on driving value to your customers and shareholders, you're focused on EBITDA and earnings, not necessarily winning new business. But obviously, over time, you got t",94,"First on new business, George, your model's a little bit different. You're really focused on driving value to your customers and shareholders, you're focused on EBITDA and earnings, not necessarily winning new business. But obviously, over time, you got to balance the two. As we think about the next couple of years, how do we think about the opportunity for you to take share? Do you think of it that way, where would you gain share? And then how do you think of Medi in that sort of balance between margin and new business?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Only challenged a little bit, Larry, first of all. I think if it was a stagnant world and you are selling just automobiles. You have to always worry about how do I sell the next car. Keep in mind that we have a totally different dynamic that's occurring i",538,"Only challenged a little bit, Larry, first of all. I think if it was a stagnant world and you are selling just automobiles. You have to always worry about how do I sell the next car. Keep in mind that we have a totally different dynamic that's occurring in our market spot. We have an under-penetration of mail, we have people that aren't fully utilizing specialty drugs, the fastest-growing part of healthcare cost in the drug space, not being properly utilized and not being properly adhere to. And then we've got members aging, the baby booms getting older, people are moving through that pipeline and becoming older. And as they do, they take more prescriptions. We see in 2014, 30 plus million more people entering into the market. So there's a whole lot of things going on. So the question you have to ask yourself is where should the company's focus be? Should it be coming up with innovative product to drive mail, generic utilization, to drive specialty cost out that all these things add value to our clients, improve health outcomes for our members and drive shareholder value, or do you want to grow new business for the sake of new business growth? What gives you the biggest returns? I've said on many, many, many calls that part of a great client-company relationship has to have built into it a common desire to meet the needs of the marketplace. There are certain clients that want to do things that don't align with our model. Those aren't good clients for us. Adding those clients would be a detraction of our call center associates, our operational associates, our account management as they're trying to conform a square peg into a round hole. Our focus has to be around growing share value and you do that through ROIC. That doesn't mean we can shrink the business over time, but what it means is we have to be disciplined about that business. We need clients that are concerned about their drug costs and spend and the improvement of health outcomes for their individuals. When we align those desires and needs with the products we have to offer and our approach, we have a marriage that works quite happily. And that's what we look for, Larry. So I think we can continue to grow EBITDA, we can continue to grow our profits without getting crazy in the marketplace by just competing on the clients that make sense. And by the way, when you're offering the client something they want and you're aligned with them, then the price is always important. But the prices points doesn't match up what they're looking for and our messaging and our pricing resonates with them and we get a sale. And guess what, even though I might make more money over some period of time with that client, they're happy because we're taking far more costs out of their equation than they expected or that they originally anticipated or they've gotten in the past. And so we got a very high, happy camper. I got happy patients as they got better health outcomes and I'm driving shareholder value to all of my valuable shareholders. That's our focus."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And I guess a follow up and a couple of things in on overall script growth you now see is a little bit stronger than you would have said six months ago for '11. Do we assume that mail script growth is kind of consistent with that overall 0% to 4% trend? A",112,"And I guess a follow up and a couple of things in on overall script growth you now see is a little bit stronger than you would have said six months ago for '11. Do we assume that mail script growth is kind of consistent with that overall 0% to 4% trend? And then just on WellPoint, I know Jeff and I are talking anymore specifically about that customer going forward, but you talked about integration costs that are to be determined. How do we framework that for '11? What kind of things could there be and can you give us any guidance as to how big or small that might be?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","You're right, we did end up with three signature accounts this year. And we did -- we're having a very successful selling season in the small to middle market area. And those things aren't finished yet, and the latter one isn't finished yet. Sometimes we",407,"You're right, we did end up with three signature accounts this year. And we did -- we're having a very successful selling season in the small to middle market area. And those things aren't finished yet, and the latter one isn't finished yet. Sometimes we don't know we got a new client win until January 15 and those are usually very small. But that last piece kind of rolls out towards the end of the year. So based on our best guess is in the pipeline and where we sit today, our selling season and success is better than we had anticipated earlier in the year. Having said all that, I don't want to get into client-specific situations, but we are pleased with where we sit. As far as mail is concerned, mail is a very important focus to us. We believe mail is important because it does drive better economics for our members, we show better adherence, better health outcomes for mail. By the same token, with certain clients, when you're going through an integration, the integration has to go first. So we got to get through this year. Finish that often. So starting next year, we're absolutely focused on mail and generic programs with WellPoint. I guess, I am talking about the clients specifically, but in this situation, we will address that. For the rest of our clients, keep in mind that one of the things that we're facing is a tough economic environment. And when a member has to pay two or three copays, upfront versus paying one at the Connery retailer in an uncertain tough environment, that's a little harder to do. And so the members struggle a little bit with that, and we do see some of our membership moving from mail into retail for that reason. But we fight hard. We try to make sure that we get them back. It's good for the client, ultimately, it's good for the member. And of course, it's very good for their healthcare outcomes. So it's going to continue to be a focus for us. I would say that you going into next year because we're just getting underway with the WellPoint situation, we expect modest to low growth in mail. But keep in mind, that's based on our current economic situation. There's a lot of things that can change over next year. And we'll obviously keep you posted quarter-by-quarter on that progress."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then any range of integration costs?",7,"And then any range of integration costs?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","So Larry, the range really hasn't changed. We've been saying from the beginning that we expect about $120 million to $150 million in integration costs. I think the difference that you're picking up now on is that now that we've got guidance into 2011. We",110,"So Larry, the range really hasn't changed. We've been saying from the beginning that we expect about $120 million to $150 million in integration costs. I think the difference that you're picking up now on is that now that we've got guidance into 2011. We still think it's going to be $120 million to $150 million. But what we don't know what the great clarity at the moment is how much of that is going to hit into 2010 how much of that is going to hit in 2011. But if some of it does push over into 2011, we still expect the same range, $120 million to $150 million."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Lisa Gill with JPMorgan.",9,"Our next question is from Lisa Gill with JPMorgan."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, I know that you just commented -- George commented around mail for 2011 as it pertains to WellPoint. Can you comment as to if there's anything in your current expectations in the current guidance or will this just be the beginning stages of trying t",52,"Jeff, I know that you just commented -- George commented around mail for 2011 as it pertains to WellPoint. Can you comment as to if there's anything in your current expectations in the current guidance or will this just be the beginning stages of trying to sell through some of these programs?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well as I said, as we said we, I said about [ph] WellPoint kicking off their programs in 2011. The overall growth in our mail, I believe, will be slightly up year-over-year. So that encompasses the whole book.",38,"Well as I said, as we said we, I said about [ph] WellPoint kicking off their programs in 2011. The overall growth in our mail, I believe, will be slightly up year-over-year. So that encompasses the whole book."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","I think that a lot of investors have been focused on how quickly you can up sell, George, to that new book of business. And I was just curious if anything was in your expectations or if this is a [indiscernible] that we're getting the integration as we'll",69,"I think that a lot of investors have been focused on how quickly you can up sell, George, to that new book of business. And I was just curious if anything was in your expectations or if this is a [indiscernible] that we're getting the integration as we'll now have the opportunity to go out and start talking about the programs rather than having something built within your expectations?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, clearly, it will be a focus of ours, Lisa. And it's certainly a focus of WellPoint. I think the reason they chose us was because they liked our approach to mail or liked our approach to generics. As we said that throughout this year though, this yea",175,"Well, clearly, it will be a focus of ours, Lisa. And it's certainly a focus of WellPoint. I think the reason they chose us was because they liked our approach to mail or liked our approach to generics. As we said that throughout this year though, this year had to be a focus on integration. So if we're finished on '11, then we change our focus next year to up-selling clinical programs and working, trying to work with them as a client. So as you might suspect, when you start that, January is all about planned design changes and making sure the book of business is stable and you're meeting all your service requirements. So these things don't start to look end of the first quarter to the second quarter and then you got to up-sell them, you got to work them through, you got to go out and talk to the clients. We got to put our people out on the street to go talk to them. So next year is the kick-off year."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then maybe could you just comment on, are you seeing any acquisition opportunities in the marketplace? This has clearly been a very successful transaction for you. What are some of your thoughts on some of the other things that are maybe out there tod",45,"And then maybe could you just comment on, are you seeing any acquisition opportunities in the marketplace? This has clearly been a very successful transaction for you. What are some of your thoughts on some of the other things that are maybe out there today?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Our position has been pretty consistent over the last several quarters. We say the same thing every time. Certainly, there are other PBMs that we think would be very attractive acquisitions for us, but we always caveat that with at the right price and the",128,"Our position has been pretty consistent over the last several quarters. We say the same thing every time. Certainly, there are other PBMs that we think would be very attractive acquisitions for us, but we always caveat that with at the right price and the right term. And so there are lots of rumors out in the market. We're not going to comment on individual specifics or individual rumors, but our position remains the same. There are PBMs we'd like to own at the right price and the right terms. We think we've proven that we can do this, integrate them better and faster than anybody else and we've proven that can create great shareholder value by doing this. And when the opportunities are right, we will execute."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then just finally, Jeff, I missed some of your prepared comments. But did you talk at all about the progression and how we should be thinking about 2011 from a quarterly progression standpoint?",34,"And then just finally, Jeff, I missed some of your prepared comments. But did you talk at all about the progression and how we should be thinking about 2011 from a quarterly progression standpoint?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Let me just back that up a little bit and talk just a little bit about how I see guidance and I think my position maybe slightly different than some of my other peers out there. But my view on guidance is actually relatively simple, which is do a really a",256,"Let me just back that up a little bit and talk just a little bit about how I see guidance and I think my position maybe slightly different than some of my other peers out there. But my view on guidance is actually relatively simple, which is do a really accurate forecast then tell investors what we really think we can do and then just hit those numbers. And certainly, since my arrival here, we have significantly improved our forecasting ability in order to execute on that vision. I also think there are only a few numbers that really matter, claims, EPS, EBITDA, cash flow. As a result, we try to only guide to those numbers because we think guiding in more detail just dilutes the focus on those metrics, the metrics that matter. We also want to stay focused on the long term so we don't guide the quarters either, again, making sure that we don't dilute our focus on hit and what matters. That said, I understand that everybody out there, all the sell-side people have models to put together. So from time to time, we give a little bit more color on different things to help you out a little bit. As we think about EPS progression for next year, I'd say it looks about like 2010 right now, a little bit more back-end loaded, quite frankly, than 2011. But just to be clear, we're not focused on hitting individual quarters. We're focused on delivering long-term shareholder value and the metrics that matter."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Robert Willoughby with Bank of America Merrill Lynch.",13,"Our next question is from Robert Willoughby with Bank of America Merrill Lynch."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","George or Jeff, you've been saying [ph] of floating rates in the past, but forgive me if someone has asked already. But you've been saying that the floating rates, when you guys moved to lock in some rates here, either turn up a bit or just take advantage",55,"George or Jeff, you've been saying [ph] of floating rates in the past, but forgive me if someone has asked already. But you've been saying that the floating rates, when you guys moved to lock in some rates here, either turn up a bit or just take advantage of the rates you're seeing out there?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Certainly, we think over long periods of time in history, being floating has certainly paid off. As we look at our current debt structure, we're clearly at the low end of our range, saying that we're comfortable at 1x to 2x EBITDA, if you look at our EPS",132,"Certainly, we think over long periods of time in history, being floating has certainly paid off. As we look at our current debt structure, we're clearly at the low end of our range, saying that we're comfortable at 1x to 2x EBITDA, if you look at our EPS guidance for '11, we're probably a little bit below 1x now. So we certainly think that for the right opportunities, we could those debt levels could come up a little bit. If we did make that change, we would certainly be looking at the potential to float things out there. Although we're also in a really unique interest rate environment where long-term debt has very low fixed rates and certainly that's all got to come into the calculates of what we end up doing."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","So the numbers for 2011, you've basically assumed status quo here? No refinancing and what in the way [ph] share repurchase then?",22,"So the numbers for 2011, you've basically assumed status quo here? No refinancing and what in the way [ph] share repurchase then?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, that's right. We assume status quo. As you think about share repurchase, obviously, our guidance range does include some share repurchase. How much cash we actually use to do that share repurchase really depends on two factors: When we're going to bu",172,"Yes, that's right. We assume status quo. As you think about share repurchase, obviously, our guidance range does include some share repurchase. How much cash we actually use to do that share repurchase really depends on two factors: When we're going to buy the shares back; and what price we're going to buy them at. Obviously, when you look at a share count as a weighted average basis based on when you buy them back, I think if you look back in our history of share repurchases, we generally do very few share repurchases in the first quarter because of the timing of our earnings release and our 10-K filing. So certainly, when you think about how much cash we may use, you'd have to consider the fact that probably not a lot of repurchases come in the first quarter. And then as I said, what price you're going to do to math with. It's hard for us to forecast stock prices going forward. So we try not to guide to that."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","But you'd have a rough idea in terms of the cash going out the door, if it's closer to $500 million versus a $1 billion?",26,"But you'd have a rough idea in terms of the cash going out the door, if it's closer to $500 million versus a $1 billion?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, at this point, it's certainly a larger number -- a large portion of our cash flow.",17,"Yes, at this point, it's certainly a larger number -- a large portion of our cash flow."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Ricky Goldwasser with Morgan Stanley.",10,"Our next question is from Ricky Goldwasser with Morgan Stanley."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, I have a couple of follow-up questions here. First of all, are the 2011 investments similar in magnitude to what you've done in 2009?",25,"Jeff, I have a couple of follow-up questions here. First of all, are the 2011 investments similar in magnitude to what you've done in 2009?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","I think I tried to answer that earlier. This is George, Ricky. We've actually increased significantly -- even on the third quarter results and our fourth quarter guidance includes an ascending amount of investment in those investments. We think we're in a",136,"I think I tried to answer that earlier. This is George, Ricky. We've actually increased significantly -- even on the third quarter results and our fourth quarter guidance includes an ascending amount of investment in those investments. We think we're in a unique opportunity right now. When change is about to occur, those companies are most nimble and can take advantage of that change and meet the marketplace, we're going to do the best. And we think we are very nimble. We think we're very innovative and creative. And so we're positioning ourselves to take advantage of the tremendous amount of flock sets occurring in our space today. So those enhancements are up each and every year since I've taken over CEO. And certainly, there are higher -- it's of an accelerating rate at this point."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","So accelerated rates from the $62 million, I think it was about $62 million that you've done in 2009.",19,"So accelerated rates from the $62 million, I think it was about $62 million that you've done in 2009."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","You're talking about CapEx. And there's two pieces to this. There's CapEx and SG&A spend and some parts, that may go through GPC. So you've got all those pieces come together. And so it's not just the investments in CapEx.",41,"You're talking about CapEx. And there's two pieces to this. There's CapEx and SG&A spend and some parts, that may go through GPC. So you've got all those pieces come together. And so it's not just the investments in CapEx."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then just one question on the third quarter, or did you forget cost in the third quarter all related to NextRx or did you also see some impact from the ramping up of the new mail facility?",38,"And then just one question on the third quarter, or did you forget cost in the third quarter all related to NextRx or did you also see some impact from the ramping up of the new mail facility?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, and I would say those things are both and those things are related. As we look at -- talking about in my prepared remarks about having a little bit of excess capacity in the system today, and we're working on optimizing that capacity. We're excited a",104,"Yes, and I would say those things are both and those things are related. As we look at -- talking about in my prepared remarks about having a little bit of excess capacity in the system today, and we're working on optimizing that capacity. We're excited about our new pharmacy here in St. Louis. It's got just unbelievable accuracy and great efficiency, and it's really, we think, a competitive advantage for us long term. But we do have a little bit of excess capacity and we've got to rationalize that in time. We're moving through all the WellPoint activity. So I would say both."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Just to add on a little bit there, the site we built in St. Louis is exceeding our expectations on capacity and accuracy. We've got a program in place with zero defects. Obviously, that's pretty hard to do. But we're down to one to two defects per million",114,"Just to add on a little bit there, the site we built in St. Louis is exceeding our expectations on capacity and accuracy. We've got a program in place with zero defects. Obviously, that's pretty hard to do. But we're down to one to two defects per million and the filling [ph]. And we are truly excited about that. No other site do we have to meet those type of numbers. So we are absolutely excited about what we do. And then on a capacity side, we have significant excess capacity to meet today's needs and tomorrow's needs. So we have to go through that in the first quarter and rationalize our overall footprint."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Ross Muken with Deutsche Bank.",10,"Our next question is from Ross Muken with Deutsche Bank."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","You talked, George, a lot about sort of the specialty opportunity longer term. In the last quarter, we did see what could we call kind of the first biosimilar of sorts to kind of come to market in terms of medroxy [ph] pairing. I mean as you think about t",115,"You talked, George, a lot about sort of the specialty opportunity longer term. In the last quarter, we did see what could we call kind of the first biosimilar of sorts to kind of come to market in terms of medroxy [ph] pairing. I mean as you think about that as maybe hopefully a catalyst event for FDA to get more constructive on biosimilars, how do you think about that in that kind of context of your business and as an opportunity going forward? And do you feel like this may be something that could be a bit more hopeful in terms of this being a more near-term opportunity or maybe a two, three-year basis?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Absolutely. The biggest disappointment, as you know, that I had in healthcare reform is the fact that we put to this significant piece of legislation and didn't address with the way we needed to address the specialty market. We gave it lip service, if you",340,"Absolutely. The biggest disappointment, as you know, that I had in healthcare reform is the fact that we put to this significant piece of legislation and didn't address with the way we needed to address the specialty market. We gave it lip service, if you will, by the biosimilars. And as you also know, and when you're talking about biosimilars instead of biogenerics, these products are probably going to be priced not nearly as advantageously as they would be priced from a client perspective as a generic. So we're facing a little bit of a two edged sword here. But to your point, having introduction of these products and having many of the generic manufacturers excited about this, the administration and Congress both know that there's a tremendous opportunity here. They're one of the largest users of the biotech drugs out there, and they know what this is costing the country. They know that they were facing deficits and have a tremendous issue, and I am excited about where this can go. Now we do still need some legislative changes to ultimately get to where we need to be. But our team, we've got a fairly large lobbying group in Washington, as well as Dr. Miller, my Chief Medical Officer, also spends a lot of time on the Hill. I spend time on the Hill. And our job is to make sure that we can try to get that legislation through. I think notwithstanding all of that, there's a real issue around adherence, proper channel and the use of biosimilars. So we're talking about rolling out -- I think we can get our arms around the trend and improve the health outcomes in the world we live today. And to your point, if we can actually tip the scale over and start getting better competition and better products, especially for those where patent protection is expired, I think there's such a great, great, great opportunity out there to continue to win in this space. And that truly is our focus."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And maybe, Jeff, I just want to touch on one thing, in terms of thinking about the profit growth here and the EBIT growth that we've seen, the guidance sort of implies roughly call it 30% type EPS growth this year. Your EPS growth CAGR over the last five",157,"And maybe, Jeff, I just want to touch on one thing, in terms of thinking about the profit growth here and the EBIT growth that we've seen, the guidance sort of implies roughly call it 30% type EPS growth this year. Your EPS growth CAGR over the last five years has been slightly below that. As you think about sort of going forward, I mean, and particularly given all the focus and sort from the investment community on margins and return on capital during this last three to six months where there was a bit of trepidation. And as you kind of go forward, maybe just in broad terms, I'm not asking for a forward guidance, but do you see any sort of change in your business or anything that would make you think that on a go-forward basis the trajectory is going to be meaningfully different than we've been used to seeing from Express Scripts historically?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, unfortunately, Ross, as much as I'd like to answer that question, I think any way I would answer that, would essentially be multiyear forward guidance. So certainly, I'm going to add -- I think we said last quarter on the call that we're excited abou",85,"Yes, unfortunately, Ross, as much as I'd like to answer that question, I think any way I would answer that, would essentially be multiyear forward guidance. So certainly, I'm going to add -- I think we said last quarter on the call that we're excited about the long-term prospects for this business. We are making significant investments as we said because we believe so strongly in our business and how our team can execute. But it's hard for me to get into any more detail."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Bust just in terms of like, given the assumptions for the core business from a margin perspective, et cetera. There was nothing that occurred during this last season or even next year that meant to you that all of a sudden, the profit trajectory of the bu",55,"Bust just in terms of like, given the assumptions for the core business from a margin perspective, et cetera. There was nothing that occurred during this last season or even next year that meant to you that all of a sudden, the profit trajectory of the business was anything meaningfully different than what we've seen."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Let me try something here then Jeff can certainly add on. We always get a question about price pressure in the marketplace. And I've said for the last three years, I saw the proof's in the pudding. I said you look at the script counts and you look at what",275,"Let me try something here then Jeff can certainly add on. We always get a question about price pressure in the marketplace. And I've said for the last three years, I saw the proof's in the pudding. I said you look at the script counts and you look at what's happened on to EBITDA per script. If we couldn't compete, then those metrics would not increase. And I think what you've seen from us, is we've grown our scripts significantly over the last five years. Our EBITDA per script overall is up. Obviously, there's been acquisitions and other things that may temporarily bring them down, but then they start to ascend again. And those things point to the health, from a historical perspective, of how the business is performing. Keeping in mind, we got three-year contracts for the most part, although we with 30% of our business have seven and 10 years or effectively seven years with two option years with the DoD. Seven and 10-year business. So those things stay very strong, obviously, over those periods of time. And so, I don't know, I mean, you look at the underlying trends in the business, and we're not going to give guidance to 2012 or '13 or '14. But I will tell you, you got an aging population, you got 30 million people coming into the market, you got a need by a country and by companies to figure how to control healthcare costs, and we have answers. So you throw all those things into the hopper, you shake it up, and I like our prospects. But again, we don't want to get into specifics."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","And next we'll go to Steve Valiquette with UBS.",10,"And next we'll go to Steve Valiquette with UBS."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","You just kind of touched on this is a little bit but I thought the 2011 EBITDA for plain [ph] guidance was pretty strong. I thought it put the rest on the concerns about PBM pricing. So I was just curious, just sort of your general  comments or thoughts a",74,"You just kind of touched on this is a little bit but I thought the 2011 EBITDA for plain [ph] guidance was pretty strong. I thought it put the rest on the concerns about PBM pricing. So I was just curious, just sort of your general  comments or thoughts about the puts and takes of the projected EBIT up for claim in 2011 as any other insights you might want to add to that?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, I think, obviously, as I said earlier, we're focused on a couple of things. And we think there a couple of things that really drive this business, that's certainly one of them. I think the team here has done just a phenomenal job getting the integrat",196,"Yes, I think, obviously, as I said earlier, we're focused on a couple of things. And we think there a couple of things that really drive this business, that's certainly one of them. I think the team here has done just a phenomenal job getting the integration done, getting our efficiencies up, bringing in new programs. There's a lot of things that we've talked to before that generics is of slightly lower year. But thankfully for Express Scripts, we've got a lot of other leverage we can pull. We've got a great team of people that are pulling them, and we've got -- we're firing at all cylinders here, we're driving EBITDA up for Rx as we continue to execute. And we're delivering products that, as George was saying, clients want to buy. And our model of alignment works at the end of the day. The more money we can save our clients, the more money we can make. And in this environment, our clients want to save money with Consumerology, we've got the tools that can help them save money with minimal member impact and the net result is the results that we're putting out."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","That's particularly true, Jeff, when you think about a year where there are low generic utilization. One or two things can happen. We consider slow generic utilization, so we can go to our clients and say sorry, but you guys all better get prepared for ba",404,"That's particularly true, Jeff, when you think about a year where there are low generic utilization. One or two things can happen. We consider slow generic utilization, so we can go to our clients and say sorry, but you guys all better get prepared for bad cost trends. Well, we probably wouldn't have any clients after that conversation. So our job is not to sit on our laurels and wait for a generic launch. Our job is to be creative and equip our account managers with products and innovation that go out and make sure they can manage those trends down. And when we do that, when we execute on that, what you see is we grow our EBITDA per script. We also, by the way, meet the clients' needs that take the cost out of the equation. If you remember a couple of years back, we had a bad generic year and we grew EBITDA per script significantly during that period. And the reason was is because we see these things three years out. So we don't sit and wait until the sky's going to fall or win anything else. We actually go out with a product portfolio to meet the needs of those clients. No CFO wants to sit there with the volatility in their cost going all over the place. Our job is to control that trend on a level of basis over the life of that contract, hopefully, over more than a couple of those contract terms. And that's our job. That's what we pay our account managers, and do in bonus [ph] them to do, and they've got to do it. So we're excited about the business and what we can do. As Jeff's pointed out, we got a lot of levers. And if it's not generics in a given year, then it's something else. But we just can't sit back and be complacent. We've got to drive those numbers and that's got to be our focus. Again, going back to Larry's question, it's not a question of just going out and trying to sell. It's a question of going out and making sure we're doing what our clients need to control their cost in very volatile markets. And when we do those things well, we can grow our business and grow our EBITDA, grow our business and meet the clients' needs, and that remains our singular focus."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Any chance of having that, just generally speaking, as far as your overall wins for next year, just generally,  would you say they were skewed towards higher margin customers that already have decent mail pen rates or lower or that's not really one you wa",51,"Any chance of having that, just generally speaking, as far as your overall wins for next year, just generally,  would you say they were skewed towards higher margin customers that already have decent mail pen rates or lower or that's not really one you want to comment on at this stage?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, we don't really like to talk about clients specifically. I think there's a lot of noise going on in our numbers only because as you know, we have the big retailer lost unintentionally halfway through the year. And then we had -- so that's a bunch of",90,"Well, we don't really like to talk about clients specifically. I think there's a lot of noise going on in our numbers only because as you know, we have the big retailer lost unintentionally halfway through the year. And then we had -- so that's a bunch of no-mail claims out. So  that's in the numbers. But as far as the winds, I think they're fairly common. I mean it's our job. I think they come to us because they have a need, and we're going to meet those needs."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","That would be from the line of Garen Sarafian with Citi Investment Research.",13,"That would be from the line of Garen Sarafian with Citi Investment Research."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","In terms of reinvesting in your business and market opportunities, I'm curious to hear your thoughts on Medicaid. State continues to have severe budget shortfalls. Would you think PMBs with skills as yours really could help lower their costs and especiall",60,"In terms of reinvesting in your business and market opportunities, I'm curious to hear your thoughts on Medicaid. State continues to have severe budget shortfalls. Would you think PMBs with skills as yours really could help lower their costs and especially with the sophisticated tools. So what really needs to change for the market to become really appealing for you?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","We're looking at that and obviously, with 40% more individuals going to be pushed into the Medicaid space, something's got to give here. States are -- if you go back, four and five and six years ago, even two years ago, many of the platforms like governor",360,"We're looking at that and obviously, with 40% more individuals going to be pushed into the Medicaid space, something's got to give here. States are -- if you go back, four and five and six years ago, even two years ago, many of the platforms like governors running for office was to trying to control the budget of the states, even before the economic downturn. Medicaid was costing the states tremendous amounts of money. Many states cut-slashed Medicaid spending and cut Medicaid enrollment by changing the qualifications, and we've seen a lot of that activity. Well, now we're going to put 40% of people on top of it. And we're going to fund it in the early years and then defund it over a period of time. The states are going to have a tremendously difficult time meeting that need. And you're exactly right, there's a tremendous opportunity for us to utilize our tools, to meet the needs of that marketplace. Today, those are being met through managed Medicaid plans. We have clients who manage Medicaid. So we picked up our share through the managed Medicaid plans, but there's an awful lot of fee-for-service out there. And to the extent that you start ratcheting down spending or you need to get control of the spend, managed Medicaids probably going to play a higher and higher role. I think we've got to figure out -- that's why we're making these investments is to figure how do we play in that space to make sure we can bring our tools and expertise to an area that truly needs to be managed and worked. And s you know, the Medicaid is far different than the other plans people are transient. Most pay close to nothing if nothing for their care. So getting adherence, getting incentives, making things work is very difficult for traditional businesses. For us though, where we use Consumerology, understand the drivers of the person, who we think were in a unique position where we can use those tools to help the states manage their business. So this is truly a focus of ours over the next couple of years."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Any reason why upcoming elections next week would impact anything for next year as to the progress you make of the Medicaid front?",23,"Any reason why upcoming elections next week would impact anything for next year as to the progress you make of the Medicaid front?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, I think -- really kind of depends on everything that happens, and that goes back to being fluid and flexible because I do believe that things have to change. I'm a citizen first and a CEO second. And we are facing tremendous deficits. We've got to a",277,"Well, I think -- really kind of depends on everything that happens, and that goes back to being fluid and flexible because I do believe that things have to change. I'm a citizen first and a CEO second. And we are facing tremendous deficits. We've got to address that issue. We've got to get our costs as a country under control. Whether it's the Democrats or the Republicans, we can't continue to spend the way we're spending. We got to do something about taxation. We've got to do something about competitive strength of our companies to be able to compete globally. There's an awful lot out there. All those things could have an impact on what happens. If the Republicans win the house and they decide not to procreate money to the healthcare bill, where does that take us? What happens if the Federal government has the right to establish the exchanges, will the states have the right to put them in? What if states don't do it, would the Federal government do it? What if there's money not appropriated? There's a lot of uncertainty out there. At the end of the day though, all those uncertainties, I view as a wonderful thing. Because the company that can change and the company that can meet the market needs and can be first to market is the one that can win. And I don't think there's anybody out there than at Express Scripts. So I love where we sit. We know that these things are at some way or form, these things are going to happen. And I think we're very well-positioned to take advantage of those opportunities."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Just switching channels a bit. I know you don't speak about specific clients coming up, but overall, how do you see the 2011 selling season as it gets underway? Maybe if you could offer just some broad color as to how it compares to 2010 in terms of size",65,"Just switching channels a bit. I know you don't speak about specific clients coming up, but overall, how do you see the 2011 selling season as it gets underway? Maybe if you could offer just some broad color as to how it compares to 2010 in terms of size and just the types of clients that are going to market next year versus this year?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Sure, I think you've heard us say this many times before. We've got two large clients that make up half of our book that are on longer term renewal cycles, which on average means that we've got 15% to 20% of our book up to renewal in any given year. And a",80,"Sure, I think you've heard us say this many times before. We've got two large clients that make up half of our book that are on longer term renewal cycles, which on average means that we've got 15% to 20% of our book up to renewal in any given year. And as we look at 2011 right now to the lower end of that range, certainly, clients up for renewal are slightly lower in '11 than it was in 2010."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Overall, is there opportunities in -- I mean, is the overall opportunity larger than 2010, or there might be some opportunities to bring on additional clients?",26,"Overall, is there opportunities in -- I mean, is the overall opportunity larger than 2010, or there might be some opportunities to bring on additional clients?"
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","We're always excited about the opportunities out there. I think we've got unique products that can really help clients save money. And we're excited about what we have to offer and certainly the sales team is out there to close every opportunity we can cl",70,"We're always excited about the opportunities out there. I think we've got unique products that can really help clients save money. And we're excited about what we have to offer and certainly the sales team is out there to close every opportunity we can close as long as the client we want to work with, the client is focused on taking out ways where we can add significant value."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, thank you all very much. I appreciate your attentiveness this morning, and look forward to bringing you up-to-date with our fourth quarter results early next year. Thank you very much.",31,"Well, thank you all very much. I appreciate your attentiveness this morning, and look forward to bringing you up-to-date with our fourth quarter results early next year. Thank you very much."
317975,114404734,82742,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation. You may now disconnect.",19,"Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation. You may now disconnect."
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Express Scripts Third Quarter 2010 Earnings Call. [Operator Instructions] Now with that being said, I'll turn the conference now to the Vice President of Investor Relations, Mr. David Myers.",40,"Ladies and gentlemen, thank you for standing by. Welcome to the Express Scripts Third Quarter 2010 Earnings Call. [Operator Instructions] Now with that being said, I'll turn the conference now to the Vice President of Investor Relations, Mr. David Myers.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, and good morning, everyone. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. Before we begin, I need to read the following Safe Harbor statement.Statements or comments made on this conference call may be forward-loo",184,"Thank you, and good morning, everyone. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. Before we begin, I need to read the following Safe Harbor statement.
Statements or comments made on this conference call may be forward-looking statements and may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors, which are discussed in detail in our filings with the SEC.
For clarity purposes, all numbers we talk about today will be on an adjusted basis. Please refer to the tables in our press release for reconciliation of GAAP to the adjusted numbers we will be discussing. The reconciliation of EBITDA to net income can also be found in our earnings release. The earnings release is posted on our website. 
At this point, I'll turn the call over to Jeff, who will talk about our third quarter results.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, David. Today, we are pleased to report another record quarter and provide guidance for 2011. Our strong results and outlook for the future are the result of our differentiated strategy. Our business model of alignment, enabled by our behavior-c",523,"Thank you, David. Today, we are pleased to report another record quarter and provide guidance for 2011. Our strong results and outlook for the future are the result of our differentiated strategy. Our business model of alignment, enabled by our behavior-centric approach, supported by market-leading technology and service levels. Our execution of this strategy helps our clients and patients drive out wasteful spending, which in turn helps us continue to deliver superior returns to our stockholders. 
Third quarter earnings per share reached a record of $0.65, up 55% over last year. The majority of these growth came from EBITDA, which grew at 45% over last year and 5% sequentially. During the quarter, we made significant progress executing our integration plans. We have now transitioned 90% of the WellPoint Live to our IT platform, and expect to complete the final migration of Live at year end. This will position us to finish the integration, retire the NextRx system and rationalize our operational footprint in the first quarter. 
Metrics for the quarter were strong and reflect our integration progress. Adjusted claims grew at 48% to $186.9 million. Total operating expenses were in line with our expectations, although the mix of expenses is weighted more towards cost of goods sold and forecasted through the excess capacity that remains in the system today. Despite this excess capacity, gross profit improved to 7.2%, up 30 basis points sequentially. We expect gross profit margin will continue to improve as the underlying fundamentals of our business continue to improve, the completion of the integration and the optimization of capacity.
EBITDA for adjusted Rx reached $3.30, up sequentially from $3.10 last quarter, and year-to-date cash flow from operations increased 99% to $1.8 billion. During the quarter, we repurchased 16.4 million shares and repaid the remaining balance of our term loan. Based on these results and our positive outlook for the remainder of the year, we have narrowed our 2010 EPS guidance range to $2.48 to $2.50. This represents growth of 26% to 27% over 2009 on an adjusted basis. 
Moving on to 2011 guidance, we expect that 2011 EPS will be in the range of $3.15 to $3.25, representing growth of 27% to 31% over 2010. We are confident we will complete the integration and achieve our synergy targets in the year. And as a result, our 2011 guidance include $1 billion of incremental EBITDA. 
Since the acquisition will be fully integrated next year and our guidance includes the achievement of synergy targets, and keeping with our long-standing practice of not commenting on specific clients, we will no longer discuss WellPoint-specific results. 
Cash flow from operations is expected to be between $2.2 billion and $2.4 billion. We see a lot of exciting opportunities, and our EPS guidance include significant investments in 2011. In addition to these significant investments flowing through our P&L, we also expect to spend $140 million to $170 million in capital investments in the year.
We are pleased with how our team has executed in 2010 and look forward to continuing to deliver strong performance in 2011 and beyond. 
And with that, I'll turn it over to George.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, Jeff, and good morning, everyone. Since our inception, we have been focused on alignment and our ability to innovate and execute. These qualities are as strong as ever, and we are now deploying new capabilities enabled by our groundbreaking wor",577,"Thank you, Jeff, and good morning, everyone. Since our inception, we have been focused on alignment and our ability to innovate and execute. These qualities are as strong as ever, and we are now deploying new capabilities enabled by our groundbreaking work in Consumerology. This week, we had our National Accounts Advisory Board meeting. Annually, we hold this meeting to bring in our diverse set of our National Account clients to get input on market conditions, medical trends and our pipeline of new products. At this meeting, I gathered feedback from many of our clients. They are overwhelmingly pleased with our ability to drive out wasteful spending while improving health outcomes, with high levels of member satisfaction. 
The NextRx acquisition is another good example of innovation and execution at work. We closed the transaction just 11 months ago. And through the focused effort of both companies, the migration of Live is nearing completion. The transition of Live was seamless and efficient with very little noise or disruption. As Jeff mentioned, we now consider NextRx part of our core business. Completing the critical migration so quickly is important so that we can focus on the potential of this strategic alliance. It will open new horizons for improving outcomes for members while driving all [ph] down our overall health care costs.
As the selling season winds down, let me summarize the results. As we pointed out last quarter, we saw high retention rates for signature accounts. Notwithstanding the stickiness in the marketplace, we won three signature accounts and again, grew our share in the middle market. Even with the client losses discussed last quarter, we expect the retention to exceed 95%. Based on our new sales activities and retention rate, we expect claims to be flat to up 4% for 2011. Our 2011 guidance not only provides strong earnings growth, it also provides for significant investments designed to keep us ahead of the competition in the evolving healthcare landscape. These projects include preparation for EBIT changes, Medicare regulations and healthcare reform. We are investing in opportunities to continue to differentiate ourselves in the marketplace by creating new products and services that meet and exceed the needs of tomorrow's marketplace.
In addition to the investments in our Consumerology platform, I'm particularly excited about two specific initiatives. First, we are investing heavily in our next-generation specialty offering that will be rolled out next year. This offering will enhance our ability manage the cost and quality, especially drug care. Part of the programs in this area had been enthusiastically endorsed by clients for their ability to drive out significant ways to the specially drug spend, the fastest-growing area of pharmaceutical costs. Second, we're tackling the issue of non-adherence by making significant investments in our predictive modeling capabilities. Through these efforts, we are able to identify in advance, those patients that are unlikely to adhere to medication therapies. We then intervene and customize ways to improve adherence. Although early, we are seeing significant improvements in medication adherence in our pilot programs. 
Our core business is strong, and we are positive on the underlying trends and opportunities in our space. This is why we are investing to position ourselves for a long-term growth. Our ability to manage trend, coupled with our behavior-centric approach, will drive out ways for clients, improve health outcomes for patients and deliver strong earnings growth for our stockholders. 
At this point, I'd like to open it up to questions. Operator?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","[Operator Instructions] First in line is Tom Gallucci with Lazard Capital Markets.",12,"[Operator Instructions] First in line is Tom Gallucci with Lazard Capital Markets.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","First, just wondering, you sort of mentioned significant investments within the 2011 expectations. Is there any way you can frame or quantify the magnitude of what we're looking at here?",30,"First, just wondering, you sort of mentioned significant investments within the 2011 expectations. Is there any way you can frame or quantify the magnitude of what we're looking at here?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","I can let Jeff chime in on that as well, but as you probably know, CMS, before healthcare reform was ultimately passed, and certainly, quickly thereafter, continued to issue more and more guidance. There was a lot of uncertainty and ambiguity in the Medic",451,"I can let Jeff chime in on that as well, but as you probably know, CMS, before healthcare reform was ultimately passed, and certainly, quickly thereafter, continued to issue more and more guidance. There was a lot of uncertainty and ambiguity in the Medicare provisions that exist. And so CMS has been very proactive in trying to get guidance out to the providers and to the insurance companies. And so as that guidance has come down, there's two ways you can approach this. We can do the minimum and make sure we hit that guidance so we can think about how we want to position ourselves in an evolving world and make sure that we can, not only meet the guidance requirements, but be ahead of the game with respect to new product innovation and meet the needs of that guidance may imply with respect to the needs of our clients and patients. So our IT and operational departments and our sales and comm management product development all work in unison to both meet the guidance requirements, as well as drive new product innovation. That, coupled with all the requirements from HIPAA, HITECH, we had DIDAD coming through, which is the new standard by which everyone has to be geared up for by 2012, in order to handle the ingredient components of compounds and expands fields. There's a tremendous amount of work that has to take place. Again, it's not just meeting those needs, but making sure that we meet them better than the competition and use it for new product innovation. Those have to go hand-in-hand. And of course, there's healthcare reform. So quite frankly, I don't want to get into the specifics but we don't want to give guidance by line items on our financials. But I will tell you that our investments in technology and operations and product development have significantly improved. They were quite a bit higher in 2010 as the year ramped out. And then in 2011, we expect continued increases. When we give our -- you often asked us how we feel about the deployment of our capital. And one of the things we say is we always like to invest in ourself first. I think that's critically important because I don't know what else gets better returns than investing in our own business. And as we look at this, that's exactly what we're doing. We're investing in ourself. Well, we invest in ourself, either it has to come through to two places, either it has to come through expenses or it has come through capital investments, depending on the type of project it is, and that's what you're seeing in the guidance we're giving.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","And next with Larry Marsh with Barclays Capital.",8,"And next with Larry Marsh with Barclays Capital.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","First on new business, George, your model's a little bit different. You're really focused on driving value to your customers and shareholders, you're focused on EBITDA and earnings, not necessarily winning new business. But obviously, over time, you got t",94,"First on new business, George, your model's a little bit different. You're really focused on driving value to your customers and shareholders, you're focused on EBITDA and earnings, not necessarily winning new business. But obviously, over time, you got to balance the two. As we think about the next couple of years, how do we think about the opportunity for you to take share? Do you think of it that way, where would you gain share? And then how do you think of Medi in that sort of balance between margin and new business?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Only challenged a little bit, Larry, first of all. I think if it was a stagnant world and you are selling just automobiles. You have to always worry about how do I sell the next car. Keep in mind that we have a totally different dynamic that's occurring i",538,"Only challenged a little bit, Larry, first of all. I think if it was a stagnant world and you are selling just automobiles. You have to always worry about how do I sell the next car. Keep in mind that we have a totally different dynamic that's occurring in our market spot. We have an under-penetration of mail, we have people that aren't fully utilizing specialty drugs, the fastest-growing part of healthcare cost in the drug space, not being properly utilized and not being properly adhere to. And then we've got members aging, the baby booms getting older, people are moving through that pipeline and becoming older. And as they do, they take more prescriptions. We see in 2014, 30 plus million more people entering into the market. So there's a whole lot of things going on. So the question you have to ask yourself is where should the company's focus be? Should it be coming up with innovative product to drive mail, generic utilization, to drive specialty cost out that all these things add value to our clients, improve health outcomes for our members and drive shareholder value, or do you want to grow new business for the sake of new business growth? What gives you the biggest returns? I've said on many, many, many calls that part of a great client-company relationship has to have built into it a common desire to meet the needs of the marketplace. There are certain clients that want to do things that don't align with our model. Those aren't good clients for us. Adding those clients would be a detraction of our call center associates, our operational associates, our account management as they're trying to conform a square peg into a round hole. Our focus has to be around growing share value and you do that through ROIC. That doesn't mean we can shrink the business over time, but what it means is we have to be disciplined about that business. We need clients that are concerned about their drug costs and spend and the improvement of health outcomes for their individuals. When we align those desires and needs with the products we have to offer and our approach, we have a marriage that works quite happily. And that's what we look for, Larry. So I think we can continue to grow EBITDA, we can continue to grow our profits without getting crazy in the marketplace by just competing on the clients that make sense. And by the way, when you're offering the client something they want and you're aligned with them, then the price is always important. But the prices points doesn't match up what they're looking for and our messaging and our pricing resonates with them and we get a sale. And guess what, even though I might make more money over some period of time with that client, they're happy because we're taking far more costs out of their equation than they expected or that they originally anticipated or they've gotten in the past. And so we got a very high, happy camper. I got happy patients as they got better health outcomes and I'm driving shareholder value to all of my valuable shareholders. That's our focus.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And I guess a follow up and a couple of things in on overall script growth you now see is a little bit stronger than you would have said six months ago for '11. Do we assume that mail script growth is kind of consistent with that overall 0% to 4% trend? A",112,"And I guess a follow up and a couple of things in on overall script growth you now see is a little bit stronger than you would have said six months ago for '11. Do we assume that mail script growth is kind of consistent with that overall 0% to 4% trend? And then just on WellPoint, I know Jeff and I are talking anymore specifically about that customer going forward, but you talked about integration costs that are to be determined. How do we framework that for '11? What kind of things could there be and can you give us any guidance as to how big or small that might be?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","You're right, we did end up with three signature accounts this year. And we did -- we're having a very successful selling season in the small to middle market area. And those things aren't finished yet, and the latter one isn't finished yet. Sometimes we",407,"You're right, we did end up with three signature accounts this year. And we did -- we're having a very successful selling season in the small to middle market area. And those things aren't finished yet, and the latter one isn't finished yet. Sometimes we don't know we got a new client win until January 15 and those are usually very small. But that last piece kind of rolls out towards the end of the year. So based on our best guess is in the pipeline and where we sit today, our selling season and success is better than we had anticipated earlier in the year. Having said all that, I don't want to get into client-specific situations, but we are pleased with where we sit. As far as mail is concerned, mail is a very important focus to us. We believe mail is important because it does drive better economics for our members, we show better adherence, better health outcomes for mail. By the same token, with certain clients, when you're going through an integration, the integration has to go first. So we got to get through this year. Finish that often. So starting next year, we're absolutely focused on mail and generic programs with WellPoint. I guess, I am talking about the clients specifically, but in this situation, we will address that. For the rest of our clients, keep in mind that one of the things that we're facing is a tough economic environment. And when a member has to pay two or three copays, upfront versus paying one at the Connery retailer in an uncertain tough environment, that's a little harder to do. And so the members struggle a little bit with that, and we do see some of our membership moving from mail into retail for that reason. But we fight hard. We try to make sure that we get them back. It's good for the client, ultimately, it's good for the member. And of course, it's very good for their healthcare outcomes. So it's going to continue to be a focus for us. I would say that you going into next year because we're just getting underway with the WellPoint situation, we expect modest to low growth in mail. But keep in mind, that's based on our current economic situation. There's a lot of things that can change over next year. And we'll obviously keep you posted quarter-by-quarter on that progress.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then any range of integration costs?",7,"And then any range of integration costs?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","So Larry, the range really hasn't changed. We've been saying from the beginning that we expect about $120 million to $150 million in integration costs. I think the difference that you're picking up now on is that now that we've got guidance into 2011. We",110,"So Larry, the range really hasn't changed. We've been saying from the beginning that we expect about $120 million to $150 million in integration costs. I think the difference that you're picking up now on is that now that we've got guidance into 2011. We still think it's going to be $120 million to $150 million. But what we don't know what the great clarity at the moment is how much of that is going to hit into 2010 how much of that is going to hit in 2011. But if some of it does push over into 2011, we still expect the same range, $120 million to $150 million.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Lisa Gill with JPMorgan.",9,"Our next question is from Lisa Gill with JPMorgan.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, I know that you just commented -- George commented around mail for 2011 as it pertains to WellPoint. Can you comment as to if there's anything in your current expectations in the current guidance or will this just be the beginning stages of trying t",52,"Jeff, I know that you just commented -- George commented around mail for 2011 as it pertains to WellPoint. Can you comment as to if there's anything in your current expectations in the current guidance or will this just be the beginning stages of trying to sell through some of these programs?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well as I said, as we said we, I said about [ph] WellPoint kicking off their programs in 2011. The overall growth in our mail, I believe, will be slightly up year-over-year. So that encompasses the whole book.",38,"Well as I said, as we said we, I said about [ph] WellPoint kicking off their programs in 2011. The overall growth in our mail, I believe, will be slightly up year-over-year. So that encompasses the whole book.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","I think that a lot of investors have been focused on how quickly you can up sell, George, to that new book of business. And I was just curious if anything was in your expectations or if this is a [indiscernible] that we're getting the integration as we'll",69,"I think that a lot of investors have been focused on how quickly you can up sell, George, to that new book of business. And I was just curious if anything was in your expectations or if this is a [indiscernible] that we're getting the integration as we'll now have the opportunity to go out and start talking about the programs rather than having something built within your expectations?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, clearly, it will be a focus of ours, Lisa. And it's certainly a focus of WellPoint. I think the reason they chose us was because they liked our approach to mail or liked our approach to generics. As we said that throughout this year though, this yea",175,"Well, clearly, it will be a focus of ours, Lisa. And it's certainly a focus of WellPoint. I think the reason they chose us was because they liked our approach to mail or liked our approach to generics. As we said that throughout this year though, this year had to be a focus on integration. So if we're finished on '11, then we change our focus next year to up-selling clinical programs and working, trying to work with them as a client. So as you might suspect, when you start that, January is all about planned design changes and making sure the book of business is stable and you're meeting all your service requirements. So these things don't start to look end of the first quarter to the second quarter and then you got to up-sell them, you got to work them through, you got to go out and talk to the clients. We got to put our people out on the street to go talk to them. So next year is the kick-off year.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then maybe could you just comment on, are you seeing any acquisition opportunities in the marketplace? This has clearly been a very successful transaction for you. What are some of your thoughts on some of the other things that are maybe out there tod",45,"And then maybe could you just comment on, are you seeing any acquisition opportunities in the marketplace? This has clearly been a very successful transaction for you. What are some of your thoughts on some of the other things that are maybe out there today?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Our position has been pretty consistent over the last several quarters. We say the same thing every time. Certainly, there are other PBMs that we think would be very attractive acquisitions for us, but we always caveat that with at the right price and the",128,"Our position has been pretty consistent over the last several quarters. We say the same thing every time. Certainly, there are other PBMs that we think would be very attractive acquisitions for us, but we always caveat that with at the right price and the right term. And so there are lots of rumors out in the market. We're not going to comment on individual specifics or individual rumors, but our position remains the same. There are PBMs we'd like to own at the right price and the right terms. We think we've proven that we can do this, integrate them better and faster than anybody else and we've proven that can create great shareholder value by doing this. And when the opportunities are right, we will execute.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then just finally, Jeff, I missed some of your prepared comments. But did you talk at all about the progression and how we should be thinking about 2011 from a quarterly progression standpoint?",34,"And then just finally, Jeff, I missed some of your prepared comments. But did you talk at all about the progression and how we should be thinking about 2011 from a quarterly progression standpoint?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Let me just back that up a little bit and talk just a little bit about how I see guidance and I think my position maybe slightly different than some of my other peers out there. But my view on guidance is actually relatively simple, which is do a really a",256,"Let me just back that up a little bit and talk just a little bit about how I see guidance and I think my position maybe slightly different than some of my other peers out there. But my view on guidance is actually relatively simple, which is do a really accurate forecast then tell investors what we really think we can do and then just hit those numbers. And certainly, since my arrival here, we have significantly improved our forecasting ability in order to execute on that vision. I also think there are only a few numbers that really matter, claims, EPS, EBITDA, cash flow. As a result, we try to only guide to those numbers because we think guiding in more detail just dilutes the focus on those metrics, the metrics that matter. We also want to stay focused on the long term so we don't guide the quarters either, again, making sure that we don't dilute our focus on hit and what matters. That said, I understand that everybody out there, all the sell-side people have models to put together. So from time to time, we give a little bit more color on different things to help you out a little bit. As we think about EPS progression for next year, I'd say it looks about like 2010 right now, a little bit more back-end loaded, quite frankly, than 2011. But just to be clear, we're not focused on hitting individual quarters. We're focused on delivering long-term shareholder value and the metrics that matter.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Robert Willoughby with Bank of America Merrill Lynch.",13,"Our next question is from Robert Willoughby with Bank of America Merrill Lynch.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","George or Jeff, you've been saying [ph] of floating rates in the past, but forgive me if someone has asked already. But you've been saying that the floating rates, when you guys moved to lock in some rates here, either turn up a bit or just take advantage",55,"George or Jeff, you've been saying [ph] of floating rates in the past, but forgive me if someone has asked already. But you've been saying that the floating rates, when you guys moved to lock in some rates here, either turn up a bit or just take advantage of the rates you're seeing out there?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Certainly, we think over long periods of time in history, being floating has certainly paid off. As we look at our current debt structure, we're clearly at the low end of our range, saying that we're comfortable at 1x to 2x EBITDA, if you look at our EPS",132,"Certainly, we think over long periods of time in history, being floating has certainly paid off. As we look at our current debt structure, we're clearly at the low end of our range, saying that we're comfortable at 1x to 2x EBITDA, if you look at our EPS guidance for '11, we're probably a little bit below 1x now. So we certainly think that for the right opportunities, we could those debt levels could come up a little bit. If we did make that change, we would certainly be looking at the potential to float things out there. Although we're also in a really unique interest rate environment where long-term debt has very low fixed rates and certainly that's all got to come into the calculates of what we end up doing.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","So the numbers for 2011, you've basically assumed status quo here? No refinancing and what in the way [ph] share repurchase then?",22,"So the numbers for 2011, you've basically assumed status quo here? No refinancing and what in the way [ph] share repurchase then?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, that's right. We assume status quo. As you think about share repurchase, obviously, our guidance range does include some share repurchase. How much cash we actually use to do that share repurchase really depends on two factors: When we're going to bu",172,"Yes, that's right. We assume status quo. As you think about share repurchase, obviously, our guidance range does include some share repurchase. How much cash we actually use to do that share repurchase really depends on two factors: When we're going to buy the shares back; and what price we're going to buy them at. Obviously, when you look at a share count as a weighted average basis based on when you buy them back, I think if you look back in our history of share repurchases, we generally do very few share repurchases in the first quarter because of the timing of our earnings release and our 10-K filing. So certainly, when you think about how much cash we may use, you'd have to consider the fact that probably not a lot of repurchases come in the first quarter. And then as I said, what price you're going to do to math with. It's hard for us to forecast stock prices going forward. So we try not to guide to that.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","But you'd have a rough idea in terms of the cash going out the door, if it's closer to $500 million versus a $1 billion?",26,"But you'd have a rough idea in terms of the cash going out the door, if it's closer to $500 million versus a $1 billion?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, at this point, it's certainly a larger number -- a large portion of our cash flow.",17,"Yes, at this point, it's certainly a larger number -- a large portion of our cash flow.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Ricky Goldwasser with Morgan Stanley.",10,"Our next question is from Ricky Goldwasser with Morgan Stanley.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, I have a couple of follow-up questions here. First of all, are the 2011 investments similar in magnitude to what you've done in 2009?",25,"Jeff, I have a couple of follow-up questions here. First of all, are the 2011 investments similar in magnitude to what you've done in 2009?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","I think I tried to answer that earlier. This is George, Ricky. We've actually increased significantly -- even on the third quarter results and our fourth quarter guidance includes an ascending amount of investment in those investments. We think we're in a",136,"I think I tried to answer that earlier. This is George, Ricky. We've actually increased significantly -- even on the third quarter results and our fourth quarter guidance includes an ascending amount of investment in those investments. We think we're in a unique opportunity right now. When change is about to occur, those companies are most nimble and can take advantage of that change and meet the marketplace, we're going to do the best. And we think we are very nimble. We think we're very innovative and creative. And so we're positioning ourselves to take advantage of the tremendous amount of flock sets occurring in our space today. So those enhancements are up each and every year since I've taken over CEO. And certainly, there are higher -- it's of an accelerating rate at this point.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","So accelerated rates from the $62 million, I think it was about $62 million that you've done in 2009.",19,"So accelerated rates from the $62 million, I think it was about $62 million that you've done in 2009.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","You're talking about CapEx. And there's two pieces to this. There's CapEx and SG&A spend and some parts, that may go through GPC. So you've got all those pieces come together. And so it's not just the investments in CapEx.",41,"You're talking about CapEx. And there's two pieces to this. There's CapEx and SG&A spend and some parts, that may go through GPC. So you've got all those pieces come together. And so it's not just the investments in CapEx.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then just one question on the third quarter, or did you forget cost in the third quarter all related to NextRx or did you also see some impact from the ramping up of the new mail facility?",38,"And then just one question on the third quarter, or did you forget cost in the third quarter all related to NextRx or did you also see some impact from the ramping up of the new mail facility?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, and I would say those things are both and those things are related. As we look at -- talking about in my prepared remarks about having a little bit of excess capacity in the system today, and we're working on optimizing that capacity. We're excited a",104,"Yes, and I would say those things are both and those things are related. As we look at -- talking about in my prepared remarks about having a little bit of excess capacity in the system today, and we're working on optimizing that capacity. We're excited about our new pharmacy here in St. Louis. It's got just unbelievable accuracy and great efficiency, and it's really, we think, a competitive advantage for us long term. But we do have a little bit of excess capacity and we've got to rationalize that in time. We're moving through all the WellPoint activity. So I would say both.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Just to add on a little bit there, the site we built in St. Louis is exceeding our expectations on capacity and accuracy. We've got a program in place with zero defects. Obviously, that's pretty hard to do. But we're down to one to two defects per million",114,"Just to add on a little bit there, the site we built in St. Louis is exceeding our expectations on capacity and accuracy. We've got a program in place with zero defects. Obviously, that's pretty hard to do. But we're down to one to two defects per million and the filling [ph]. And we are truly excited about that. No other site do we have to meet those type of numbers. So we are absolutely excited about what we do. And then on a capacity side, we have significant excess capacity to meet today's needs and tomorrow's needs. So we have to go through that in the first quarter and rationalize our overall footprint.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Ross Muken with Deutsche Bank.",10,"Our next question is from Ross Muken with Deutsche Bank.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","You talked, George, a lot about sort of the specialty opportunity longer term. In the last quarter, we did see what could we call kind of the first biosimilar of sorts to kind of come to market in terms of medroxy [ph] pairing. I mean as you think about t",115,"You talked, George, a lot about sort of the specialty opportunity longer term. In the last quarter, we did see what could we call kind of the first biosimilar of sorts to kind of come to market in terms of medroxy [ph] pairing. I mean as you think about that as maybe hopefully a catalyst event for FDA to get more constructive on biosimilars, how do you think about that in that kind of context of your business and as an opportunity going forward? And do you feel like this may be something that could be a bit more hopeful in terms of this being a more near-term opportunity or maybe a two, three-year basis?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Absolutely. The biggest disappointment, as you know, that I had in healthcare reform is the fact that we put to this significant piece of legislation and didn't address with the way we needed to address the specialty market. We gave it lip service, if you",340,"Absolutely. The biggest disappointment, as you know, that I had in healthcare reform is the fact that we put to this significant piece of legislation and didn't address with the way we needed to address the specialty market. We gave it lip service, if you will, by the biosimilars. And as you also know, and when you're talking about biosimilars instead of biogenerics, these products are probably going to be priced not nearly as advantageously as they would be priced from a client perspective as a generic. So we're facing a little bit of a two edged sword here. But to your point, having introduction of these products and having many of the generic manufacturers excited about this, the administration and Congress both know that there's a tremendous opportunity here. They're one of the largest users of the biotech drugs out there, and they know what this is costing the country. They know that they were facing deficits and have a tremendous issue, and I am excited about where this can go. Now we do still need some legislative changes to ultimately get to where we need to be. But our team, we've got a fairly large lobbying group in Washington, as well as Dr. Miller, my Chief Medical Officer, also spends a lot of time on the Hill. I spend time on the Hill. And our job is to make sure that we can try to get that legislation through. I think notwithstanding all of that, there's a real issue around adherence, proper channel and the use of biosimilars. So we're talking about rolling out -- I think we can get our arms around the trend and improve the health outcomes in the world we live today. And to your point, if we can actually tip the scale over and start getting better competition and better products, especially for those where patent protection is expired, I think there's such a great, great, great opportunity out there to continue to win in this space. And that truly is our focus.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And maybe, Jeff, I just want to touch on one thing, in terms of thinking about the profit growth here and the EBIT growth that we've seen, the guidance sort of implies roughly call it 30% type EPS growth this year. Your EPS growth CAGR over the last five",157,"And maybe, Jeff, I just want to touch on one thing, in terms of thinking about the profit growth here and the EBIT growth that we've seen, the guidance sort of implies roughly call it 30% type EPS growth this year. Your EPS growth CAGR over the last five years has been slightly below that. As you think about sort of going forward, I mean, and particularly given all the focus and sort from the investment community on margins and return on capital during this last three to six months where there was a bit of trepidation. And as you kind of go forward, maybe just in broad terms, I'm not asking for a forward guidance, but do you see any sort of change in your business or anything that would make you think that on a go-forward basis the trajectory is going to be meaningfully different than we've been used to seeing from Express Scripts historically?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, unfortunately, Ross, as much as I'd like to answer that question, I think any way I would answer that, would essentially be multiyear forward guidance. So certainly, I'm going to add -- I think we said last quarter on the call that we're excited abou",85,"Yes, unfortunately, Ross, as much as I'd like to answer that question, I think any way I would answer that, would essentially be multiyear forward guidance. So certainly, I'm going to add -- I think we said last quarter on the call that we're excited about the long-term prospects for this business. We are making significant investments as we said because we believe so strongly in our business and how our team can execute. But it's hard for me to get into any more detail.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Bust just in terms of like, given the assumptions for the core business from a margin perspective, et cetera. There was nothing that occurred during this last season or even next year that meant to you that all of a sudden, the profit trajectory of the bu",55,"Bust just in terms of like, given the assumptions for the core business from a margin perspective, et cetera. There was nothing that occurred during this last season or even next year that meant to you that all of a sudden, the profit trajectory of the business was anything meaningfully different than what we've seen.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Let me try something here then Jeff can certainly add on. We always get a question about price pressure in the marketplace. And I've said for the last three years, I saw the proof's in the pudding. I said you look at the script counts and you look at what",275,"Let me try something here then Jeff can certainly add on. We always get a question about price pressure in the marketplace. And I've said for the last three years, I saw the proof's in the pudding. I said you look at the script counts and you look at what's happened on to EBITDA per script. If we couldn't compete, then those metrics would not increase. And I think what you've seen from us, is we've grown our scripts significantly over the last five years. Our EBITDA per script overall is up. Obviously, there's been acquisitions and other things that may temporarily bring them down, but then they start to ascend again. And those things point to the health, from a historical perspective, of how the business is performing. Keeping in mind, we got three-year contracts for the most part, although we with 30% of our business have seven and 10 years or effectively seven years with two option years with the DoD. Seven and 10-year business. So those things stay very strong, obviously, over those periods of time. And so, I don't know, I mean, you look at the underlying trends in the business, and we're not going to give guidance to 2012 or '13 or '14. But I will tell you, you got an aging population, you got 30 million people coming into the market, you got a need by a country and by companies to figure how to control healthcare costs, and we have answers. So you throw all those things into the hopper, you shake it up, and I like our prospects. But again, we don't want to get into specifics.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","And next we'll go to Steve Valiquette with UBS.",10,"And next we'll go to Steve Valiquette with UBS.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","You just kind of touched on this is a little bit but I thought the 2011 EBITDA for plain [ph] guidance was pretty strong. I thought it put the rest on the concerns about PBM pricing. So I was just curious, just sort of your general  comments or thoughts a",74,"You just kind of touched on this is a little bit but I thought the 2011 EBITDA for plain [ph] guidance was pretty strong. I thought it put the rest on the concerns about PBM pricing. So I was just curious, just sort of your general  comments or thoughts about the puts and takes of the projected EBIT up for claim in 2011 as any other insights you might want to add to that?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, I think, obviously, as I said earlier, we're focused on a couple of things. And we think there a couple of things that really drive this business, that's certainly one of them. I think the team here has done just a phenomenal job getting the integrat",196,"Yes, I think, obviously, as I said earlier, we're focused on a couple of things. And we think there a couple of things that really drive this business, that's certainly one of them. I think the team here has done just a phenomenal job getting the integration done, getting our efficiencies up, bringing in new programs. There's a lot of things that we've talked to before that generics is of slightly lower year. But thankfully for Express Scripts, we've got a lot of other leverage we can pull. We've got a great team of people that are pulling them, and we've got -- we're firing at all cylinders here, we're driving EBITDA up for Rx as we continue to execute. And we're delivering products that, as George was saying, clients want to buy. And our model of alignment works at the end of the day. The more money we can save our clients, the more money we can make. And in this environment, our clients want to save money with Consumerology, we've got the tools that can help them save money with minimal member impact and the net result is the results that we're putting out.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","That's particularly true, Jeff, when you think about a year where there are low generic utilization. One or two things can happen. We consider slow generic utilization, so we can go to our clients and say sorry, but you guys all better get prepared for ba",404,"That's particularly true, Jeff, when you think about a year where there are low generic utilization. One or two things can happen. We consider slow generic utilization, so we can go to our clients and say sorry, but you guys all better get prepared for bad cost trends. Well, we probably wouldn't have any clients after that conversation. So our job is not to sit on our laurels and wait for a generic launch. Our job is to be creative and equip our account managers with products and innovation that go out and make sure they can manage those trends down. And when we do that, when we execute on that, what you see is we grow our EBITDA per script. We also, by the way, meet the clients' needs that take the cost out of the equation. If you remember a couple of years back, we had a bad generic year and we grew EBITDA per script significantly during that period. And the reason was is because we see these things three years out. So we don't sit and wait until the sky's going to fall or win anything else. We actually go out with a product portfolio to meet the needs of those clients. No CFO wants to sit there with the volatility in their cost going all over the place. Our job is to control that trend on a level of basis over the life of that contract, hopefully, over more than a couple of those contract terms. And that's our job. That's what we pay our account managers, and do in bonus [ph] them to do, and they've got to do it. So we're excited about the business and what we can do. As Jeff's pointed out, we got a lot of levers. And if it's not generics in a given year, then it's something else. But we just can't sit back and be complacent. We've got to drive those numbers and that's got to be our focus. Again, going back to Larry's question, it's not a question of just going out and trying to sell. It's a question of going out and making sure we're doing what our clients need to control their cost in very volatile markets. And when we do those things well, we can grow our business and grow our EBITDA, grow our business and meet the clients' needs, and that remains our singular focus.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Any chance of having that, just generally speaking, as far as your overall wins for next year, just generally,  would you say they were skewed towards higher margin customers that already have decent mail pen rates or lower or that's not really one you wa",51,"Any chance of having that, just generally speaking, as far as your overall wins for next year, just generally,  would you say they were skewed towards higher margin customers that already have decent mail pen rates or lower or that's not really one you want to comment on at this stage?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, we don't really like to talk about clients specifically. I think there's a lot of noise going on in our numbers only because as you know, we have the big retailer lost unintentionally halfway through the year. And then we had -- so that's a bunch of",90,"Well, we don't really like to talk about clients specifically. I think there's a lot of noise going on in our numbers only because as you know, we have the big retailer lost unintentionally halfway through the year. And then we had -- so that's a bunch of no-mail claims out. So  that's in the numbers. But as far as the winds, I think they're fairly common. I mean it's our job. I think they come to us because they have a need, and we're going to meet those needs.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","That would be from the line of Garen Sarafian with Citi Investment Research.",13,"That would be from the line of Garen Sarafian with Citi Investment Research.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","In terms of reinvesting in your business and market opportunities, I'm curious to hear your thoughts on Medicaid. State continues to have severe budget shortfalls. Would you think PMBs with skills as yours really could help lower their costs and especiall",60,"In terms of reinvesting in your business and market opportunities, I'm curious to hear your thoughts on Medicaid. State continues to have severe budget shortfalls. Would you think PMBs with skills as yours really could help lower their costs and especially with the sophisticated tools. So what really needs to change for the market to become really appealing for you?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","We're looking at that and obviously, with 40% more individuals going to be pushed into the Medicaid space, something's got to give here. States are -- if you go back, four and five and six years ago, even two years ago, many of the platforms like governor",360,"We're looking at that and obviously, with 40% more individuals going to be pushed into the Medicaid space, something's got to give here. States are -- if you go back, four and five and six years ago, even two years ago, many of the platforms like governors running for office was to trying to control the budget of the states, even before the economic downturn. Medicaid was costing the states tremendous amounts of money. Many states cut-slashed Medicaid spending and cut Medicaid enrollment by changing the qualifications, and we've seen a lot of that activity. Well, now we're going to put 40% of people on top of it. And we're going to fund it in the early years and then defund it over a period of time. The states are going to have a tremendously difficult time meeting that need. And you're exactly right, there's a tremendous opportunity for us to utilize our tools, to meet the needs of that marketplace. Today, those are being met through managed Medicaid plans. We have clients who manage Medicaid. So we picked up our share through the managed Medicaid plans, but there's an awful lot of fee-for-service out there. And to the extent that you start ratcheting down spending or you need to get control of the spend, managed Medicaids probably going to play a higher and higher role. I think we've got to figure out -- that's why we're making these investments is to figure how do we play in that space to make sure we can bring our tools and expertise to an area that truly needs to be managed and worked. And s you know, the Medicaid is far different than the other plans people are transient. Most pay close to nothing if nothing for their care. So getting adherence, getting incentives, making things work is very difficult for traditional businesses. For us though, where we use Consumerology, understand the drivers of the person, who we think were in a unique position where we can use those tools to help the states manage their business. So this is truly a focus of ours over the next couple of years.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Any reason why upcoming elections next week would impact anything for next year as to the progress you make of the Medicaid front?",23,"Any reason why upcoming elections next week would impact anything for next year as to the progress you make of the Medicaid front?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, I think -- really kind of depends on everything that happens, and that goes back to being fluid and flexible because I do believe that things have to change. I'm a citizen first and a CEO second. And we are facing tremendous deficits. We've got to a",277,"Well, I think -- really kind of depends on everything that happens, and that goes back to being fluid and flexible because I do believe that things have to change. I'm a citizen first and a CEO second. And we are facing tremendous deficits. We've got to address that issue. We've got to get our costs as a country under control. Whether it's the Democrats or the Republicans, we can't continue to spend the way we're spending. We got to do something about taxation. We've got to do something about competitive strength of our companies to be able to compete globally. There's an awful lot out there. All those things could have an impact on what happens. If the Republicans win the house and they decide not to procreate money to the healthcare bill, where does that take us? What happens if the Federal government has the right to establish the exchanges, will the states have the right to put them in? What if states don't do it, would the Federal government do it? What if there's money not appropriated? There's a lot of uncertainty out there. At the end of the day though, all those uncertainties, I view as a wonderful thing. Because the company that can change and the company that can meet the market needs and can be first to market is the one that can win. And I don't think there's anybody out there than at Express Scripts. So I love where we sit. We know that these things are at some way or form, these things are going to happen. And I think we're very well-positioned to take advantage of those opportunities.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Just switching channels a bit. I know you don't speak about specific clients coming up, but overall, how do you see the 2011 selling season as it gets underway? Maybe if you could offer just some broad color as to how it compares to 2010 in terms of size",65,"Just switching channels a bit. I know you don't speak about specific clients coming up, but overall, how do you see the 2011 selling season as it gets underway? Maybe if you could offer just some broad color as to how it compares to 2010 in terms of size and just the types of clients that are going to market next year versus this year?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Sure, I think you've heard us say this many times before. We've got two large clients that make up half of our book that are on longer term renewal cycles, which on average means that we've got 15% to 20% of our book up to renewal in any given year. And a",80,"Sure, I think you've heard us say this many times before. We've got two large clients that make up half of our book that are on longer term renewal cycles, which on average means that we've got 15% to 20% of our book up to renewal in any given year. And as we look at 2011 right now to the lower end of that range, certainly, clients up for renewal are slightly lower in '11 than it was in 2010.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Overall, is there opportunities in -- I mean, is the overall opportunity larger than 2010, or there might be some opportunities to bring on additional clients?",26,"Overall, is there opportunities in -- I mean, is the overall opportunity larger than 2010, or there might be some opportunities to bring on additional clients?
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","We're always excited about the opportunities out there. I think we've got unique products that can really help clients save money. And we're excited about what we have to offer and certainly the sales team is out there to close every opportunity we can cl",70,"We're always excited about the opportunities out there. I think we've got unique products that can really help clients save money. And we're excited about what we have to offer and certainly the sales team is out there to close every opportunity we can close as long as the client we want to work with, the client is focused on taking out ways where we can add significant value.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, thank you all very much. I appreciate your attentiveness this morning, and look forward to bringing you up-to-date with our fourth quarter results early next year. Thank you very much.",31,"Well, thank you all very much. I appreciate your attentiveness this morning, and look forward to bringing you up-to-date with our fourth quarter results early next year. Thank you very much.
"
317975,114404734,82758,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation. You may now disconnect.",19,"Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation. You may now disconnect.

"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Express Scripts Third Quarter 2010 Earnings Call. [Operator Instructions] Now with that being said, I'll turn the conference now to the Vice President of Investor Relations, Mr. David Myers.",40,"Ladies and gentlemen, thank you for standing by. Welcome to the Express Scripts Third Quarter 2010 Earnings Call. [Operator Instructions] Now with that being said, I'll turn the conference now to the Vice President of Investor Relations, Mr. David Myers."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, and good morning, everyone. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. Before we begin, I need to read the following Safe Harbor statement.Statements or comments made on this conference call may be forward-loo",184,"Thank you, and good morning, everyone. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. Before we begin, I need to read the following Safe Harbor statement.
Statements or comments made on this conference call may be forward-looking statements and may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors, which are discussed in detail in our filings with the SEC.
For clarity purposes, all numbers we talk about today will be on an adjusted basis. Please refer to the tables in our press release for reconciliation of GAAP to the adjusted numbers we will be discussing. The reconciliation of EBITDA to net income can also be found in our earnings release. The earnings release is posted on our website. 
At this point, I'll turn the call over to Jeff, who will talk about our third quarter results."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, David. Today, we are pleased to report another record quarter and provide guidance for 2011. Our strong results and outlook for the future are the result of our differentiated strategy. Our business model of alignment, enabled by our behavior-c",523,"Thank you, David. Today, we are pleased to report another record quarter and provide guidance for 2011. Our strong results and outlook for the future are the result of our differentiated strategy. Our business model of alignment, enabled by our behavior-centric approach, supported by market-leading technology and service levels. Our execution of this strategy helps our clients and patients drive out wasteful spending, which in turn helps us continue to deliver superior returns to our stockholders. 
Third quarter earnings per share reached a record of $0.65, up 55% over last year. The majority of this growth came from EBITDA, which grew at 45% over last year and 5% sequentially. During the quarter, we made significant progress executing our integration plans. We have now transitioned 90% of the WellPoint Live to our IT platform, and expect to complete the final migration of Live at year end. This will position us to finish the integration, retire the NextRx system and rationalize our operational footprint in the first quarter. 
Metrics for the quarter were strong and reflect our integration progress. Adjusted claims grew at 48% to $186.9 million. Total operating expenses were in line with our expectations, although the mix of expenses was weighted more towards cost of goods sold than forecasted through the excess capacity that remains in the system today. Despite this excess capacity, gross profit improved to 7.2%, up 30 basis points sequentially. We expect gross profit margin will continue to improve as the underlying fundamentals of our business continue to improve, the completion of the integration and the optimization of capacity.
EBITDA for adjusted Rx reached $3.30, up sequentially from $3.10 last quarter, and year-to-date cash flow from operations increased 99% to $1.8 billion. During the quarter, we repurchased 16.4 million shares and repaid the remaining balance of our term loan. Based on these results and our positive outlook for the remainder of the year, we have narrowed our 2010 EPS guidance range to $2.48 to $2.50. This represents growth of 26% to 27% over 2009 on an adjusted basis. 
Moving on to 2011 guidance, we expect that 2011 EPS will be in the range of $3.15 to $3.25, representing growth of 27% to 31% over 2010. We are confident we will complete the integration and achieve our synergy targets in the year. And as a result, our 2011 guidance includes $1 billion of incremental EBITDA. 
Since the acquisition will be fully integrated next year and our guidance includes the achievement of synergy targets, in keeping with our long-standing practice of not commenting on specific clients, we will no longer discuss WellPoint-specific results. 
Cash flow from operations is expected to be between $2.2 billion and $2.4 billion. We see a lot of exciting opportunities, and our EPS guidance includes significant investments in 2011. In addition to these significant investments flowing through our P&L, we also expect to spend $140 million to $170 million in capital investments in the year.
We are pleased with how our team has executed in 2010 and look forward to continuing to deliver strong performance in 2011 and beyond. 
And with that, I'll turn it over to George."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Thank you, Jeff, and good morning, everyone. Since our inception, we have been focused on alignment and our ability to innovate and execute. These qualities are as strong as ever, and we are now deploying new capabilities enabled by our groundbreaking wor",574,"Thank you, Jeff, and good morning, everyone. Since our inception, we have been focused on alignment and our ability to innovate and execute. These qualities are as strong as ever, and we are now deploying new capabilities enabled by our groundbreaking work in Consumerology. This week, we had our National Accounts Advisory Board meeting. Annually, we hold this meeting to bring in a diverse set of our National Account clients to get input on market conditions, medical trends and our pipeline of new products. At this meeting, I gathered feedback from many of our clients. They are overwhelmingly pleased with our ability to drive out wasteful spending while improving health outcomes, with high levels of member satisfaction. 
The NextRx acquisition is another good example of innovation and execution at work. We closed the transaction just 11 months ago. And through the focused effort of both companies, the migration of Live is nearing completion. The transition of Live was seamless and efficient with very little noise or disruption. As Jeff mentioned, we now consider NextRx part of our core business. Completing the critical migration so quickly is important so that we can focus on the potential of this strategic alliance. It will open new horizons for improving outcomes for members while driving down our overall health care costs.
As the selling season winds down, let me summarize the results. As we pointed out last quarter, we saw high retention rates for signature accounts. Notwithstanding the stickiness in the marketplace, we won three signature accounts and again, grew our share in the middle market. Even with the client losses discussed last quarter, we expect retention to exceed 95%. Based on our new sales activities and retention rate, we expect claims to be flat to up 4% for 2011. Our 2011 guidance not only provides strong earnings growth, it also provides for significant investments designed to keep us ahead of the competition in the evolving healthcare landscape. These projects include preparation for HIPAA changes, Medicare regulations and healthcare reform. We are investing in opportunities to continue to differentiate ourselves in the marketplace by creating new products and services that meet and exceed the needs of tomorrow's marketplace.
In addition to the investments in our Consumerology platform, I'm particularly excited about two specific initiatives. First, we are investing heavily in our next-generation specialty offering that will be rolled out next year. This offering will enhance our ability to manage the cost and quality of specialty drug care. Pilot programs in this area had been enthusiastically endorsed by clients for their ability to drive out significant waste to the specialty drug spend, the fastest-growing area of pharmaceutical costs. Second, we're tackling the issue of non-adherence by making significant investments in our predictive modeling capabilities. Through these efforts, we are able to identify, in advance, those patients that are unlikely to adhere to medication therapies. We then intervene and customize ways to improve adherence. Although early, we are seeing significant improvements in medication adherence in our pilot programs. 
Our core business is strong, and we are positive on the underlying trends and opportunities in our space. This is why we are investing to position ourselves for a long-term growth. Our ability to manage trend, coupled with our behavior-centric approach, will drive out ways for clients, improve health outcomes for patients and deliver strong earnings growth for our stockholders. 
At this point, I'd like to open it up to questions. Operator?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","[Operator Instructions] First in line is Tom Gallucci with Lazard Capital Markets.",12,"[Operator Instructions] First in line is Tom Gallucci with Lazard Capital Markets."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","First, just wondering, you sort of mentioned significant investments within the 2011 expectations. Is there any way you can frame or quantify the magnitude of what we're looking at here?",30,"First, just wondering, you sort of mentioned significant investments within the 2011 expectations. Is there any way you can frame or quantify the magnitude of what we're looking at here?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","I can let Jeff chime in on that as well, but as you probably know, CMS, before healthcare reform was ultimately passed, and certainly, quickly thereafter, continued to issue more and more guidance. There was a lot of uncertainty and ambiguity in the Medic",452,"I can let Jeff chime in on that as well, but as you probably know, CMS, before healthcare reform was ultimately passed, and certainly, quickly thereafter, continued to issue more and more guidance. There was a lot of uncertainty and ambiguity in the Medicare provisions that exist. And so CMS has been very proactive in trying to get guidance out to the providers and to the insurance companies. And so as that guidance has come down, there's two ways you can approach this. We can do the minimum and make sure we hit that guidance, or we can think about how we want to position ourselves in an evolving world and make sure that we can, not only meet the guidance requirements, but be ahead of the game with respect to new product innovation and meet the needs that, that guidance may imply with respect to the needs of our clients and patients. So our IT and operational departments and our sales and account management product development all work in unison to both meet the guidance requirements, as well as drive new product innovation. That, coupled with all the requirements from HIPAA, HITECH, we had D.0 coming through, which is the new standard by which everyone has to be geared up for by 2012, in order to handle the ingredient components of compounds and expands fields. There's a tremendous amount of work that has to take place. Again, it's not just meeting those needs, but making sure that we meet them better than the competition and use it for new product innovation. Those have to go hand-in-hand. And then, of course, there's healthcare reform. So quite frankly, I don't want to get into the specifics but we don't want to give guidance by line items on our financials. But I will tell you that our investments in technology and operations and product development have significantly improved. They were quite a bit higher in 2010 as the year ramped out. And then in 2011, we expect continued increases. When we give our -- you often ask us how we feel about the deployment of our capital. And one of the things we say is we always like to invest in ourself first. I think that's critically important because I don't know what else gets better returns than investing in our own business. And as we look at this, that's exactly what we're doing. We're investing in ourself. Well, we invest in ourself, either it has to come through to two places, either it has to come through expenses or it has come through capital investments, depending on the type of project it is, and that's what you're seeing in the guidance we're giving."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","And next with Larry Marsh with Barclays Capital.",8,"And next with Larry Marsh with Barclays Capital."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","First on new business, George, your model's a little bit different. You're really focus on driving value to your customers and shareholders. You focus on EBITDA and earnings, not necessarily winning new business. But obviously, over time, you got to balan",95,"First on new business, George, your model's a little bit different. You're really focus on driving value to your customers and shareholders. You focus on EBITDA and earnings, not necessarily winning new business. But obviously, over time, you got to balance the two. As we think about the next couple of years, how do we think about the opportunity for you to take share? Do you think of it that way, where would you gain share? And then how do you think of Med D and that sort of balance between margin and new business?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Let me challenge you a little bit, Larry, first of all. I think if it was a stagnant world and you were selling just automobiles, youd have to always worry about how do I sell the next car. Keep in mind that we have a totally different dynamic that's o",540,"Let me challenge you a little bit, Larry, first of all. I think if it was a stagnant world and you were selling just automobiles, youd have to always worry about how do I sell the next car. Keep in mind that we have a totally different dynamic that's occurring in our market spot. We have an under-penetration of mail. We have people that aren't fully utilizing specialty drugs, the fastest-growing part of healthcare cost in the drug space, not being properly utilized and not being properly adhered to. And then we've got members aging, the baby booms getting older, people are moving through that pipeline and becoming older. And as they do, they take more prescriptions. We see in 2014, 30-plus million more people entering into the market. So there's a whole lot of things going on. So the question you have to ask yourself is where should the company's focus be? Should it be coming up with innovative and creative products to drive mail, generic utilization, to drive specialty cost out that all these things add value to our clients, improve health outcomes for our members and drive shareholder value, or do you want to grow new business for the sake of new business growth? What gives you the biggest returns? I've said on many, many, many calls that part of a great client-company relationship has to have built into it a common desire to meet the needs of the marketplace. There are certain clients that want to do things that don't align with our model. Those aren't good clients for us. Adding those clients would be a detraction of our call center associates, our operational associates, our account management as they're trying to conform a square peg into a round hole. Our focus has to be around growing shareholder value, and you do that through ROIC. That doesn't mean we can shrink the business over time, but what it means is we have to be disciplined about that business. We need clients that are concerned about their drug costs and spend and the improvement of health outcomes for their individuals. When we align those desires and needs with the products we have to offer and our approach, we have a marriage that works quite happily. And that's what we look for, Larry. So I think we can continue to grow EBITDA, we can continue to grow our profits without getting crazy in the marketplace by just competing on the clients that make sense. And by the way, when you're offering the client something they want and you're aligned with them, then the price is always important. But the prices points doesn't match up what they're looking for and our messaging and our pricing resonates with them, and we get a sale. And guess what, even though I might make more money over some period of time with that client, they're happy because we're taking far more costs out of their equation than they expected or that they originally anticipated or they've gotten in the past. And so we got a very happy camper. I got happy patients as they got better health outcomes and I'm driving shareholder value to all of my valuable shareholders. That's our focus."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And I guess a follow up and a couple of things in on overall script growth you now see is a little bit stronger than you would have said six months ago for '11. Do we assume that mail script growth is kind of consistent with that overall 0% to 4% trend? A",112,"And I guess a follow up and a couple of things in on overall script growth you now see is a little bit stronger than you would have said six months ago for '11. Do we assume that mail script growth is kind of consistent with that overall 0% to 4% trend? And then just on WellPoint, I know Jeff and I are talking anymore specifically about that customer going forward, but you talked about integration costs that are to be determined. How do we framework that for '11? What kind of things could there be and can you give us any guidance as to how big or small that might be?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","You're right. We did end up with three signature accounts this year. And we did -- we're having a very successful selling season in the small to middle market area. And those things aren't finished yet, and the latter one isn't finished yet. Sometimes we",407,"You're right. We did end up with three signature accounts this year. And we did -- we're having a very successful selling season in the small to middle market area. And those things aren't finished yet, and the latter one isn't finished yet. Sometimes we don't know we got a new client win until January 15, and those are usually very small. But that last piece kind of rolls out towards the end of the year. So based on our best guesses in the pipeline and where we sit today, our selling season and success is better than we had anticipated earlier in the year. Having said all that, I don't want to get into client-specific situations, but we are pleased with where we sit. As far as mail is concerned, mail is a very important focus to us. We believe mail is important because it does drive better economics for our members, we show better adherence, better health outcomes with mail. By the same token, with certain clients, when you're going through an integration, the integration has to go first. So we got to get through this year. Finish that often. So starting next year, we're absolutely focused on mail and generic programs with WellPoint. I guess, I am talking about the clients specifically, but in this situation, we will address that. For the rest of our clients, keep in mind that one of the things that we're facing is a tough economic environment. And when a member has to pay two or three co-pays, upfront versus paying one at the counter at retailer in an uncertain tough environment, that's a little harder to do. And so the members struggle a little bit with that, and we do see some of our membership moving from mail into retail for that reason. But we fight hard. We try to make sure that we get them back. It's good for the client. Ultimately, it's good for the member. And of course, it's very good for their healthcare outcomes. So it's going to continue to be a focus for us. I would say that you going into next year because we're just getting underway with the WellPoint situation, we expect moderate to low growth in mail. But keep in mind, that's based on our current economic situation. There's a lot of things that can change over next year. And we'll obviously keep you posted quarter-by-quarter on that progress."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then any range of integration costs?",7,"And then any range of integration costs?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","So Larry, the range really hasn't changed. We've been saying from the beginning that we expect about $120 million to $150 million in integration costs. I think the difference that you're picking up now on is that now that we've got guidance into 2011, we",110,"So Larry, the range really hasn't changed. We've been saying from the beginning that we expect about $120 million to $150 million in integration costs. I think the difference that you're picking up now on is that now that we've got guidance into 2011, we still think it's going to be $120 million to $150 million. But what we don't know what the great clarity at the moment is how much of that is going to hit into 2010 how much of that is going to hit in 2011. But if some of it does push over into 2011, we still expect the same range, $120 million to $150 million."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Lisa Gill with JPMorgan.",9,"Our next question is from Lisa Gill with JPMorgan."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, I know that you just commented -- George commented around mail for 2011 as it pertains to WellPoint. Can you comment as to if there's anything in your current expectations in the current guidance, or will this just be the beginning stages of trying",52,"Jeff, I know that you just commented -- George commented around mail for 2011 as it pertains to WellPoint. Can you comment as to if there's anything in your current expectations in the current guidance, or will this just be the beginning stages of trying to sell through some of these programs?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well as I said, Lisa, we -- I was talking about WellPoint kicking off their programs in 2011. The overall growth in our mail, I believe, will be slightly up year-over-year. So that encompasses the whole book.",37,"Well as I said, Lisa, we -- I was talking about WellPoint kicking off their programs in 2011. The overall growth in our mail, I believe, will be slightly up year-over-year. So that encompasses the whole book."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","I think that a lot of investors have been focused on how quickly you can up sell, George, to that new book of business. And I was just curious if anything was in your expectations or if this is -- now that we're getting the integration behind us, we'll no",70,"I think that a lot of investors have been focused on how quickly you can up sell, George, to that new book of business. And I was just curious if anything was in your expectations or if this is -- now that we're getting the integration behind us, we'll now have the opportunity to go out and start talking about the programs rather than having something built within your expectations?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, clearly, it will be a focus for us, Lisa. And it's certainly a focus of WellPoints. I think the reason they chose us was because they liked our approach to mail or liked our approach to generics. As we said that throughout this year though, this",176,"Well, clearly, it will be a focus for us, Lisa. And it's certainly a focus of WellPoints. I think the reason they chose us was because they liked our approach to mail or liked our approach to generics. As we said that throughout this year though, this year had to be a focus on integration. So if we're finished on 1/1, then we change our focus next year to up-selling clinical programs and working, trying to work with them as a client. So as you might suspect, when you start that, January is all about planned design changes and making sure the book of business is stable and you're meeting all your service requirements. So these things don't start to look -- end of the first quarter to the second quarter and then you got to up-sell them, you got to work them through, you got to go out and talk to the clients. We got to put our people out on the street to go talk to them. So next year is the kick-off year."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then maybe could you just comment on, are you seeing any acquisition opportunities in the marketplace? This has clearly been a very successful transaction for you. What are some of your thoughts on some of the other things that are maybe out there tod",45,"And then maybe could you just comment on, are you seeing any acquisition opportunities in the marketplace? This has clearly been a very successful transaction for you. What are some of your thoughts on some of the other things that are maybe out there today?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Our position has been pretty consistent over the last several quarters. We say the same thing every time. Certainly, there are other PBMs that we think would be very attractive acquisitions for us, but we always caveat that with at the right price and the",128,"Our position has been pretty consistent over the last several quarters. We say the same thing every time. Certainly, there are other PBMs that we think would be very attractive acquisitions for us, but we always caveat that with at the right price and the right term. And so there are lots of rumors out in the market. We're not going to comment on individual specifics or individual rumors, but our position remains the same. There are PBMs we'd like to own at the right price and the right terms. We think we've proven that we can do this, integrate them better and faster than anybody else and we've proven that can create great shareholder value by doing this. And when the opportunities are right, we will execute."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then just finally, Jeff, I missed some of your prepared comments. But did you talk at all about the progression and how we should be thinking about 2011 from a quarterly progression standpoint?",34,"And then just finally, Jeff, I missed some of your prepared comments. But did you talk at all about the progression and how we should be thinking about 2011 from a quarterly progression standpoint?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Let me just back that up a little bit and talk just a little bit about how I see guidance and I think my position may be slightly different than some of my other peers out there. But my view on guidance is actually relatively simple, which is I do a reall",257,"Let me just back that up a little bit and talk just a little bit about how I see guidance and I think my position may be slightly different than some of my other peers out there. But my view on guidance is actually relatively simple, which is I do a really accurate forecast then tell investors what we really think we can do and then just hit those numbers. And certainly, since my arrival here, we have significantly improved our forecasting ability in order to execute on that vision. I also think there are only a few numbers that really matter, claims, EPS, EBITDA, cash flow. As a result, we try to only guide to those numbers because we think guiding in more detail just dilutes the focus on those metrics, the metrics that matter. We also want to stay focused on the long term so we don't guide the quarters either, again, making sure that we don't dilute our focus on hitting what matters. That said, I understand that everybody out there, all the sell-side people have models to put together. So from time to time, we give a little bit more color on different things to help you out a little bit. As we think about EPS progression for next year, I'd say it looks about like 2010 right now, a little bit more back-end loaded, quite frankly, than 2010. But just to be clear, we're not focused on hitting individual quarters. We're focused on delivering long-term shareholder value and the metrics that matter."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Robert Willoughby with Bank of America Merrill Lynch.",13,"Our next question is from Robert Willoughby with Bank of America Merrill Lynch."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","George or Jeff, you've been fans of floating rates in the past, and forgive me if someone has asked already. But you've been fans of the floating rates here, when you guys moved to lock in some rates here, and either term up a bit or just take advantage o",56,"George or Jeff, you've been fans of floating rates in the past, and forgive me if someone has asked already. But you've been fans of the floating rates here, when you guys moved to lock in some rates here, and either term up a bit or just take advantage of the rates you're seeing out there?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Certainly, we think over long periods of time in history, being floating has certainly paid off. As we look at our current debt structure, we're clearly at the low end of our range, saying that we're comfortable at 1x to 2x EBITDA, if you look at our EPS",130,"Certainly, we think over long periods of time in history, being floating has certainly paid off. As we look at our current debt structure, we're clearly at the low end of our range, saying that we're comfortable at 1x to 2x EBITDA, if you look at our EPS guidance for '11, we're probably a little bit below 1x now. So we certainly think that for the right opportunities, those debt levels could come up a little bit. If we did make that change, we would certainly be looking at the potential to float things out there. Although we're also in a really unique interest rate environment where long-term debt has very low fixed rates and certainly that's all got to come into the calculates of what we end up doing."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","So the numbers for 2011, you've basically assumed status quo here? No refinancing and what in the way share repurchase then?",21,"So the numbers for 2011, you've basically assumed status quo here? No refinancing and what in the way share repurchase then?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, that's right. We assume status quo. As you think about share repurchase, obviously, our guidance range does include some share repurchase. How much cash we actually use to do that share repurchase really depends on two factors: When we're going to bu",173,"Yes, that's right. We assume status quo. As you think about share repurchase, obviously, our guidance range does include some share repurchase. How much cash we actually use to do that share repurchase really depends on two factors: When we're going to buy the shares back; and what price we're going to buy them at. Obviously, when you look at a share count as a weighted average basis based on when you buy them back, I think if you look back in our history of share repurchases, we generally do very few share repurchases in the first quarter because of the timing of our earnings release and our 10-K filing. So certainly, when you think about how much cash we may use, you'd have to consider the fact that probably not a lot of repurchases come in, in the first quarter. And then as I said, what price you're going to do to math with. It's hard for us to forecast stock prices going forward. So we try not to guide to that."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","But you'd have a rough idea in terms of the cash going out the door, if it's closer to $500 million versus a $1 billion?",26,"But you'd have a rough idea in terms of the cash going out the door, if it's closer to $500 million versus a $1 billion?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, at this point, it's certainly a larger number -- a large portion of our cash flow.",17,"Yes, at this point, it's certainly a larger number -- a large portion of our cash flow."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Ricky Goldwasser with Morgan Stanley.",10,"Our next question is from Ricky Goldwasser with Morgan Stanley."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Jeff, I have a couple of follow-up questions here. First of all, are the 2011 investments similar in magnitude to what you've done in 2009?",25,"Jeff, I have a couple of follow-up questions here. First of all, are the 2011 investments similar in magnitude to what you've done in 2009?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","I think I tried to answer that earlier. This is George, Ricky. We've actually increased significantly -- even on the third quarter results and our fourth quarter guidance includes an ascending amount of investment in those investments. We think we're in a",137,"I think I tried to answer that earlier. This is George, Ricky. We've actually increased significantly -- even on the third quarter results and our fourth quarter guidance includes an ascending amount of investment in those investments. We think we're in a unique opportunity right now. When change is about to occur, those companies are most nimble and can take advantage of that change and meet the marketplace, we're going to do the best. And we think we are very nimble. We think we're very innovative and creative. And so we're positioning ourselves to take advantage of the tremendous amount of flock sets occurring in our space today. So those enhancements are up each and every year since I've taken over as CEO. And certainly, there are higher -- it's at an accelerating rate at this point."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","So accelerated rates from the $62 million, I think it was about $62 million that you've done in 2009.",19,"So accelerated rates from the $62 million, I think it was about $62 million that you've done in 2009."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","You're talking about CapEx. And there's two pieces to this. There's CapEx and SG&A spend and some parts that may go through GPC. So you've got all those pieces come together. And so it's not just the investments in CapEx.",41,"You're talking about CapEx. And there's two pieces to this. There's CapEx and SG&A spend and some parts that may go through GPC. So you've got all those pieces come together. And so it's not just the investments in CapEx."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And then just one question on the third quarter, or did you forget cost in the third quarter all related to NextRx or did you also see some impact from the ramping up of the new mail facility?",38,"And then just one question on the third quarter, or did you forget cost in the third quarter all related to NextRx or did you also see some impact from the ramping up of the new mail facility?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, and I would say those things are both and those things are related. As we look at -- talking about in my prepared remarks about having a little bit of excess capacity in the system today, and we're working on optimizing that capacity. We're excited a",106,"Yes, and I would say those things are both and those things are related. As we look at -- talking about in my prepared remarks about having a little bit of excess capacity in the system today, and we're working on optimizing that capacity. We're excited about our new pharmacy here in St. Louis. It's got just unbelievable accuracy and great efficiency, and it's really, we think, a competitive advantage for us long term. But we do have a little bit of excess capacity, and we've got to rationalize that at the same time. We're moving through all the WellPoint activity. So I would say both."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Just to add on a little bit there, the site we built in St. Louis is exceeding our expectations on capacity and accuracy. We've got a program in place with zero defects. Obviously, that's pretty hard to do. But we're down to one to two defects per million",114,"Just to add on a little bit there, the site we built in St. Louis is exceeding our expectations on capacity and accuracy. We've got a program in place with zero defects. Obviously, that's pretty hard to do. But we're down to one to two defects per million and the filling [ph]. And we are truly excited about that. No other site do we have to meets those type of numbers. So we are absolutely excited about what we do. And then on a capacity side, we have significant excess capacity to meet today's needs and tomorrow's needs. So we have to go through that in the first quarter and rationalize our overall footprint."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Our next question is from Ross Muken with Deutsche Bank.",10,"Our next question is from Ross Muken with Deutsche Bank."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","You talked, George, a lot about sort of the specialty opportunity longer term. In the last quarter, we did see what could be called kind of the first biosimilar of sorts to kind of come to market in terms of M-Enoxaparin [ph]. I mean as you think about th",114,"You talked, George, a lot about sort of the specialty opportunity longer term. In the last quarter, we did see what could be called kind of the first biosimilar of sorts to kind of come to market in terms of M-Enoxaparin [ph]. I mean as you think about that as maybe hopefully a catalyst event for FDA to get more constructive on biosimilars, how do you think about that in that kind of context of your business and as an opportunity going forward? And do you feel like this may be something that could be a bit more hopeful in terms of this being a more near-term opportunity on maybe a two, three-year basis?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Absolutely. The biggest disappointment, as you know, that I had in healthcare reform is the fact that we put through this significant piece of legislation and didn't address with the way we needed to address the specialty market. We gave it lip service, i",338,"Absolutely. The biggest disappointment, as you know, that I had in healthcare reform is the fact that we put through this significant piece of legislation and didn't address with the way we needed to address the specialty market. We gave it lip service, if you will, by the biosimilars. And as you also know, and when you're talking about biosimilars instead of biogenerics, these products are probably going to be priced not nearly as advantageously as they would be priced from a client perspective as a generic. So we're facing a little bit of a two-edged sword here. But to your point, having introduction of these products and having many of the generic manufacturers excited about this, the administration and Congress both know that there's a tremendous opportunity here. They're one of the larger users of the biotech drugs out there, and they know what this is costing the country. They know that they were facing deficits and have a tremendous issue, and I am excited about where this can go. Now we do still need some legislative changes to ultimately get to where we need to be. But our team, we've got a fairly large lobbying group in Washington, as well as Dr. Miller, my Chief Medical Officer, also spends a lot of time on the Hill. I spend time on the Hill. And our job is to make sure that we can try to get that legislation through. I think notwithstanding all of that, there's a real issue around adherence, proper channel and the use of biosimilars. So we're talking about rolling out -- I think we can get our arms around the trend and improve the health outcomes in the world we live today. And to your point, if we can actually tip the scale over and start getting better competition and better products, especially for those where patent protection is expired, I think there's such a great, great opportunity out there to continue to win in this space. And that truly is our focus."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","And maybe, Jeff, I just want to touch on one thing, in terms of thinking about the profit growth here and the EBIT growth that we've seen, the guidance sort of implies roughly call it 30% type EPS growth this year. Your EPS growth CAGR over the last five",156,"And maybe, Jeff, I just want to touch on one thing, in terms of thinking about the profit growth here and the EBIT growth that we've seen, the guidance sort of implies roughly call it 30% type EPS growth this year. Your EPS growth CAGR over the last five years has been slightly below that. As you think about sort of going forward, I mean, and particularly given all the focus and sort from the investment community on margins and return on capital during this last three to six months where there was a bit of trepidation. And as you kind of go forward, maybe just in broad terms, I'm not asking for forward guidance, but do you see any sort of change in your business or anything that would make you think that on a go-forward basis the trajectory is going to be meaningfully different than we've been used to seeing from Express Scripts historically?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, unfortunately, Ross, as much as I'd like to answer that question, I think any way I would answer that, would essentially be multiyear forward guidance. So certainly, I'm not going to add -- I think we said last quarter on the call that we're excited",86,"Yes, unfortunately, Ross, as much as I'd like to answer that question, I think any way I would answer that, would essentially be multiyear forward guidance. So certainly, I'm not going to add -- I think we said last quarter on the call that we're excited about the long-term prospects for this business. We are making significant investments as we said because we believe so strongly in our business and how our team can execute. But it's hard for me to get into any more detail."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","But just in terms of like, even the assumptions for the core business from a margin perspective, et cetera. There was nothing that occurred during this last season for even next year that meant to you that all of a sudden, the profit trajectory of the bus",55,"But just in terms of like, even the assumptions for the core business from a margin perspective, et cetera. There was nothing that occurred during this last season for even next year that meant to you that all of a sudden, the profit trajectory of the business was anything meaningfully different than what we've seen."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Let me try something here and then Jeff can certainly add on. We always get the question about price pressure in the marketplace. And I've said for the last three years, Ive said the proof's in the pudding. I said you look at the script counts and you",276,"Let me try something here and then Jeff can certainly add on. We always get the question about price pressure in the marketplace. And I've said for the last three years, Ive said the proof's in the pudding. I said you look at the script counts and you look at what's happened on to EBITDA per script. If we couldn't compete, then those metrics would not increase. And I think what you've seen from us, is we've grown our scripts significantly over the last five years. Our EBITDA per script overall is up. Obviously, there's been acquisitions and other things that may temporarily bring them down, but then they start to ascend again. And those things point to the health, from a historical perspective, of how the business is performing. Keeping in mind, we got three-year contracts for the most part, although we with 30% of our business have seven and 10 years or effectively seven years with two option years with the DoD. Seven and 10-year business. So those things stay very strong, obviously, over those periods of time. And so, I don't know, I mean, you look at the underlying trends in the business, and we're not going to give guidance to 2012 or '13 or '14. But I will tell you, you got an aging population, you got 30 million people coming into the market, you got a need by a country and by companies to figure how to control healthcare costs, and we have answers. So you throw all those things into the hopper, you shake it up, and I like our prospects. But again, we don't want to get into specifics."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","And next we'll go to Steve Valiquette with UBS.",10,"And next we'll go to Steve Valiquette with UBS."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","You just kind of touched on this is a little bit but I thought the 2011 EBITDA for planned guidance was pretty strong. I thought it put the rest on the concerns about PBM pricing. So I was just curious, just sort of your general comments or thoughts about",82,"You just kind of touched on this is a little bit but I thought the 2011 EBITDA for planned guidance was pretty strong. I thought it put the rest on the concerns about PBM pricing. So I was just curious, just sort of your general comments or thoughts about the puts and takes or drivers of the projected healthy increase of EBITDA for claim for 11, in particular, or if theres any other insights you might want to add on to that?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Yes, I think, obviously, as I said earlier, we're focused on a couple of things. And we think there a couple of things that really drive this business, that's certainly one of them. I think the team here has done just a phenomenal job getting the integrat",198,"Yes, I think, obviously, as I said earlier, we're focused on a couple of things. And we think there a couple of things that really drive this business, that's certainly one of them. I think the team here has done just a phenomenal job getting the integration done, getting our efficiencies up, bringing in new programs. There's a lot of things that we've talked to before that generics -- it is a slightly lower year. But thankfully for Express Scripts, we've got a lot of other leverage we can pull. We've got a great team of people that are pulling them, and we've got -- we're firing at all cylinders here, we're driving EBITDA up for Rx as we continue to execute. And we're delivering products that, as George was saying, clients want to buy. And our model of alignment works at the end of the day. The more money we can save our clients, the more money we can make. And in this environment, our clients want to save money. With Consumerology, we've got the tools that can help them save money with minimal member impact, and the net result is the results that we're putting out."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","That's particularly true, Jeff, when you think about a year where there are low generic utilization. One of two things can happen. We can say theres low generic utilization, so we can go to our clients and say sorry, but you guys all better get prepare",405,"That's particularly true, Jeff, when you think about a year where there are low generic utilization. One of two things can happen. We can say theres low generic utilization, so we can go to our clients and say sorry, but you guys all better get prepared for bad cost trends. Well, we probably wouldn't have any clients after that conversation. So our job is not to sit on our laurels and wait for a generic launch. Our job is to be creative and equip our account managers with products and innovation to go out and make sure they can manage those trends down. And when we do that, when we execute on that, what you see is we grow our EBITDA per script. We also, by the way, meet the clients' needs that take the costs out of the equation. If you remember a couple of years back, we had a bad generic year and we grew EBITDA per script significantly during that period. And the reason was is because we see these things three years out. So we don't sit and wait until the sky's going to fall or win anything else. We actually go out with a product portfolio to meet the needs of those clients. No CFO wants to sit there with the volatility in their cost going all over the place. Our job is to control that trend on a level of basis over the life of that contract, hopefully, over more than a couple of those contract terms. And that's our job. That's what we pay our account managers to do and bonus them to do, and they've got to do it. So we're excited about the business and what we can do. As Jeff's pointed out, we got a lot of levers. And if it's not generics in a given year, then it's something else. But we just can't sit back and be complacent. We've got to drive those numbers, and that's got to be our focus. Again, going back to Larry's question, it's not a question of just going out and trying to sell. It's a question of going out and making sure we're doing what our clients need to control their cost in very volatile markets. And when we do those things well, we can grow our business and grow our EBITDA, grow our business and meet the clients' needs, and that remains our singular focus."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Any chance youll comment on, just generally speaking, as far as your overall wins for next year, just generally,  would you say they were skewed towards higher margin customers that already have decent mail pen rates or lower or that's not really one y",52,"Any chance youll comment on, just generally speaking, as far as your overall wins for next year, just generally,  would you say they were skewed towards higher margin customers that already have decent mail pen rates or lower or that's not really one you want to comment on at this stage?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, we don't really like to talk about clients specifically. I think there's a lot of noise going on in our numbers only because as you know, we had the big retailer we lost unintentionally halfway through the year. And then we had -- so that took a bun",92,"Well, we don't really like to talk about clients specifically. I think there's a lot of noise going on in our numbers only because as you know, we had the big retailer we lost unintentionally halfway through the year. And then we had -- so that took a bunch of no-mail claims out. So that's in the numbers. But as far as the wins, I think they're fairly common. I mean it's our job. I think they come to us because they have a need, and we're going to meet those needs."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","That would be from the line of Garen Sarafian with Citi Investment Research.",13,"That would be from the line of Garen Sarafian with Citi Investment Research."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","In terms of reinvesting in your business and market opportunities, I'm curious to hear your thoughts on Medicaid. States continue to have severe budget shortfalls. Would you think PMBs with skills as yours really could help lower their costs and especiall",60,"In terms of reinvesting in your business and market opportunities, I'm curious to hear your thoughts on Medicaid. States continue to have severe budget shortfalls. Would you think PMBs with skills as yours really could help lower their costs and especially with the sophisticated tools. So what really needs to change for the market to become really appealing for you?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","We're looking at that, and obviously, with 40% more individuals going to be pushed into the Medicaid space, something's got to give here. States are -- if you go back, four and five and six years ago, even two years ago, many of the platforms like governo",360,"We're looking at that, and obviously, with 40% more individuals going to be pushed into the Medicaid space, something's got to give here. States are -- if you go back, four and five and six years ago, even two years ago, many of the platforms like governors running for office was to try to control the budget of the states, even before the economic downturn. Medicaid was costing the states tremendous amounts of money. Many states cut-slashed Medicaid spending and cut Medicaid enrollment by changing the qualifications, and we've seen a lot of that activity. Well, now we're going to put 40% of people on top of it. And we're going to fund it in the early years and then defund it over a period of time. The states are going to have a tremendously difficult time meeting that need. And you're exactly right, there's a tremendous opportunity for us to utilize our tools, to meet the needs of that marketplace. Today, those are being met through managed Medicaid plans. We have clients who manage Medicaid. So we picked up our share through the managed Medicaid plans, but there's an awful lot of fee-for-service out there. And to the extent that you start ratcheting down spending or you need to get control of the spend, managed Medicaids probably going to play a higher and higher role. I think we've got to figure out -- that's why we're making these investments is to figure how do we play in that space to make sure we can bring our tools and expertise to an area that truly needs to be managed and worked. And as you know, the Medicaid is far different than the other plans. People are transient. Most pay close to nothing if not nothing for their care. So getting adherence, getting incentives, making things work is very difficult for traditional businesses. For us though, where we use Consumerology, understand the drivers of the person, we think were in a unique position where we can use those tools to help the states manage their business. So this is truly a focus of ours over the next couple of years."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Any reason why upcoming elections next week would impact anything for next year as to the progress you make of the Medicaid front?",23,"Any reason why upcoming elections next week would impact anything for next year as to the progress you make of the Medicaid front?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, I think -- it really kind of depends on everything that happens, and that goes back to being fluid and flexible because I do believe that things have to change. I'm a citizen first and a CEO second. And we are facing tremendous deficits. We've got t",278,"Well, I think -- it really kind of depends on everything that happens, and that goes back to being fluid and flexible because I do believe that things have to change. I'm a citizen first and a CEO second. And we are facing tremendous deficits. We've got to address that issue. We've got to get our costs as a country under control. Whether it's the Democrats or the Republicans, we can't continue to spend the way we're spending. We got to do something about taxation. We've got to do something about competitive strength of our companies to be able to compete globally. There's an awful lot out there. All those things could have an impact on what happens. If the Republicans win the house and they decide not to procreate money to the healthcare bill, where does that take us? What happens if the Federal government has the right to establish the exchanges, will the states have the right to put them in? What if states don't do it, would the Federal government do it? What if there's money not appropriated? There's a lot of uncertainty out there. At the end of the day though, all those uncertainties, I view as a wonderful thing. Because the company that can change and the company that can meet the market needs and can be first to market is the one that can win. And I don't think there's anybody better than that than Express Scripts. So I love where we sit. We know that these things are at some way or form, these things are going to happen. And I think we're very well-positioned to take advantage of those opportunities."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Just switching channels a bit. I know you don't speak about specific clients coming up, but overall, how do you see the 2011 selling season as it gets underway? Maybe if you could offer just some broad color as to how it compares to 2010 in terms of size",65,"Just switching channels a bit. I know you don't speak about specific clients coming up, but overall, how do you see the 2011 selling season as it gets underway? Maybe if you could offer just some broad color as to how it compares to 2010 in terms of size and just the types of clients that are going to market next year versus this year?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Sure, I think you've heard us say this many times before. We've got two large clients that make up half of our book that are on longer term renewal cycles, which on average means that we've got 15% to 20% of our book up to renewal in any given year. And a",80,"Sure, I think you've heard us say this many times before. We've got two large clients that make up half of our book that are on longer term renewal cycles, which on average means that we've got 15% to 20% of our book up to renewal in any given year. And as we look at 2011 right now to the lower end of that range, certainly, clients up for renewal are slightly lower in '11 than it was in 2010."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts","Overall, is there opportunities then -- I mean, is the overall opportunity larger than 2010, or there might be some opportunities to bring on additional clients?",26,"Overall, is there opportunities then -- I mean, is the overall opportunity larger than 2010, or there might be some opportunities to bring on additional clients?"
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","We're always excited about the opportunities out there. I think we've got unique products that can really help clients save money. And we're excited about what we have to offer and certainly the sales team is out there to close every opportunity we can cl",70,"We're always excited about the opportunities out there. I think we've got unique products that can really help clients save money. And we're excited about what we have to offer and certainly the sales team is out there to close every opportunity we can close as long as the client we want to work with, the client is focused on taking out waste where we can add significant value."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives","Well, thank you all very much. I appreciate your attentiveness this morning and look forward to bringing you up-to-date with our fourth quarter results early next year. Thank you very much.",31,"Well, thank you all very much. I appreciate your attentiveness this morning and look forward to bringing you up-to-date with our fourth quarter results early next year. Thank you very much."
317975,114404734,83756,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator","Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation. You may now disconnect.",19,"Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation. You may now disconnect."
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator"," Ladies and gentlemen, thank you for standing by. Welcome to the Express Scripts Third Quarter 2010 Earnings Call. [Operator Instructions] Now with that being said, I'll turn the conference now to the Vice President of Investor Relations, Mr. David Myers.",40," Ladies and gentlemen, thank you for standing by. Welcome to the Express Scripts Third Quarter 2010 Earnings Call. [Operator Instructions] Now with that being said, I'll turn the conference now to the Vice President of Investor Relations, Mr. David Myers.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Thank you, and good morning, everyone. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. Before we begin, I need to read the following Safe Harbor statement. Statements or comments made on this conference call may be forward-l",184," Thank you, and good morning, everyone. With me today are George Paz, our Chairman and CEO; and Jeff Hall, our CFO. Before we begin, I need to read the following Safe Harbor statement.
 Statements or comments made on this conference call may be forward-looking statements and may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors, which are discussed in detail in our filings with the SEC.
 For clarity purposes, all numbers we talk about today will be on an adjusted basis. Please refer to the tables in our press release for reconciliation of GAAP to the adjusted numbers we will be discussing. The reconciliation of EBITDA to net income can also be found in our earnings release. The earnings release is posted on our website.
 At this point, I'll turn the call over to Jeff, who will talk about our third quarter results.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Thank you, David. Today, we are pleased to report another record quarter and provide guidance for 2011. Our strong results and outlook for the future are the result of our differentiated strategy. Our business model of alignment, enabled by our behavior-",523," Thank you, David. Today, we are pleased to report another record quarter and provide guidance for 2011. Our strong results and outlook for the future are the result of our differentiated strategy. Our business model of alignment, enabled by our behavior-centric approach, supported by market-leading technology and service levels. Our execution of this strategy helps our clients and patients drive out wasteful spending, which in turn helps us continue to deliver superior returns to our stockholders.
 Third quarter earnings per share reached a record of $0.65, up 55% over last year. The majority of these growth came from EBITDA, which grew at 45% over last year and 5% sequentially. During the quarter, we made significant progress executing our integration plans. We have now transitioned 90% of the WellPoint Live to our IT platform, and expect to complete the final migration of Live at year end. This will position us to finish the integration, retire the NextRx system and rationalize our operational footprint in the first quarter.
 Metrics for the quarter were strong and reflect our integration progress. Adjusted claims grew at 48% to $186.9 million. Total operating expenses were in line with our expectations, although the mix of expenses is weighted more towards cost of goods sold and forecasted through the excess capacity that remains in the system today. Despite this excess capacity, gross profit improved to 7.2%, up 30 basis points sequentially. We expect gross profit margin will continue to improve as the underlying fundamentals of our business continue to improve, the completion of the integration and the optimization of capacity.
 EBITDA for adjusted Rx reached $3.30, up sequentially from $3.10 last quarter, and year-to-date cash flow from operations increased 99% to $1.8 billion. During the quarter, we repurchased 16.4 million shares and repaid the remaining balance of our term loan. Based on these results and our positive outlook for the remainder of the year, we have narrowed our 2010 EPS guidance range to $2.48 to $2.50. This represents growth of 26% to 27% over 2009 on an adjusted basis.
 Moving on to 2011 guidance, we expect that 2011 EPS will be in the range of $3.15 to $3.25, representing growth of 27% to 31% over 2010. We are confident we will complete the integration and achieve our synergy targets in the year. And as a result, our 2011 guidance include $1 billion of incremental EBITDA.
 Since the acquisition will be fully integrated next year and our guidance includes the achievement of synergy targets, and keeping with our long-standing practice of not commenting on specific clients, we will no longer discuss WellPoint-specific results.
 Cash flow from operations is expected to be between $2.2 billion and $2.4 billion. We see a lot of exciting opportunities, and our EPS guidance include significant investments in 2011. In addition to these significant investments flowing through our P&L, we also expect to spend $140 million to $170 million in capital investments in the year.
 We are pleased with how our team has executed in 2010 and look forward to continuing to deliver strong performance in 2011 and beyond.
 And with that, I'll turn it over to George.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Thank you, Jeff, and good morning, everyone. Since our inception, we have been focused on alignment and our ability to innovate and execute. These qualities are as strong as ever, and we are now deploying new capabilities enabled by our groundbreaking wo",577," Thank you, Jeff, and good morning, everyone. Since our inception, we have been focused on alignment and our ability to innovate and execute. These qualities are as strong as ever, and we are now deploying new capabilities enabled by our groundbreaking work in Consumerology. This week, we had our National Accounts Advisory Board meeting. Annually, we hold this meeting to bring in our diverse set of our National Account clients to get input on market conditions, medical trends and our pipeline of new products. At this meeting, I gathered feedback from many of our clients. They are overwhelmingly pleased with our ability to drive out wasteful spending while improving health outcomes, with high levels of member satisfaction.
 The NextRx acquisition is another good example of innovation and execution at work. We closed the transaction just 11 months ago. And through the focused effort of both companies, the migration of Live is nearing completion. The transition of Live was seamless and efficient with very little noise or disruption. As Jeff mentioned, we now consider NextRx part of our core business. Completing the critical migration so quickly is important so that we can focus on the potential of this strategic alliance. It will open new horizons for improving outcomes for members while driving all [ph] down our overall health care costs.
 As the selling season winds down, let me summarize the results. As we pointed out last quarter, we saw high retention rates for signature accounts. Notwithstanding the stickiness in the marketplace, we won three signature accounts and again, grew our share in the middle market. Even with the client losses discussed last quarter, we expect the retention to exceed 95%. Based on our new sales activities and retention rate, we expect claims to be flat to up 4% for 2011. Our 2011 guidance not only provides strong earnings growth, it also provides for significant investments designed to keep us ahead of the competition in the evolving healthcare landscape. These projects include preparation for EBIT changes, Medicare regulations and healthcare reform. We are investing in opportunities to continue to differentiate ourselves in the marketplace by creating new products and services that meet and exceed the needs of tomorrow's marketplace.
 In addition to the investments in our Consumerology platform, I'm particularly excited about two specific initiatives. First, we are investing heavily in our next-generation specialty offering that will be rolled out next year. This offering will enhance our ability manage the cost and quality, especially drug care. Part of the programs in this area had been enthusiastically endorsed by clients for their ability to drive out significant ways to the specially drug spend, the fastest-growing area of pharmaceutical costs. Second, we're tackling the issue of non-adherence by making significant investments in our predictive modeling capabilities. Through these efforts, we are able to identify in advance, those patients that are unlikely to adhere to medication therapies. We then intervene and customize ways to improve adherence. Although early, we are seeing significant improvements in medication adherence in our pilot programs.
 Our core business is strong, and we are positive on the underlying trends and opportunities in our space. This is why we are investing to position ourselves for a long-term growth. Our ability to manage trend, coupled with our behavior-centric approach, will drive out ways for clients, improve health outcomes for patients and deliver strong earnings growth for our stockholders.
 At this point, I'd like to open it up to questions. Operator?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator"," [Operator Instructions] First in line is Tom Gallucci with Lazard Capital Markets.",12," [Operator Instructions] First in line is Tom Gallucci with Lazard Capital Markets.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," First, just wondering, you sort of mentioned significant investments within the 2011 expectations. Is there any way you can frame or quantify the magnitude of what we're looking at here?",30," First, just wondering, you sort of mentioned significant investments within the 2011 expectations. Is there any way you can frame or quantify the magnitude of what we're looking at here?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," I can let Jeff chime in on that as well, but as you probably know, CMS, before healthcare reform was ultimately passed, and certainly, quickly thereafter, continued to issue more and more guidance. There was a lot of uncertainty and ambiguity in the Medi",451," I can let Jeff chime in on that as well, but as you probably know, CMS, before healthcare reform was ultimately passed, and certainly, quickly thereafter, continued to issue more and more guidance. There was a lot of uncertainty and ambiguity in the Medicare provisions that exist. And so CMS has been very proactive in trying to get guidance out to the providers and to the insurance companies. And so as that guidance has come down, there's two ways you can approach this. We can do the minimum and make sure we hit that guidance so we can think about how we want to position ourselves in an evolving world and make sure that we can, not only meet the guidance requirements, but be ahead of the game with respect to new product innovation and meet the needs of that guidance may imply with respect to the needs of our clients and patients. So our IT and operational departments and our sales and comm management product development all work in unison to both meet the guidance requirements, as well as drive new product innovation. That, coupled with all the requirements from HIPAA, HITECH, we had DIDAD coming through, which is the new standard by which everyone has to be geared up for by 2012, in order to handle the ingredient components of compounds and expands fields. There's a tremendous amount of work that has to take place. Again, it's not just meeting those needs, but making sure that we meet them better than the competition and use it for new product innovation. Those have to go hand-in-hand. And of course, there's healthcare reform. So quite frankly, I don't want to get into the specifics but we don't want to give guidance by line items on our financials. But I will tell you that our investments in technology and operations and product development have significantly improved. They were quite a bit higher in 2010 as the year ramped out. And then in 2011, we expect continued increases. When we give our -- you often asked us how we feel about the deployment of our capital. And one of the things we say is we always like to invest in ourself first. I think that's critically important because I don't know what else gets better returns than investing in our own business. And as we look at this, that's exactly what we're doing. We're investing in ourself. Well, we invest in ourself, either it has to come through to two places, either it has to come through expenses or it has come through capital investments, depending on the type of project it is, and that's what you're seeing in the guidance we're giving.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator"," And next with Larry Marsh with Barclays Capital.",8," And next with Larry Marsh with Barclays Capital.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," First on new business, George, your model's a little bit different. You're really focused on driving value to your customers and shareholders, you're focused on EBITDA and earnings, not necessarily winning new business. But obviously, over time, you got",94," First on new business, George, your model's a little bit different. You're really focused on driving value to your customers and shareholders, you're focused on EBITDA and earnings, not necessarily winning new business. But obviously, over time, you got to balance the two. As we think about the next couple of years, how do we think about the opportunity for you to take share? Do you think of it that way, where would you gain share? And then how do you think of Medi in that sort of balance between margin and new business?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Only challenged a little bit, Larry, first of all. I think if it was a stagnant world and you are selling just automobiles. You have to always worry about how do I sell the next car. Keep in mind that we have a totally different dynamic that's occurring",538," Only challenged a little bit, Larry, first of all. I think if it was a stagnant world and you are selling just automobiles. You have to always worry about how do I sell the next car. Keep in mind that we have a totally different dynamic that's occurring in our market spot. We have an under-penetration of mail, we have people that aren't fully utilizing specialty drugs, the fastest-growing part of healthcare cost in the drug space, not being properly utilized and not being properly adhere to. And then we've got members aging, the baby booms getting older, people are moving through that pipeline and becoming older. And as they do, they take more prescriptions. We see in 2014, 30 plus million more people entering into the market. So there's a whole lot of things going on. So the question you have to ask yourself is where should the company's focus be? Should it be coming up with innovative product to drive mail, generic utilization, to drive specialty cost out that all these things add value to our clients, improve health outcomes for our members and drive shareholder value, or do you want to grow new business for the sake of new business growth? What gives you the biggest returns? I've said on many, many, many calls that part of a great client-company relationship has to have built into it a common desire to meet the needs of the marketplace. There are certain clients that want to do things that don't align with our model. Those aren't good clients for us. Adding those clients would be a detraction of our call center associates, our operational associates, our account management as they're trying to conform a square peg into a round hole. Our focus has to be around growing share value and you do that through ROIC. That doesn't mean we can shrink the business over time, but what it means is we have to be disciplined about that business. We need clients that are concerned about their drug costs and spend and the improvement of health outcomes for their individuals. When we align those desires and needs with the products we have to offer and our approach, we have a marriage that works quite happily. And that's what we look for, Larry. So I think we can continue to grow EBITDA, we can continue to grow our profits without getting crazy in the marketplace by just competing on the clients that make sense. And by the way, when you're offering the client something they want and you're aligned with them, then the price is always important. But the prices points doesn't match up what they're looking for and our messaging and our pricing resonates with them and we get a sale. And guess what, even though I might make more money over some period of time with that client, they're happy because we're taking far more costs out of their equation than they expected or that they originally anticipated or they've gotten in the past. And so we got a very high, happy camper. I got happy patients as they got better health outcomes and I'm driving shareholder value to all of my valuable shareholders. That's our focus.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," And I guess a follow up and a couple of things in on overall script growth you now see is a little bit stronger than you would have said six months ago for '11. Do we assume that mail script growth is kind of consistent with that overall 0% to 4% trend?",112," And I guess a follow up and a couple of things in on overall script growth you now see is a little bit stronger than you would have said six months ago for '11. Do we assume that mail script growth is kind of consistent with that overall 0% to 4% trend? And then just on WellPoint, I know Jeff and I are talking anymore specifically about that customer going forward, but you talked about integration costs that are to be determined. How do we framework that for '11? What kind of things could there be and can you give us any guidance as to how big or small that might be?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," You're right, we did end up with three signature accounts this year. And we did -- we're having a very successful selling season in the small to middle market area. And those things aren't finished yet, and the latter one isn't finished yet. Sometimes we",407," You're right, we did end up with three signature accounts this year. And we did -- we're having a very successful selling season in the small to middle market area. And those things aren't finished yet, and the latter one isn't finished yet. Sometimes we don't know we got a new client win until January 15 and those are usually very small. But that last piece kind of rolls out towards the end of the year. So based on our best guess is in the pipeline and where we sit today, our selling season and success is better than we had anticipated earlier in the year. Having said all that, I don't want to get into client-specific situations, but we are pleased with where we sit. As far as mail is concerned, mail is a very important focus to us. We believe mail is important because it does drive better economics for our members, we show better adherence, better health outcomes for mail. By the same token, with certain clients, when you're going through an integration, the integration has to go first. So we got to get through this year. Finish that often. So starting next year, we're absolutely focused on mail and generic programs with WellPoint. I guess, I am talking about the clients specifically, but in this situation, we will address that. For the rest of our clients, keep in mind that one of the things that we're facing is a tough economic environment. And when a member has to pay two or three copays, upfront versus paying one at the Connery retailer in an uncertain tough environment, that's a little harder to do. And so the members struggle a little bit with that, and we do see some of our membership moving from mail into retail for that reason. But we fight hard. We try to make sure that we get them back. It's good for the client, ultimately, it's good for the member. And of course, it's very good for their healthcare outcomes. So it's going to continue to be a focus for us. I would say that you going into next year because we're just getting underway with the WellPoint situation, we expect modest to low growth in mail. But keep in mind, that's based on our current economic situation. There's a lot of things that can change over next year. And we'll obviously keep you posted quarter-by-quarter on that progress.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," And then any range of integration costs?",7," And then any range of integration costs?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," So Larry, the range really hasn't changed. We've been saying from the beginning that we expect about $120 million to $150 million in integration costs. I think the difference that you're picking up now on is that now that we've got guidance into 2011. We",110," So Larry, the range really hasn't changed. We've been saying from the beginning that we expect about $120 million to $150 million in integration costs. I think the difference that you're picking up now on is that now that we've got guidance into 2011. We still think it's going to be $120 million to $150 million. But what we don't know what the great clarity at the moment is how much of that is going to hit into 2010 how much of that is going to hit in 2011. But if some of it does push over into 2011, we still expect the same range, $120 million to $150 million.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator"," Our next question is from Lisa Gill with JPMorgan.",9," Our next question is from Lisa Gill with JPMorgan.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," Jeff, I know that you just commented -- George commented around mail for 2011 as it pertains to WellPoint. Can you comment as to if there's anything in your current expectations in the current guidance or will this just be the beginning stages of trying",52," Jeff, I know that you just commented -- George commented around mail for 2011 as it pertains to WellPoint. Can you comment as to if there's anything in your current expectations in the current guidance or will this just be the beginning stages of trying to sell through some of these programs?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Well as I said, as we said we, I said about [ph] WellPoint kicking off their programs in 2011. The overall growth in our mail, I believe, will be slightly up year-over-year. So that encompasses the whole book.",38," Well as I said, as we said we, I said about [ph] WellPoint kicking off their programs in 2011. The overall growth in our mail, I believe, will be slightly up year-over-year. So that encompasses the whole book.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," I think that a lot of investors have been focused on how quickly you can up sell, George, to that new book of business. And I was just curious if anything was in your expectations or if this is a [indiscernible] that we're getting the integration as we'l",69," I think that a lot of investors have been focused on how quickly you can up sell, George, to that new book of business. And I was just curious if anything was in your expectations or if this is a [indiscernible] that we're getting the integration as we'll now have the opportunity to go out and start talking about the programs rather than having something built within your expectations?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Well, clearly, it will be a focus of ours, Lisa. And it's certainly a focus of WellPoint. I think the reason they chose us was because they liked our approach to mail or liked our approach to generics. As we said that throughout this year though, this ye",175," Well, clearly, it will be a focus of ours, Lisa. And it's certainly a focus of WellPoint. I think the reason they chose us was because they liked our approach to mail or liked our approach to generics. As we said that throughout this year though, this year had to be a focus on integration. So if we're finished on '11, then we change our focus next year to up-selling clinical programs and working, trying to work with them as a client. So as you might suspect, when you start that, January is all about planned design changes and making sure the book of business is stable and you're meeting all your service requirements. So these things don't start to look end of the first quarter to the second quarter and then you got to up-sell them, you got to work them through, you got to go out and talk to the clients. We got to put our people out on the street to go talk to them. So next year is the kick-off year.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," And then maybe could you just comment on, are you seeing any acquisition opportunities in the marketplace? This has clearly been a very successful transaction for you. What are some of your thoughts on some of the other things that are maybe out there to",45," And then maybe could you just comment on, are you seeing any acquisition opportunities in the marketplace? This has clearly been a very successful transaction for you. What are some of your thoughts on some of the other things that are maybe out there today?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Our position has been pretty consistent over the last several quarters. We say the same thing every time. Certainly, there are other PBMs that we think would be very attractive acquisitions for us, but we always caveat that with at the right price and th",128," Our position has been pretty consistent over the last several quarters. We say the same thing every time. Certainly, there are other PBMs that we think would be very attractive acquisitions for us, but we always caveat that with at the right price and the right term. And so there are lots of rumors out in the market. We're not going to comment on individual specifics or individual rumors, but our position remains the same. There are PBMs we'd like to own at the right price and the right terms. We think we've proven that we can do this, integrate them better and faster than anybody else and we've proven that can create great shareholder value by doing this. And when the opportunities are right, we will execute.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," And then just finally, Jeff, I missed some of your prepared comments. But did you talk at all about the progression and how we should be thinking about 2011 from a quarterly progression standpoint?",34," And then just finally, Jeff, I missed some of your prepared comments. But did you talk at all about the progression and how we should be thinking about 2011 from a quarterly progression standpoint?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Let me just back that up a little bit and talk just a little bit about how I see guidance and I think my position maybe slightly different than some of my other peers out there. But my view on guidance is actually relatively simple, which is do a really",256," Let me just back that up a little bit and talk just a little bit about how I see guidance and I think my position maybe slightly different than some of my other peers out there. But my view on guidance is actually relatively simple, which is do a really accurate forecast then tell investors what we really think we can do and then just hit those numbers. And certainly, since my arrival here, we have significantly improved our forecasting ability in order to execute on that vision. I also think there are only a few numbers that really matter, claims, EPS, EBITDA, cash flow. As a result, we try to only guide to those numbers because we think guiding in more detail just dilutes the focus on those metrics, the metrics that matter. We also want to stay focused on the long term so we don't guide the quarters either, again, making sure that we don't dilute our focus on hit and what matters. That said, I understand that everybody out there, all the sell-side people have models to put together. So from time to time, we give a little bit more color on different things to help you out a little bit. As we think about EPS progression for next year, I'd say it looks about like 2010 right now, a little bit more back-end loaded, quite frankly, than 2011. But just to be clear, we're not focused on hitting individual quarters. We're focused on delivering long-term shareholder value and the metrics that matter.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator"," Our next question is from Robert Willoughby with Bank of America Merrill Lynch.",13," Our next question is from Robert Willoughby with Bank of America Merrill Lynch.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," George or Jeff, you've been saying [ph] of floating rates in the past, but forgive me if someone has asked already. But you've been saying that the floating rates, when you guys moved to lock in some rates here, either turn up a bit or just take advantag",55," George or Jeff, you've been saying [ph] of floating rates in the past, but forgive me if someone has asked already. But you've been saying that the floating rates, when you guys moved to lock in some rates here, either turn up a bit or just take advantage of the rates you're seeing out there?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Certainly, we think over long periods of time in history, being floating has certainly paid off. As we look at our current debt structure, we're clearly at the low end of our range, saying that we're comfortable at 1x to 2x EBITDA, if you look at our EPS",132," Certainly, we think over long periods of time in history, being floating has certainly paid off. As we look at our current debt structure, we're clearly at the low end of our range, saying that we're comfortable at 1x to 2x EBITDA, if you look at our EPS guidance for '11, we're probably a little bit below 1x now. So we certainly think that for the right opportunities, we could those debt levels could come up a little bit. If we did make that change, we would certainly be looking at the potential to float things out there. Although we're also in a really unique interest rate environment where long-term debt has very low fixed rates and certainly that's all got to come into the calculates of what we end up doing.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," So the numbers for 2011, you've basically assumed status quo here? No refinancing and what in the way [ph] share repurchase then?",22," So the numbers for 2011, you've basically assumed status quo here? No refinancing and what in the way [ph] share repurchase then?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Yes, that's right. We assume status quo. As you think about share repurchase, obviously, our guidance range does include some share repurchase. How much cash we actually use to do that share repurchase really depends on two factors: When we're going to b",172," Yes, that's right. We assume status quo. As you think about share repurchase, obviously, our guidance range does include some share repurchase. How much cash we actually use to do that share repurchase really depends on two factors: When we're going to buy the shares back; and what price we're going to buy them at. Obviously, when you look at a share count as a weighted average basis based on when you buy them back, I think if you look back in our history of share repurchases, we generally do very few share repurchases in the first quarter because of the timing of our earnings release and our 10-K filing. So certainly, when you think about how much cash we may use, you'd have to consider the fact that probably not a lot of repurchases come in the first quarter. And then as I said, what price you're going to do to math with. It's hard for us to forecast stock prices going forward. So we try not to guide to that.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," But you'd have a rough idea in terms of the cash going out the door, if it's closer to $500 million versus a $1 billion?",26," But you'd have a rough idea in terms of the cash going out the door, if it's closer to $500 million versus a $1 billion?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Yes, at this point, it's certainly a larger number -- a large portion of our cash flow.",17," Yes, at this point, it's certainly a larger number -- a large portion of our cash flow.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator"," Our next question is from Ricky Goldwasser with Morgan Stanley.",10," Our next question is from Ricky Goldwasser with Morgan Stanley.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," Jeff, I have a couple of follow-up questions here. First of all, are the 2011 investments similar in magnitude to what you've done in 2009?",25," Jeff, I have a couple of follow-up questions here. First of all, are the 2011 investments similar in magnitude to what you've done in 2009?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," I think I tried to answer that earlier. This is George, Ricky. We've actually increased significantly -- even on the third quarter results and our fourth quarter guidance includes an ascending amount of investment in those investments. We think we're in",136," I think I tried to answer that earlier. This is George, Ricky. We've actually increased significantly -- even on the third quarter results and our fourth quarter guidance includes an ascending amount of investment in those investments. We think we're in a unique opportunity right now. When change is about to occur, those companies are most nimble and can take advantage of that change and meet the marketplace, we're going to do the best. And we think we are very nimble. We think we're very innovative and creative. And so we're positioning ourselves to take advantage of the tremendous amount of flock sets occurring in our space today. So those enhancements are up each and every year since I've taken over CEO. And certainly, there are higher -- it's of an accelerating rate at this point.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," So accelerated rates from the $62 million, I think it was about $62 million that you've done in 2009.",19," So accelerated rates from the $62 million, I think it was about $62 million that you've done in 2009.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," You're talking about CapEx. And there's two pieces to this. There's CapEx and SG&A spend and some parts, that may go through GPC. So you've got all those pieces come together. And so it's not just the investments in CapEx.",41," You're talking about CapEx. And there's two pieces to this. There's CapEx and SG&A spend and some parts, that may go through GPC. So you've got all those pieces come together. And so it's not just the investments in CapEx.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," And then just one question on the third quarter, or did you forget cost in the third quarter all related to NextRx or did you also see some impact from the ramping up of the new mail facility?",38," And then just one question on the third quarter, or did you forget cost in the third quarter all related to NextRx or did you also see some impact from the ramping up of the new mail facility?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Yes, and I would say those things are both and those things are related. As we look at -- talking about in my prepared remarks about having a little bit of excess capacity in the system today, and we're working on optimizing that capacity. We're excited",104," Yes, and I would say those things are both and those things are related. As we look at -- talking about in my prepared remarks about having a little bit of excess capacity in the system today, and we're working on optimizing that capacity. We're excited about our new pharmacy here in St. Louis. It's got just unbelievable accuracy and great efficiency, and it's really, we think, a competitive advantage for us long term. But we do have a little bit of excess capacity and we've got to rationalize that in time. We're moving through all the WellPoint activity. So I would say both.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Just to add on a little bit there, the site we built in St. Louis is exceeding our expectations on capacity and accuracy. We've got a program in place with zero defects. Obviously, that's pretty hard to do. But we're down to one to two defects per millio",114," Just to add on a little bit there, the site we built in St. Louis is exceeding our expectations on capacity and accuracy. We've got a program in place with zero defects. Obviously, that's pretty hard to do. But we're down to one to two defects per million and the filling [ph]. And we are truly excited about that. No other site do we have to meet those type of numbers. So we are absolutely excited about what we do. And then on a capacity side, we have significant excess capacity to meet today's needs and tomorrow's needs. So we have to go through that in the first quarter and rationalize our overall footprint.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator"," Our next question is from Ross Muken with Deutsche Bank.",10," Our next question is from Ross Muken with Deutsche Bank.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," You talked, George, a lot about sort of the specialty opportunity longer term. In the last quarter, we did see what could we call kind of the first biosimilar of sorts to kind of come to market in terms of medroxy [ph] pairing. I mean as you think about",115," You talked, George, a lot about sort of the specialty opportunity longer term. In the last quarter, we did see what could we call kind of the first biosimilar of sorts to kind of come to market in terms of medroxy [ph] pairing. I mean as you think about that as maybe hopefully a catalyst event for FDA to get more constructive on biosimilars, how do you think about that in that kind of context of your business and as an opportunity going forward? And do you feel like this may be something that could be a bit more hopeful in terms of this being a more near-term opportunity or maybe a two, three-year basis?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Absolutely. The biggest disappointment, as you know, that I had in healthcare reform is the fact that we put to this significant piece of legislation and didn't address with the way we needed to address the specialty market. We gave it lip service, if yo",340," Absolutely. The biggest disappointment, as you know, that I had in healthcare reform is the fact that we put to this significant piece of legislation and didn't address with the way we needed to address the specialty market. We gave it lip service, if you will, by the biosimilars. And as you also know, and when you're talking about biosimilars instead of biogenerics, these products are probably going to be priced not nearly as advantageously as they would be priced from a client perspective as a generic. So we're facing a little bit of a two edged sword here. But to your point, having introduction of these products and having many of the generic manufacturers excited about this, the administration and Congress both know that there's a tremendous opportunity here. They're one of the largest users of the biotech drugs out there, and they know what this is costing the country. They know that they were facing deficits and have a tremendous issue, and I am excited about where this can go. Now we do still need some legislative changes to ultimately get to where we need to be. But our team, we've got a fairly large lobbying group in Washington, as well as Dr. Miller, my Chief Medical Officer, also spends a lot of time on the Hill. I spend time on the Hill. And our job is to make sure that we can try to get that legislation through. I think notwithstanding all of that, there's a real issue around adherence, proper channel and the use of biosimilars. So we're talking about rolling out -- I think we can get our arms around the trend and improve the health outcomes in the world we live today. And to your point, if we can actually tip the scale over and start getting better competition and better products, especially for those where patent protection is expired, I think there's such a great, great, great opportunity out there to continue to win in this space. And that truly is our focus.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," And maybe, Jeff, I just want to touch on one thing, in terms of thinking about the profit growth here and the EBIT growth that we've seen, the guidance sort of implies roughly call it 30% type EPS growth this year. Your EPS growth CAGR over the last five",157," And maybe, Jeff, I just want to touch on one thing, in terms of thinking about the profit growth here and the EBIT growth that we've seen, the guidance sort of implies roughly call it 30% type EPS growth this year. Your EPS growth CAGR over the last five years has been slightly below that. As you think about sort of going forward, I mean, and particularly given all the focus and sort from the investment community on margins and return on capital during this last three to six months where there was a bit of trepidation. And as you kind of go forward, maybe just in broad terms, I'm not asking for a forward guidance, but do you see any sort of change in your business or anything that would make you think that on a go-forward basis the trajectory is going to be meaningfully different than we've been used to seeing from Express Scripts historically?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Yes, unfortunately, Ross, as much as I'd like to answer that question, I think any way I would answer that, would essentially be multiyear forward guidance. So certainly, I'm going to add -- I think we said last quarter on the call that we're excited abo",85," Yes, unfortunately, Ross, as much as I'd like to answer that question, I think any way I would answer that, would essentially be multiyear forward guidance. So certainly, I'm going to add -- I think we said last quarter on the call that we're excited about the long-term prospects for this business. We are making significant investments as we said because we believe so strongly in our business and how our team can execute. But it's hard for me to get into any more detail.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," Bust just in terms of like, given the assumptions for the core business from a margin perspective, et cetera. There was nothing that occurred during this last season or even next year that meant to you that all of a sudden, the profit trajectory of the b",55," Bust just in terms of like, given the assumptions for the core business from a margin perspective, et cetera. There was nothing that occurred during this last season or even next year that meant to you that all of a sudden, the profit trajectory of the business was anything meaningfully different than what we've seen.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Let me try something here then Jeff can certainly add on. We always get a question about price pressure in the marketplace. And I've said for the last three years, I saw the proof's in the pudding. I said you look at the script counts and you look at wha",275," Let me try something here then Jeff can certainly add on. We always get a question about price pressure in the marketplace. And I've said for the last three years, I saw the proof's in the pudding. I said you look at the script counts and you look at what's happened on to EBITDA per script. If we couldn't compete, then those metrics would not increase. And I think what you've seen from us, is we've grown our scripts significantly over the last five years. Our EBITDA per script overall is up. Obviously, there's been acquisitions and other things that may temporarily bring them down, but then they start to ascend again. And those things point to the health, from a historical perspective, of how the business is performing. Keeping in mind, we got three-year contracts for the most part, although we with 30% of our business have seven and 10 years or effectively seven years with two option years with the DoD. Seven and 10-year business. So those things stay very strong, obviously, over those periods of time. And so, I don't know, I mean, you look at the underlying trends in the business, and we're not going to give guidance to 2012 or '13 or '14. But I will tell you, you got an aging population, you got 30 million people coming into the market, you got a need by a country and by companies to figure how to control healthcare costs, and we have answers. So you throw all those things into the hopper, you shake it up, and I like our prospects. But again, we don't want to get into specifics.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator"," And next we'll go to Steve Valiquette with UBS.",10," And next we'll go to Steve Valiquette with UBS.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," You just kind of touched on this is a little bit but I thought the 2011 EBITDA for plain [ph] guidance was pretty strong. I thought it put the rest on the concerns about PBM pricing. So I was just curious, just sort of your general  comments or thoughts",74," You just kind of touched on this is a little bit but I thought the 2011 EBITDA for plain [ph] guidance was pretty strong. I thought it put the rest on the concerns about PBM pricing. So I was just curious, just sort of your general  comments or thoughts about the puts and takes of the projected EBIT up for claim in 2011 as any other insights you might want to add to that?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Yes, I think, obviously, as I said earlier, we're focused on a couple of things. And we think there a couple of things that really drive this business, that's certainly one of them. I think the team here has done just a phenomenal job getting the integra",196," Yes, I think, obviously, as I said earlier, we're focused on a couple of things. And we think there a couple of things that really drive this business, that's certainly one of them. I think the team here has done just a phenomenal job getting the integration done, getting our efficiencies up, bringing in new programs. There's a lot of things that we've talked to before that generics is of slightly lower year. But thankfully for Express Scripts, we've got a lot of other leverage we can pull. We've got a great team of people that are pulling them, and we've got -- we're firing at all cylinders here, we're driving EBITDA up for Rx as we continue to execute. And we're delivering products that, as George was saying, clients want to buy. And our model of alignment works at the end of the day. The more money we can save our clients, the more money we can make. And in this environment, our clients want to save money with Consumerology, we've got the tools that can help them save money with minimal member impact and the net result is the results that we're putting out.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," That's particularly true, Jeff, when you think about a year where there are low generic utilization. One or two things can happen. We consider slow generic utilization, so we can go to our clients and say sorry, but you guys all better get prepared for b",404," That's particularly true, Jeff, when you think about a year where there are low generic utilization. One or two things can happen. We consider slow generic utilization, so we can go to our clients and say sorry, but you guys all better get prepared for bad cost trends. Well, we probably wouldn't have any clients after that conversation. So our job is not to sit on our laurels and wait for a generic launch. Our job is to be creative and equip our account managers with products and innovation that go out and make sure they can manage those trends down. And when we do that, when we execute on that, what you see is we grow our EBITDA per script. We also, by the way, meet the clients' needs that take the cost out of the equation. If you remember a couple of years back, we had a bad generic year and we grew EBITDA per script significantly during that period. And the reason was is because we see these things three years out. So we don't sit and wait until the sky's going to fall or win anything else. We actually go out with a product portfolio to meet the needs of those clients. No CFO wants to sit there with the volatility in their cost going all over the place. Our job is to control that trend on a level of basis over the life of that contract, hopefully, over more than a couple of those contract terms. And that's our job. That's what we pay our account managers, and do in bonus [ph] them to do, and they've got to do it. So we're excited about the business and what we can do. As Jeff's pointed out, we got a lot of levers. And if it's not generics in a given year, then it's something else. But we just can't sit back and be complacent. We've got to drive those numbers and that's got to be our focus. Again, going back to Larry's question, it's not a question of just going out and trying to sell. It's a question of going out and making sure we're doing what our clients need to control their cost in very volatile markets. And when we do those things well, we can grow our business and grow our EBITDA, grow our business and meet the clients' needs, and that remains our singular focus.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," Any chance of having that, just generally speaking, as far as your overall wins for next year, just generally,  would you say they were skewed towards higher margin customers that already have decent mail pen rates or lower or that's not really one you w",51," Any chance of having that, just generally speaking, as far as your overall wins for next year, just generally,  would you say they were skewed towards higher margin customers that already have decent mail pen rates or lower or that's not really one you want to comment on at this stage?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Well, we don't really like to talk about clients specifically. I think there's a lot of noise going on in our numbers only because as you know, we have the big retailer lost unintentionally halfway through the year. And then we had -- so that's a bunch o",90," Well, we don't really like to talk about clients specifically. I think there's a lot of noise going on in our numbers only because as you know, we have the big retailer lost unintentionally halfway through the year. And then we had -- so that's a bunch of no-mail claims out. So  that's in the numbers. But as far as the winds, I think they're fairly common. I mean it's our job. I think they come to us because they have a need, and we're going to meet those needs.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator"," That would be from the line of Garen Sarafian with Citi Investment Research.",13," That would be from the line of Garen Sarafian with Citi Investment Research.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," In terms of reinvesting in your business and market opportunities, I'm curious to hear your thoughts on Medicaid. State continues to have severe budget shortfalls. Would you think PMBs with skills as yours really could help lower their costs and especial",60," In terms of reinvesting in your business and market opportunities, I'm curious to hear your thoughts on Medicaid. State continues to have severe budget shortfalls. Would you think PMBs with skills as yours really could help lower their costs and especially with the sophisticated tools. So what really needs to change for the market to become really appealing for you?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," We're looking at that and obviously, with 40% more individuals going to be pushed into the Medicaid space, something's got to give here. States are -- if you go back, four and five and six years ago, even two years ago, many of the platforms like governo",360," We're looking at that and obviously, with 40% more individuals going to be pushed into the Medicaid space, something's got to give here. States are -- if you go back, four and five and six years ago, even two years ago, many of the platforms like governors running for office was to trying to control the budget of the states, even before the economic downturn. Medicaid was costing the states tremendous amounts of money. Many states cut-slashed Medicaid spending and cut Medicaid enrollment by changing the qualifications, and we've seen a lot of that activity. Well, now we're going to put 40% of people on top of it. And we're going to fund it in the early years and then defund it over a period of time. The states are going to have a tremendously difficult time meeting that need. And you're exactly right, there's a tremendous opportunity for us to utilize our tools, to meet the needs of that marketplace. Today, those are being met through managed Medicaid plans. We have clients who manage Medicaid. So we picked up our share through the managed Medicaid plans, but there's an awful lot of fee-for-service out there. And to the extent that you start ratcheting down spending or you need to get control of the spend, managed Medicaids probably going to play a higher and higher role. I think we've got to figure out -- that's why we're making these investments is to figure how do we play in that space to make sure we can bring our tools and expertise to an area that truly needs to be managed and worked. And s you know, the Medicaid is far different than the other plans people are transient. Most pay close to nothing if nothing for their care. So getting adherence, getting incentives, making things work is very difficult for traditional businesses. For us though, where we use Consumerology, understand the drivers of the person, who we think were in a unique position where we can use those tools to help the states manage their business. So this is truly a focus of ours over the next couple of years.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," Any reason why upcoming elections next week would impact anything for next year as to the progress you make of the Medicaid front?",23," Any reason why upcoming elections next week would impact anything for next year as to the progress you make of the Medicaid front?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Well, I think -- really kind of depends on everything that happens, and that goes back to being fluid and flexible because I do believe that things have to change. I'm a citizen first and a CEO second. And we are facing tremendous deficits. We've got to",277," Well, I think -- really kind of depends on everything that happens, and that goes back to being fluid and flexible because I do believe that things have to change. I'm a citizen first and a CEO second. And we are facing tremendous deficits. We've got to address that issue. We've got to get our costs as a country under control. Whether it's the Democrats or the Republicans, we can't continue to spend the way we're spending. We got to do something about taxation. We've got to do something about competitive strength of our companies to be able to compete globally. There's an awful lot out there. All those things could have an impact on what happens. If the Republicans win the house and they decide not to procreate money to the healthcare bill, where does that take us? What happens if the Federal government has the right to establish the exchanges, will the states have the right to put them in? What if states don't do it, would the Federal government do it? What if there's money not appropriated? There's a lot of uncertainty out there. At the end of the day though, all those uncertainties, I view as a wonderful thing. Because the company that can change and the company that can meet the market needs and can be first to market is the one that can win. And I don't think there's anybody out there than at Express Scripts. So I love where we sit. We know that these things are at some way or form, these things are going to happen. And I think we're very well-positioned to take advantage of those opportunities.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," Just switching channels a bit. I know you don't speak about specific clients coming up, but overall, how do you see the 2011 selling season as it gets underway? Maybe if you could offer just some broad color as to how it compares to 2010 in terms of size",65," Just switching channels a bit. I know you don't speak about specific clients coming up, but overall, how do you see the 2011 selling season as it gets underway? Maybe if you could offer just some broad color as to how it compares to 2010 in terms of size and just the types of clients that are going to market next year versus this year?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Sure, I think you've heard us say this many times before. We've got two large clients that make up half of our book that are on longer term renewal cycles, which on average means that we've got 15% to 20% of our book up to renewal in any given year. And",80," Sure, I think you've heard us say this many times before. We've got two large clients that make up half of our book that are on longer term renewal cycles, which on average means that we've got 15% to 20% of our book up to renewal in any given year. And as we look at 2011 right now to the lower end of that range, certainly, clients up for renewal are slightly lower in '11 than it was in 2010.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Analysts"," Overall, is there opportunities in -- I mean, is the overall opportunity larger than 2010, or there might be some opportunities to bring on additional clients?",26," Overall, is there opportunities in -- I mean, is the overall opportunity larger than 2010, or there might be some opportunities to bring on additional clients?
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," We're always excited about the opportunities out there. I think we've got unique products that can really help clients save money. And we're excited about what we have to offer and certainly the sales team is out there to close every opportunity we can c",70," We're always excited about the opportunities out there. I think we've got unique products that can really help clients save money. And we're excited about what we have to offer and certainly the sales team is out there to close every opportunity we can close as long as the client we want to work with, the client is focused on taking out ways where we can add significant value.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Executives"," Well, thank you all very much. I appreciate your attentiveness this morning, and look forward to bringing you up-to-date with our fourth quarter results early next year. Thank you very much.",31," Well, thank you all very much. I appreciate your attentiveness this morning, and look forward to bringing you up-to-date with our fourth quarter results early next year. Thank you very much.
"
317975,114404734,86284,"Express Scripts Inc., Q3 2010 Earnings Call, Oct 28, 2010",2010-10-28,"Earnings Calls","Evernorth Health, Inc.","Operator"," Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation. You may now disconnect.",19," Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation. You may now disconnect.
 
"
